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ABSTRACT 
HIV/AIDS continues to be one of the greatest health challenges which South Africa faces. 
The epidemic in children is closely linked to that in women, the prevalence of which 
continues to grow according to antenatal statistics from the South African Department of 
Health (DOH). HIV is known to invade the central nervous system at the time of infection, 
and causes widespead damage. In children, this leads to a well-researched condition 
known as HIV encephalopathy, which affects all areas of neurodevelopment. The effects 
of timely initiation of antiretroviral therapy on alleviating the impact of encephalopathy 
have been well described.  
 
Neurodevelopmental delay is a stage four disease indicator according to the World Health 
Organisation (WHO), and therefore is a criterion for initiation of Highly Active Antiretroviral 
Therapy (HAART). HAART is often only administered according to the virologic and 
immunologic status of a child, as standardised neurodevelopmental assessment tools are 
not widely available in South African clinics. When HAART initation is dependent on 
immunologic status, it is often too late to prevent encephalopahy. To date, the only means 
of prevention of this condition is early initation of HAART, which has not been widely 
available in South Africa. Stringent guidelines for the commencement of this therapy 
according to the WHO, and the South African Department of Health (DOH) have had to 
be followed, leading to late initiation of HAART, and widespread central nervous system 
encephalopathy. Studies which have been carried out in South African clinics have 
demonstrated the high prevalence of this condition. Once there is evidence of 
encephalopathy, children should be referred for assessments in all facets of development, 
and where necessary, for rehabilitation. A standardised developmental screening tool 
which is suitable for use in a developing country is therefore necessary in order to screen 
for neurodevelopmental delays to allow for further assessment and referral to 
rehabilitation services, as well as providing an additional assessment criterion for initiation 
of HAART.     
 
Paediatric HIV clinics in developing countries are understaffed, and children may be seen 
by junior staff or screened by nurses due to the high numbers of clinic attendees. This 
often results in neurodevelopment being inadequately assessed and children are 
therefore not referred for intervention services. A standardised screening tool, which 
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could be administered by clinic staff in order to ensure correct and timely referral of 
children for further assessment and intervention is therefore necessary. This is of 
importance both locally and internationally where a screening tool, which has been 
developed specifically for this purpose, does not exist.  
 
The aim of this study was therefore to evaluate the agreement between the Bayley-III 
Screening Test and the Bayley Scales of Infant Development (3rd version) in a population 
of HIV positive infants in order to evaluate its appropriateness for use in South Africa. The 
Bayley Scales of Infant Development have long been considered the ‘gold standard’ in 
infant developmental assessment, which is why this tool was chosen to evaluate the 
Bayley-III Screening Test against. The developmental scores in each facet (cognitive, 
motor or language) were evaluated to determine which should be included in an 
assessment tool for this population. Further objectives for the study were to adapt the 
screening tool to the needs of the population, or to develop a new screening tool should 
the Bayley-III Screening Test not prove suitable for use in this population.  
 
In order to meet the aims and objectives, a cross-sectional study was conducted where 
112 HIV positive infants between the ages of six and eighteen months were assessed 
using the Bayley-III Screening Test and the Bayley Scales of Infant Development (3rd 
version) (BSID III). The infants were stratified into four age groups namely 6-8 months, 9-
12 months, 13-16 months, and 17-18 months. Children were recruited from Harriet Shezi 
Children’s Clinic at Chris Hani Baragwanath Hospital in Soweto.  
 
The agreement between the Bayley-III Screening Test and the Bayley Scales of Infant 
Development (3rd version) was analysed using Kappa, for the overall group, and for each 
age group. Overall agreement between the tools was as follows: K=0.58 for the Cognitive 
facet, K=0.82 for the Expressive Communication facet, K=0.76 for the Receptive 
Communication facet, K=0.44 for the Fine Motor facet and K=0.57 for the Gross Motor 
facet.  These values indicate that the Bayley-III Screening Test is therefore not 
acceptable for clinical use, as excellent agreement (k≥0.75) in all facets would be 
necessary for this purpose.  
 
A new screening tool therefore had to be developed. The infant’s developmental scores 
from the BSID III were analysed to determine which facets of development were most 
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severely affected, and therefore which facets should be included in a new screening tool. 
Gross motor function was demonstrated to be the area which was most severely affected, 
followed by cognitive function. A gross motor screening tool would therefore be suitable 
for use in this population, as no equipment would be necessary. Gross motor 
development is the most universally similar aspect of development, which is not 
completely dependent on cultural or socioeconomic factors which often have an influence 
on language and cognitive development.  
 
Item selection from the BSID III was undertaken to determine which items should be 
included in a brief screening tool. In each of the four age groups, item selection occurred 
as follows: Two items which discriminated the At-Risk, from Emerging and Competent 
groups (less than 20% in the At-Risk group, and 100% in the other groups) were selected. 
Two items, which discriminated between children in the ‘Emerging’ and ‘Competent’ 
categories on the BSID III were selected (0-5% of children who were At-Risk obtained 
credit, 30-50% of the Emerging group obtained credit, and 100% of the Competent group 
obtained credit). Lastly, two items were selected which discriminated the Competent 
group from the other two groups (100% or as high as possible in the Competent group, 
and 0% in the other groups).  
 
The new gross motor screening tool was assembled using the selected items, scoring 
was allocated, and it was tested against the scores obtained on the Gross Motor facet of 
the BSID III for the initial 112 infants. Agreement between the tools was analysed using 
Kappa, and refinements were made according to the discrepancies. This was done three 
times, until the Kappa value revealed excellent agreement between the tools (k = 0.87). A 
panel of experts was then invited to examine the new gross motor screening tool, and to 
comment on it, and further adjustments were made accordingly.  
 
Preliminary concurrent validity testing of the new gross motor screening tool was then 
carried out against the Gross Motor facet of the BSID III on 60 children, who were 
recruited from the Harriet Shezi Children’s Clinic at Chris Hani Baragwanath Hospital in 
Soweto. Statistical analysis revealed that the agreement between the BSID III and the 
new screening tool was excellent (k=0.85). The diagnostic properties of the new gross 
motor screening tool were as follows: sensitivity 97.4%, specificity 85.7%, positive 
predictive value 92.7%, and negative predictive value 94.7%. These values indicate that 
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the statistical properties of the tool are excellent, and the tool will not be predisposed to 
underreferrals or over-referrals.  Preliminary reliability testing was carried out on 15 
children for test-retest/intrarater reliability and 15 children for interrater reliability. 
Interrater, test-retest and intrarater reliability were excellent (r=1, r=0.98, r=0.98 
respectively). Further testing of reliablity and validity should be undertaken in order to 
establish these properties, and standardisation should also be carried out on healthy 
children. Given the need for an assessment tool of this nature in South Africa and other 
developing countries, and the statistical properties thus far, the tool may be used clinically 
for the purposes for which it was developed.  
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DEFINITION OF TERMS 
 
CD4 count 
The CD4 count is used to quantify the immune status of a patient. The CD4 count is the 
absolute number of CD4+ T lymphocytes (McFarland, 2005). Children who attend Harriet 
Shezi clinic have their CD4 count taken at baseline, and then at three monthly intervals. 
CD4 counts are used to determine eligibility for highly active antiretroviral therapy 
(HAART) and to monitor treatment response. Interpretation of CD4 numbers in children 
requires the recognition that the normal number of cells declines with age over the first six 
years of life. Normal values for age have therefore been calculated.  
 
CD4 percentage 
CD4 percentage is the fraction of total lymphocytes that express CD3 and CD4 cell 
surface markers. CD4+ T-cell percentage fluctuates less than absolute counts, as 
variations in total white cell count do not affect the percentage as much (McFarland, 
2005). The CD4 percentage threshold for the commencement of HAART is as follows: 
less than 25% for infants less than 12 months and less than 20% for children aged 12 to 
36 months. Children older than three years are eligible for HAART when the CD4 count is 
less than 15% (Department of Health, 2008).  
 
International paediatric guidelines recommend monitoring both percentage and absolute 
CD4 cell count, and determining disease staging based on the lower of the two values. A 
sustained decrease of 50% in the absolute count or percentage is accepted as significant 
evidence of disease progression (McFarland, 2005). 
 
HIV-1 
There are two major types of HIV: HIV-1 and HIV-2. Although similar to HIV-1, HIV-2 has 
a different sequence of nucleotides in its genome. Studies suggest that both HIV-1 and 
HIV-2 evolved from Simian Immunodeficiency Virus (SIV), but from different simian 
species. HIV-1 diverged from chimpanzee SIV and HIV-2 from sooty mangabey SIV. HIV-
2 is less transmissible than HIV-1 both vertically and between partners, and progression 
to end-stage AIDS is slower. HIV-2 is more commonly found in countries in West Africa 
(Pratt, 2003).  
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Viral load 
Viral load is an indication of the amount of viral RNA in the plasma, and is a direct 
representation of the amount of circulating virus. The measure is used to monitor the 
child’s response to HAART, and no change or an increase in viral load, despite having 
commenced highly active antiretroviral therapy (HAART) is an indication of poor response 
or adherence. Harriet Shezi Clinic uses the nucleic acid sequence based amplification 
(NASBA), with the optimal result on this test being a viral load of less than 25.  
 
Antiretroviral regimen 
Children who are managed at the Harriet Shezi Clinic need to meet the South African 
Department of Health criteria for the commencement of antiretroviral therapy. The clinic 
aims to start every child who meets the Department of Health Criteria on HAART using 
the following regimen: Stavudine (d4T) (NRTI), Lamivudine (3TC) (NRTI), 
Lopinavir/ritonavir (Kaletra®) (PI). HAART exposure is defined as the concomitant use of 
at least three drugs from at least two classes of HIV drugs (NRTI, NNRTI and PI) (WHO, 
2008), and therefore the combination of drugs used at the clinic qualifies as HAART.  
 
Composite Score (For the Bayley Scales of Infant Development III)  
Composite scores are derived from sums of subtest scaled scores. They are scaled to a 
metric with a mean of 100 and a standard deviation (SD) of 15, and range from 40-160 
(Bayley, 2006a). The interpretation of the scores is shown in Table 1 below:  
 
Table 1.1 Interpretation of BSID III Composite Scores 
Composite Classification 
130 and above Very Superior 
120 – 129 Superior 
110 – 119 High Average 
90 – 109 Average 
80 – 89 Low Average 
70 – 79 Borderline 
69 and below Extremely Low 
(Bayley, 2006b) 
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Scaled Score (For the Bayley Scales of Infant Development III)  
Scaled scores are derived from the subtest total raw score, and range from one to 19, 
with a mean of 10, and a SD of three (Bayley, 2006a). The conversion of the scaled score 
to the categories on the Bayley-III Screening Test for comparison is shown in Table 1.2 
below:  
 
Table 1.2 Conversion from BSID III to Bayley-III Screening Test Category 
Scaled Score on BSID III Category on the Bayley-III Screening Test 
1 – 4 At-Risk 
5 – 7  Emerging 
8 + Competent 
(Bayley, 2006c) 
 
Kappa 
In this study, Kappa has been used to evaluate agreement between two 
assessment tools. It is an index that compares the agreement against that which 
might be expected by chance (Portney and Watkins, 2000). The interpretation that 
will be used in this study is shown in the table below:  
 
Table 1.3 Interpretation of Kappa scores 
Kappa Score Interpretation 
≤ 0.4 Poor Agreement 
> 0.4 - < 0.75 Moderate agreement 
≥ 0.75 Excellent agreement 
 (Landis and Koch, 1977) 
 
Z-score 
 
Z-score (or SD-score) = observed value - median value of the reference population  
                     ------------------------------------------------------------------------------- 
                                            standard deviation value of reference population  
(WHO, 1997) 
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The z-score system expresses the anthropometric value as a number of standard 
deviations or z-scores below or above the reference mean or median value.   The 
advantages of using z-scores are as follows: z-scores have the same statistical relation to 
the distribution of the reference around the mean at all ages, which makes results 
comparable across ages groups and indicators, and z-scores are sex-independent. These 
characteristics allow further computation of means, standard deviations, and standard 
error to classify a population’s growth status (WHO, 1997). 
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Chapter 1 
INTRODUCTION 
 
It is estimated that 33.4 million people worldwide were living with the Human 
Immunodeficiency Virus (HIV) in 2008, over half of whom were women (UNAIDS, 
2009). In 2008, an estimated 390 000 children in sub-Saharan Africa were infected 
(UNAIDS, 2009). The HIV epidemic amongst children is closely linked to that of 
women, since the majority of paediatric infections are the result of vertical 
transmission from mother to child (UNAIDS, 2006; Thorne and Newell, 2000). 
 
More than twenty years have elapsed since the original description of the effects of 
HIV on the central nervous system (CNS) (Epstein et al, 1985), and the nervous 
system has been described as one of the most frequent and serious targets of HIV 
(Raskino et al, 1999; Simpson and Berger, 1996). Involvement of the nervous system 
in patients infected with HIV is a well-described condition known as HIV 
encephalopathy, and may come about as a result of direct HIV action, opportunistic 
infection caused by the immunodeficiency, or both (Fragoso et al, 1999).  
 
Significant delays in mental and motor development of HIV infected infants have been 
found over the first two years of life (Potterton et al, 2009a; Potterton et al, 2009b; 
Baillieu and Potterton, 2008; Van Rie et al, 2008; McGrath et al, 2006a; Drotar et al, 
1997; Msellati et al, 1993). In a study conducted in South Africa on children under 
three and a half years of age, it was found that 72% had severe motor delay, and 52% 
had severe cognitive delay (Potterton et al, 2009b). Such impairments are likely to 
become more severe as the children get older (Blanchette et al, 2001; Belman, 1992).  
 
Neurological and developmental signs are often markers of HIV infection in infants, 
which may precede other signs of disease progression (Bisiacchi et al, 2000; Belman, 
1992). HIV infection of the developing CNS of infants and children is characterised by 
either a progressive or static loss of previously acquired developmental milestones 
with cognitive, behavioural and motor manifestations (Udgirkar et al, 2003; Belman et 
al, 1988; Epstein et al, 1986; Sharer et al, 1986; Belman et al, 1985).  
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Development of encephalopathy is one of the most severe complications of HIV but its 
frequency at different ages has long been disputed (Tardieu et al, 1992). HIV 
encephalopathy may occur very early in the course of HIV infection and 88.1% of 
children who develop it do so within the first two years of life (Newell et al, 1998). This 
is more common in children infected with HIV who present in early infancy and show 
rapid progression, as they may have been infected in-utero during the last weeks of 
pregnancy, which is the period of fastest brain growth (Newell et al, 1998).  
 
The most frequent manifestations of HIV-associated progressive encephalopathy are: 
cognitive impairment, developmental delays, corticospinal tract lesions, acquired 
microcephaly, movement disorders, and ataxia. Progressive motor dysfunction is 
common and often results in a loss of milestones (Belman, 1992). Risk factors for 
paediatric CNS involvement include the timing of infection, advanced maternal 
disease at delivery, rapid progression with early advanced immune suppression, high 
plasma viral load in infancy, and factors such as home environment and 
socioeconomic status (Robertson et al, 2008).  
 
HIV encephalopathy is one of the criteria for initiation of Highly Active Antiretroviral 
Therapy (HAART) (ANNECCA, 2005). Encephalopathy is one of the most common 
CNS disorders amongst HIV infected children worldwide, and while this is a HAART 
eligibility criterion, neurodevelopmental assessment is rarely performed in developing 
countries due to a shortage of skilled staff and a lack of validated assessment tools for 
these settings (Van Rie et al, 2007). This results in missed opportunities for timely 
initiation of HAART as well as for the prevention and management of HIV-associated 
neurodevelopmental impairment. Validation and standardisation of 
neurodevelopmental assessment tools for developing-world contexts are vital in order 
to identify early warning signs of HIV-associated CNS disorders and to allow the 
integration of neurodevelopmental assessment into paediatric HIV care and treatment 
programmes worldwide (Van Rie et al, 2007).  
 
The Bayley Scales of Infant Development II (Bayley, 1996), have been extensively 
used in HIV/AIDS research worldwide, and therefore have been used in South Africa 
in order to be able to compare results with worldwide studies (Potterton et al, 2009a; 
Potterton et al, 2009b; Baillieu and Potterton, 2008; McGrath et al, 2006a; Aina and 
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Morakinyo, 2005; Chase et al, 2000; Drotar et al, 1997; Gay et al, 1995). The Bayley 
Scales have been found to be sensitive to developmental changes in the first two 
years of life of infants who are medically fragile (Niccols and Latchman, 2002), and 
these findings support the clinical validity of the scale, which can be applied to those 
with HIV. Like its predecessors (Bayley Scales of Infant Development I and II), the 
Bayley Scales of Infant Development III (BSID III) is an individually administered 
instrument that assesses developmental functioning of infants and young children 1-
42 months of age. The primary purpose of the BSID III is to identify children with 
developmental delay and to provide information for intervention planning (Bayley, 
2006a). The BSID III is a revision of the BSID II, in order to improve the quality and 
enhance the utility of the instrument. The BSID III was standardised on a national 
sample of 1,700 children in the United States of America who were stratified by age, 
sex, race/ethnicity, parent education level and region (Bayley, 2006b). The BSID III is 
reliable and valid, and is predictive of later developmental outcome (Bayley, 2006b), 
however, this is not an appropriate tool to use in busy HIV clinics in South Africa, as 
the administrator needs to be trained and the assessment is lengthy.  
 
The BSID I (Bayley, 1993) was normed on over 700 South African children from both 
urban and rural areas, and was found to be suitable for use on South African infants 
(Richter and Griesel, 1992; Richter et al, 1988). The South African infants scored 
above the test norms up to 10 months of age on both the Mental and Motor Scales, 
and from 10 months up to the middle of the second year the groups obtained very 
similar scores. The trend across the whole age range in the South African sample was 
for urban children to score higher than rural children on both the Mental and Motor 
scales, although this was not statistically significant across the age range (Richter and 
Griesel, 1988). Based on these findings, the authors recommended that the BSID be 
used without adaptation on South African children. A study was also done in Uganda, 
examining normative data for the BSID II on infants between eight weeks and 30 
months (Aina and Morakinyo, 2005). The infants scored above the normal values in 
both the Mental and Motor scale of the BSID II, and furthermore, their scores in the 
motor scale were significantly higher, especially in the lower age groups of eight, 16 
and 32 weeks when compared with data from the Western World (Aina and 
Morakinyo, 2005).  The BSID I, II and III are well correlated (Bayley, 2006b; Bayley, 
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1996), and therefore the results from the above can be applied to the BSID III and its 
applicability for use on South African infants.  
 
The Bayley-III Screening Test (Bayley, 2006c) was developed using items from the  
BSID III. It is designed to assess briefly the cognitive, language and motor functioning 
of infants and young children between 1-42 months of age. The primary purpose is to 
determine whether a child shows competence in age-appropriate tasks, shows 
evidence of emerging age-appropriate skills, or shows evidence of being at-risk for 
developmental delay. It was standardised on a sample of 1,675 children and included 
representative proportions of infants according to selected demographic variables. It is 
also reliable and valid (Bayley, 2006c).   
 
Screening is the process by which conditions are identified by tests that can be 
applied rapidly on a large scale (Beaglehole et al, 1993). The screening test should be 
cost-effective, reliable and valid, and should be sensitive and specific (Beaglehole et 
al, 1993). Even though there is no gold standard (an ideal test covering all areas of 
development, being equally applicable to all ages, with construct validity, and an 
accuracy approaching values of 100% for sensitivity and specificity), many screening 
tests are well standardised, with acceptable levels of sensitivity and specificity in the 
context of documented developmental delays. The test should be acceptable to the 
population and should be non-invasive and culturally sensitive (Rydz et al, 2006).  
 
There is therefore a need for an assessment tool which can be administered by 
doctors or nurses at the HIV clinics, which is less lengthy, yet is able to identify those 
children who need referral to services for encephalopathy and developmental delay. 
At present, South African children are not being screened, and therefore are not 
adequately referred for services (Potterton et al, 2009a). The development of a 
screening tool which is suitable for use in this setting has been incorporated into the 
National Strategic Plan (NSP) for HIV for 2007-2011, and the South African 
government has made a commitment to ensuring that all HIV positive children under 
three years of age undergo developmental screening (NSP, 2007 – 2011).  
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1.2 Problem statement  
HIV is known to affect the CNS, and consequently neurodevelopment in infants and 
children. Paediatric HIV clinics in developing countries are understaffed, and doctors 
often see over 100 children a morning; children may be seen by junior staff or 
screened by nurses due to the high numbers of clinic attendees. This often results in 
inadequate assessment of neurodevelopment and children are therefore not referred 
for intervention services. A standardised screening tool is needed, which is able to be 
administered by clinic staff in order to ensure correct and timely referral of children for 
further assessment and intervention. Children who are clinically eligible for HAART 
due to the presence of encephalopathy are not being detected and therefore a 
screening tool would assist with this. This is of importance both locally and 
internationally where a screening tool, which has been developed specifically for this 
purpose, does not exist.  
1.3 Aim of the study  
The aim of this study was to evaluate the agreement between the Bayley-III Screening 
Test and the Bayley Scales of Infant Development (3rd version) in a population of HIV 
positive infants in order to determine its appropriateness for use in South Africa. The 
separate areas of the tool were evaluated to determine which facet (cognitive, motor 
or language) is most valuable, and could be used alone. The tool was to be adapted 
accordingly to make it feasible for use in terms of time, equipment and technical 
expertise. Should the tool not be suitable for use, a more appropriate screening tool 
was to be developed.  
1.4 Objectives  
 To determine how the Bayley-III Screening Test needed to be adapted for use 
in developing countries such as South Africa by shortening the assessment 
time and decreasing the need for equipment; 
 To determine which areas of the screening tool were most useful for use on 
this population.  
 To test and compare results from the  BSID III and the Bayley-III Screening 
Test on a sample of HIV positive infants; 
 To determine the socioeconomic status of the sample, and whether there was 
a relationship between health status and developmental outcomes; 
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 To evaluate the suitability of the Bayley-III Screening Test for use in this 
population; 
 Should the Bayley-III Screening Test not prove to be suitable, a new tool was 
to be developed, and preliminary testing of the new tool against the BSID III 
was to be undertaken.  
1.5 Organisation of the Thesis 
 
Figure 1.1 below outlines the way in which the study was conducted.  
 
 
Figure 1.1 Diagram depicting the organisation of the thesis  
 
As can be seen above, the sections of the thesis are divided into a number of different 
studies, which are each presented in a separate chapter. Study one consisted of the 
testing of The Bayley-III Screening Test against the Bayley Scales of Infant and 
Toddler development III (BSID III) in order to determine its suitability for use as a 
screening tool in South Africa. It was found to be unsuitable (K<0.75), and therefore 
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the final objective of the study was undertaken, and a new screening tool had to be 
developed. This is described in chapter four. 
 
Study two was then undertaken: this involved analysis of developmental scores in 
order to determine which facet of development was most severely affected, and which 
areas of development should be included in a new screening tool.  Item analysis of the 
Bayley Scales of Infant and Toddler Development III was undertaken in order to 
determine which items should be included in a new tool. Study two is discussed in 
chapter five.  
 
Study three: Once the items for the new tool had been selected, and scoring had 
been allocated, testing of the first version against the BSID III was undertaken. 
Following analysis of the results, the relevant sections were refined, and the second 
version was tested against the BSID III. Again, the results were analysed and the 
relevant sections were adjusted. Study three is discussed in chapter six.  
 
Study four consisted of a meeting with a panel of experts who were asked to 
comment on the new screening tool. Suggestions were put forward by the panel 
members and discussed within this meeting, and relevant changes were made to the 
tool following this discussion. This is described in chapter seven.  
 
Study five consisted of the testing of the final version of the screening tool against the 
BSID III on 60 infants between the ages of 6 and 18 months. This is described in 
chapter eight.  
 
All results are discussed in detail in chapter nine, and conclusions are drawn in 
chapter ten.  
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Chapter 2 
LITERATURE REVIEW 
2.1 Introduction 
In this chapter an overview of paediatric HIV will be given with a more detailed 
discussion on the neurological complications of this disease. The impact of paediatric  
HIV on growth will be presented, and the socioeconomic implications on development 
and growth will be discussed. Developmental screening and surveillance in 
paediatrics will be presented, and necessary properties of standardised assessment 
tools are discussed. Six commonly used standardised paediatric developmental 
screening tools are compared to illustrate this.   
  
Articles were sourced for this review using Pubmed, CINAHL, PSYCHInfo, and 
Cochrane Collaboration searches. A hand search was also conducted in the Health 
Sciences Library of the University of the Witwatersrand. Key words used in searches 
included; HIV, children, encephalopathy, developmental delay, neurodevelopment, 
socioeconomics.  
2.2 Epidemiology of the HIV/AIDS Pandemic 
Globally, an estimated 33.4 million (31.1-35.8 million) people worldwide were living 
with HIV in 2008, over half of whom were women (UNAIDS, 2009). Whilst the 
prevalence of people living with HIV has stabilised since 2000, the overall number of 
people living with HIV has increased as new infections occur each year and 
outnumber deaths due to HIV/AIDS.  
 
Sub-Saharan Africa remains the region most heavily affected by HIV. In 2008, sub-
Saharan Africa accounted for 67% of HIV infections worldwide, 68% of new HIV 
infections among adults, and 91% of new HIV infections among children. The region 
also accounted for 72% of the world’s AIDS-related deaths in 2008 (UNAIDS, 2009). 
Mother-to-child transmission continues to account for a substantial portion of new HIV 
infections in many African countries. In 2008, an estimated 390 000 [210 000–570 
000] children were infected in sub-Saharan Africa (UNAIDS, 2009).  
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In 2008, an estimated 1.9 million [1.6 million–2.2 million] people living in sub-Saharan 
Africa became newly infected with HIV. This brought the total number of people living 
with HIV to 22.4 million [20.8 million– 24.1 million].  The rate of new HIV infections in 
sub-Saharan Africa has slowly declined, with the number of new infections in 2008 
approximately 25% lower than at the epidemic’s peak in the region in 1995, but the 
number of people living with HIV in sub-Saharan Africa slightly increased in 2008, 
which is partly due to improved access to HIV treatment, with the number of new 
infections now exceeding the number of deaths. Adult (15–49 years) HIV prevalence 
declined from 5.8% [5.5–6.0%] in 2001 to 5.2% [4.9–5.4%] in 2008. In 2008, an 
estimated 1.4 million [1.1 million–1.7 million] AIDS-related deaths occurred in sub-
Saharan Africa, which represents an 18% decline in annual HIV-related mortality in 
the region since 2004. South Africa is home to the world’s largest population of people 
living with HIV (5.7 million) (UNAIDS, 2009).  
 
Globally, new HIV infections in children peaked in 2000-2002, and are now decreasing 
due to the stabilisation of HIV prevalence among women overall, as well as increasing 
coverage of programmes for preventing mother-to-child transmission of HIV (UNAIDS, 
2009). This is not the case in most countries in Sub-Saharan Africa, where rates are 
not decreasing as quickly.  
 
In South Africa, Botswana and Zimbabwe, HIV is the underlying cause of more than 
one third of all deaths among children under the age of five (Mason, 2006). Without 
antiretroviral treatment, the progression of HIV infection in children is particularly 
aggressive, and many children die at a young age (Brahmbhatt et al, 2006; Newell et 
al, 2004; Taha et al, 2000). HIV data from antenatal clinics in South Africa suggest 
that the country’s epidemic may be stabilising (Department of Health, South Africa, 
2007), but there is no evidence of major changes in HIV-related behaviour. 
Meanwhile, the estimated number of maternal, paternal, and double orphans due to 
HIV/AIDS in South Africa in 2008 stood at 1.7 million (UNAIDS, 2009).  
2.3 Mother-to-Child Transmission 
The HIV epidemic amongst children is closely linked to that amongst women, since 
the majority of paediatric infections are the result of vertical transmission from mother 
to child (UNAIDS, 2009). Over 95% of HIV positive children in sub-Saharan Africa are 
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infected as a result of vertical infection (Dabis and Ekpini, 2002). Vertically transmitted 
HIV occurs in an immature and developing organism by transplacental or intrapartum 
transmission from mother to child (Rausch and Stover, 2001; Belman, 1992). HIV 
infection rates among pregnant women attending South African antenatal clinics have 
steadily increased from less than one percent in 1990 to 29.1% in 2006 (UNAIDS, 
2008). Encouragingly, this represents a slight drop from its peak of 30.2% in 2005, but 
the pandemic is still not under control (UNAIDS, 2008). The cumulative rates of HIV 
transmission from mother-to-child are 25-40% with the breakdown as follows: under 
10% are infected during pregnancy, 10% to 20% at birth, and 10% to 20% during 
breastfeeding (Luzuriaga and Sullivan, 2002). Maternal-, obstetric- and infant-related 
factors have been associated with the risk of vertical transmission, with the most 
important maternal factor being viral load (European Collaborative Study, 1996). 
Overall, in the absence of interventions to prevent transmission, two-thirds of mother-
to-child transmission takes place in the peri-partum period, which can either occur in 
utero (around a third of cases), mostly late in the third trimester or intra-partum 
(around two-thirds of cases) (Chouquet et al, 1999).  
 
Obstetric risk factors associated with an increased risk of mother-to-child transmission 
include vaginal delivery, ascending infection after prolonged rupture of membranes, 
chorioamnionitis, materno-foetal micro-transfusions during uterine contractions and 
absorption of the virus through the infant’s digestive tract (Newell, 1998), as well as 
invasive obstetric procedures and co-infection with another sexually transmitted 
infection (European Collaborative Study 1999; The European Mode of Delivery 
Collaboration, 1999; Van Dyke et al, 1999; Mandelbrot et al, 1998; Landesman et al, 
1996; Tovo et al, 1996; Ryder et al, 1989). The onset of perinatally acquired HIV 
infection is early with most infected infants showing signs of disease by six months of 
age. Children who are infected through vertical transmission are more likely to suffer 
from neurodevelopmental problems compared with those infected later on, as the 
most significant period of brain development is affected (Willen, 2006). 
 
In a randomised trial of breastfeeding versus formula feeding which was undertaken in 
Kenya, 44% of infections in the breast-feeding group were attributable to breast-milk 
transmission (Coutsoudis et al, 2004; Nduati et al, 2000). The first few weeks of life 
are a particularly high-risk period, since colostrum and early milk have a higher viral 
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load than milk that is produced later (Nduati et al, 2001). However, transmission can 
take place at any time during breastfeeding; a meta-analysis of nine trials showed a 
cumulative risk that remains constant from one month to 18 months of age 
(Coutsoudis et al, 2004). Acquisition of infection through breastfeeding is often 
attributable to mixed feeding, where children who experience mixed feeding as 
opposed to exclusive breastfeeding during the first six months of life are at a higher 
risk of vertical transmission (Coovadia and Bland 2007; Coovadia and Coutsoudis 
2007).  
2.4 Entry of HIV into the Central Nervous System 
Over twenty years have elapsed since the original description of the assault of HIV on 
the central nervous system (CNS) (Epstein et al, 1985) and the nervous system is 
among the most frequent and serious targets of HIV (Simpson and Berger, 1996). The 
incidence of CNS involvement is not known, although it is thought to occur in most 
HIV infected children (Fragoso et al, 1999). Early encephalopathy may be related to 
the occurrence of pathological events during late foetal life (Rausch and Stover, 2001; 
Tardieu et al, 2000). Studies have shown that significantly more children under three 
years of age show evidence of CNS disease, compared with children who have 
survived to over six years of age (Blanche et al, 1990). Involvement of the nervous 
system in HIV infected patients may come about as a result of direct HIV action, 
opportunistic infection caused by the immunodeficiency, or both (Zink et al, 2006; 
Fragoso et al, 1999). In children, CNS effects usually result directly from HIV-1 
infection and not from opportunistic infections (Belman, 1992). The pathogenesis of 
brain injury in HIV-1 infected patients remains incompletely understood and is 
confounded by factors such as timing of infection, variable treatments, and lack of 
access to brain tissue for evaluation (Fuller et al, 2004).  
 
The CNS is a viral reservoir for HIV-1 (Kolson, 2002). It has been well established that 
HIV-1 invades the CNS early in infection, and HIV has been found in the cerebrospinal 
fluid (CSF) at or near the time of seroconversion (Spector et al, 1993; Davis et al, 
1992; Epstein et al, 1987; Goudsmit et al, 1986; Ho et al, 1985; Resnick et al, 1985), 
as well as in the aborted foetuses of HIV infected mothers as early as fifteen weeks of 
gestation (Lyman et al, 1990). Once inside the CNS, viral replication occurs (Trujillo et 
al, 2007; Lipton and Gendelman, 1995; Davis et al, 1992). Although there is evidence 
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of primary HIV CNS injury, the virus does not directly infect neurons, and instead 
causes neuronal damage indirectly by infecting CD4+ lymphocytes, macrophages and 
other cells in the CNS (Ellis et al, 2009; Davis et al, 1992; Peluso et al, 1985). Mature 
viral particles feature a glycoprotein coat, or envelope, that allows them to identify, 
attach to, and enter these specific cell types (Ellis et al, 2009). The neurodegenerative 
process is unleashed by HIV itself, and once inside the CNS, HIV produces distinctive 
pathological changes (Trujillo et al, 2007; Masliah et al, 2000).  
 
There is little evidence for direct invasion of the CNS by cell-free viruses (Dunfee et 
al, 2009; Brouwers et al, 1995; Epstein and Gendelman, 1993). The primary immune 
cell targets of HIV infection within the CNS are microglia/macrophage cells derived 
from monocytes (Dunfee et al, 2009; Ellis et al, 2009; Zink et al, 2006; Williams et al, 
2001; Takahashi et al, 1996). Outside the CNS, HIV infects T-Lymphocytes (T-cells) 
and monocytes through virus interaction with the CD4+ receptor and co-receptors on 
the surface of these cells. HIV infection of T-cells results in cell lysis and death, yet 
HIV infection of monocytes, while productive, does not kill these cells (Ellis et al, 
2009). Actively infected monocytes in the blood traffic into the brain, whereupon they 
differentiate into a host of CNS cell types, most notably perivascular macrophages, 
perivascular microglia and resident microglia (Dunfee et al, 2009; Zink et al, 2006; 
Hickey and Williams, 1999). Once inside the brain, HIV particles and proteins can be 
localised within monocyte derived cells (Zink et al, 2006; Gabuzda et al, 1986; Wiley 
et al, 1986).  
 
Primary HIV infection of the CNS results in neural tissue damage (Ellis et al, 2009; 
Brouwers et al, 1995; Davis et al, 1992; Navia et al, 1986; Sharer et al, 1986; Wiley et 
al, 1986) and neuron dysfunction and death are the indirect consequences of HIV 
infection of microglia and macrophages (Zink et al, 2006; Epstein and Gendelman, 
1993; Pulliam et al, 1991). These infected cells secrete a battery of pro-inflammatory 
cytokines and other soluble factors including HIV proteins, which, over a sustained 
period of time, and in high concentrations, are toxic to nearby neurons (Ellis et al, 
2009; Zink et al, 2006). Pro-inflammatory cytokines, neurotoxic metabolites and viral 
gene products, which may cause damage to cells, are expressed in the brain 
parenchyma shortly after infection and throughout the course of infection (Banks et al, 
2006). Therefore neuronal cell damage may begin long before neurological symptoms 
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appear (Kolson, 2002). Infected or activated T-lymphocytes trafficking into the CNS 
may also contribute to the cytotoxic cascade (Ellis et al, 2009; Pulliam et al, 1991). 
HIV-1 infection of brain macrophages may limit the proliferation of nearby astrocytes 
(Tardieu et al, 1992). While HIV can infect astrocytes and endothelial cells (the cell 
types that form the blood brain barrier) to a limited extent, HIV does not productively 
infect neurons (Ellis et al, 2009; Takahashi et al, 1996; Wiley et al, 1986). Neurons 
and astrocytes can be destroyed by HIV-1 infected monocytic cells after adhesion of 
these cells to their membranes (Zink et al, 2006; Tardieu et al, 1992). 
 
The pathological hallmarks of HIV include the multi-nucleated giant cell, which is 
formed by fusion of infected cells of monocyte lineage (Zink et al, 2006; Price et al, 
1988; Navia et al, 1986). Other pathological features of CNS infection include 
perivascular infiltration of immune cells, white matter pallor, reactive astrocytosis 
(proliferation of astrocytes), microglial nodules, inflammation of the choroid plexus 
and various degrees of neuronal loss and damage to dendrites (Kaul et al, 2006; 
Masliah et al, 1997; Belman et al, 1988; Price et al, 1988; Wiley et al, 1986). 
 
In summary, the neuropathological findings in HIV-1 infected brain tissue can be 
explained by the following process: the HIV infected monocyte 
(macrophage/microglia) is the initiator of the pathological process (Zink et al, 2006; 
Sharer et al, 1986). There is cell-to-cell communication between the HIV infected 
monocytes and astrocytes, which establish an interaction that amplifies production of 
glial proliferatory and neurotoxic factors (Ellis et al, 2009; Banks et al, 2006; Brouwers 
et al, 1995; Wiley et al, 1986).  
 
The changes in the CNS are localised to sub-cortical structures, including deep white 
matter and basal ganglia, but may be found to some extent in the cortex (Ellis et al, 
2009; Rausch and Stover, 2001; Belman et al, 1988). A striking finding in the brains 
of infected children is the presence of mineralisations consisting of calcium salts and 
iron in the basal ganglia and cerebral white matter (Rausch and Stover, 2001; Belman 
et al, 1988). Vascular inflammation is found frequently in children, and is 
characterised by lesions consisting of cuffing and infiltration of lymphocytes, 
monocytes and multinucleated giant cells into the walls of the small and medium 
sized parenchymal vessels (Rausch and Stover, 2001). 
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2.5 Central Nervous System Involvement in HIV 
HIV encephalopathy and neurodevelopmental delay in HIV will be discussed together, 
as neurodevelopmental delay is a sign of encephalopathy in infants and young 
children.  
 
Neurological and developmental abnormalities are frequent complications of HIV 
infection in children, especially in younger perinatally affected children (Potterton et al, 
2009a; Potterton et al, 2009b; Baillieu and Potterton, 2008; Raskino et al, 1999; 
Nozyce et al, 1994; Belman, 1992). Development of encephalopathy is one of the 
most severe complications of HIV, but its frequency at different ages has long been 
disputed (Tardieu et al, 1992). HIV encephalopathy may occur very early in the course 
of HIV infection, and 88.1% of children who develop it do so within the first two years 
of life (Newell et al, 1998). This is more common in HIV infected children who present 
in early infancy and have rapid progression, as they may have been infected in utero 
during or before the last weeks of pregnancy, which is the period of fastest brain 
growth (Newell et al, 1998). In the absence of antiretroviral therapy and co-
trimoxazole prophylaxis, about 20% of infants vertically infected with HIV develop a 
rapidly progressing form of the disease, and progress to AIDS or die within the first 
year of life (European Collaborative Study, 1994).  These infants are more likely to be 
born to mothers with advanced disease or to be infected in utero than children whose 
disease course is slower (Ioannidis et al, 2004; Williams et al, 2001; Kuhn et al, 1999). 
Since the most rapid brain growth occurs in the first four years of life, children infected 
at an older age are less likely to suffer the major neuro-cognitive deficits seen among 
HIV infected infants and young children. In general, there is strong evidence of 
neuropsychological deficits associated with symptomatic paediatric HIV disease 
(Fowler, 1994).  
 
In children with vertically transmitted HIV, infection of the CNS may occur early in the 
disease process while the CNS is still immature. The pattern of disease therefore 
depends on the stage of brain development when CNS infection occurs (Belman, 
1990). Neurological and developmental signs are often markers of HIV-1 disease in 
infants and may precede other signs of disease progression (Bisiacchi et al, 2000; 
Belman, 1992).  CNS involvement is the first AIDS-defining symptom in as many as 
18% of paediatric patients (Tardieu et al, 2000; Gabuzda and Hirsch, 1986). There are 
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many risk factors for HIV encephalopathy, including the timing of infection, advanced 
stage of maternal disease at delivery, rapid disease progression with early immune 
suppression, high plasma viral load in infancy, as well as factors such as home 
environment and socioeconomic status (Robertson et al, 2008).  
 
The timing and severity of HIV-related paediatric central nervous system disorders 
vary greatly (Epstein et al, 1986). The majority of HIV infected children have 
developmental delay and deficits in cognitive function, language and motor skills, 
impaired brain growth and loss of developmental milestones, as well as cerebellar, 
sensory and primitive reflex dysfunction (Potterton et al, 2009b; Baillieu and Potterton, 
2008; Udgirkar et al, 2003; Blanchette et al, 2001; Pearson et al, 2000; Fragoso et al, 
1999; Drotar et al, 1997; Wolters et al, 1997; Belman et al, 1996; Pollack et al, 1996; 
Chase et al, 1995; Nozyce et al, 1994; Belman, 1992; Belman et al, 1988; Epstein et 
al, 1986; Belman et al, 1985; Ultmann et al, 1985). Studies have shown that these 
delays may begin as early as four months of age, continue into the preschool years, 
and manifest as either global or selective delays in neurodevelopment (Chase et al, 
2000; Wolters et al, 1995). 
 
HIV-1 infection of the developing CNS of infants and children is characterised by 
either a progressive or static loss of previously acquired developmental milestones 
with cognitive, behavioural and motor manifestations (Udgirkar et al, 2003; Belman et 
al, 1988; Epstein et al, 1986; Sharer et al, 1986; Belman et al, 1985). Significant 
delays in mental and motor development of HIV infected infants have been found over 
the first two years of life (Blanchette et al, 2001; Chase et al, 2000; Smith et al, 2000; 
Gay et al, 1995). Such impairments are likely to become more severe as the children 
are expected to reach more complex and integrative milestones (Blanchette et al, 
2001; Belman, 1992). Neural development does not cease after two years of age, and 
therefore further delays can be expected to evolve over time, which may be important 
indicators of disease progression (Blanchette et al, 2001; Chase et al, 2000; Gay et al, 
1995). 
2.5.1 CNS Abnormalities Associated with Encephalopathy 
A variety of CNS abnormalities are associated with HIV infection. These include 
cortical atrophy, calcification of the basal ganglia and frontal white matter, ventricular 
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enlargement, and white matter low attenuation (Wolters et al, 1995; DeCarli et al, 
1993). The most important finding from a developmental perspective is that of 
myelinopathy. During infancy the brain still experiences a period of rapid myelination, 
which coincides with the attainment of significant motor, cognitive, and behavioural 
milestones. In particular, myelination of the frontal and parietal regions of the brain 
continues throughout childhood and even into early adulthood. These regions are 
responsible for higher cortical functions, such as language, sequence and the 
integration of multiple stimuli. Destruction of the myelination processes of these areas 
by HIV will cause significant delays in higher functioning. Since many of the more 
advanced developmental skills do not develop until after two years of age, delays can 
be expected in areas such as visual–motor processing, verbal memory, processing 
speed, and sequential processing (Blanchette et al, 2001; Gay et al, 1995).  
2.5.2 The Pathophysiology of Encephalopathy 
An initial pathophysiological hypothesis is that early encephalopathy may be the 
consequence of pre-natal HIV-1 infection of the brain, inducing a reduction in brain 
cell proliferation during late pregnancy, leading to decreases in intrauterine brain 
growth and parenchymal atrophy (Tardieu et al, 2000; Tornatore et al, 1994). 
Neurodevelopmental impairment may be a marker of overall host susceptibility, as 
some infants may be more susceptible to HIV-related CNS disease, resulting in faster 
progression and greater mortality rate (Ellis et al, 2009). Infected monocytes with the 
ability to cross the blood-brain-barrier and adhere to neural cells may play a major role 
in the induction of HIV-1 related encephalopathy (Tardieu et al, 1992). An 
accumulation of the HIV-1 nef protein has been described in astrocytes from brains of 
children with early encephalopathy (Epstein and Gendelman, 1993), and the presence 
of viral protein in developing astrocytes may also limit their proliferation during late 
pregnancy.  
2.5.3 Definition and Presentation of Encephalopathy 
Encephalopathy was first described by A Belman in 1988. Since her description and 
definition, it has been widely studied, and more current definitions are now available. 
These include “The failure to attain or loss of developmental milestones or loss of 
intellectual ability, verified by standard developmental scales or neurophysiological 
tests” (Brady et al, 1995).  
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The WHO (2007) defines HIV encephalopathy as at least one of the following 
progressing over at least two months in the absence of another illness:  
1) Gross discrepancy between the actual and developmental age; failure to attain 
or loss of developmental milestones; loss of intellectual ability; or 
2) Progressive impaired brain growth demonstrated by stagnation of head    
circumference or 
3) Acquired symmetric motor deficit accompanied by two or more of the following: 
paresis, pathological reflexes, ataxia, gait disturbances 
Along with the above, the WHO (2007) recommends that brain computed tomography 
(CT) scan or magnetic resonance imaging (MRI) should be performed to exclude 
other causes.  
 
Tindyebwa et al (2004), have developed a simplified definition of encephalopathy to 
cater for resource-poor settings, where diagnosis is dependent on the presence of two 
of the following for at least two months:  
1) Any child who is HIV positive;  
2) Lack of growth in head circumference assessed by serial measurements at least     
three months apart;  
3) Neurodevelopmental milestones such as loss of skills (particularly motor) and 
lack of acquisition of skills;  
4) Diffuse symmetrical hyperreflexia 
Along with the above, Tindyebwa et al (2004) recommended lumbar puncture to 
exclude CNS infections.  
 
The WHO (2007) and Tindyebwa et al’s (2004) definitions are similar, but in resource-
poor settings, a few problems may arise with the WHO (2007) definition, namely, to 
detect discrepancies between actual and developmental age requires standardised 
assessment tools which may not be available, loss of intellectual ability requires 
cognitive testing, which is not readily available, and requires equipment. Brain CT or 
MRI scans are expensive, and are not available in many rural hospitals or clinic 
settings. Several patterns of encephalopathy have been recognised: a) A subacute 
progressive course (the most severe), b) plateau (followed by deterioration or 
improvement) or c) static/stable course (Belman, 1994). 
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2.5.3.1 Subacute Progressive Encephalopathy 
Subacute progressive encephalopathy, is characterised by a gradual and insidious 
loss of previously obtained cognitive and motor milestones, although children may 
remain relatively stable for extended time periods before a new loss is appreciated 
(Simpson and Berger, 1996; Armstrong et al, 1993).  
 
2.5.3.2 Plateau Encephalopathy 
Plateau encephalopathy refers to those children who do not progress in their 
development, but who may not show deterioration for lengthy periods of time. 
Nevertheless, these children eventually deteriorate and lose previously acquired skills. 
As a result, they experience severe cognitive and motor impairments, and this unique 
course has been associated with the presence of HIV in, or clearance from cortical 
and subcortical regions of the brain (Armstrong et al, 1993).  
 
2.5.3.3 Static Encephalopathy 
The third major type of encephalopathy that has been identified in children vertically 
infected with HIV has been termed static encephalopathy. This involves no 
deterioration of attained milestones, but is characterised by significantly delayed 
development; that is, acquisition of new skills at a much slower rate than would be 
anticipated based on the child’s age. These children may display cognitive skills 
ranging from low-average to markedly impaired, depending on their individual rates of 
new development (Brouwers et al, 1995; Armstrong et al, 1993). In children with a 
static encephalopathic course, poor maternal nutrition, disturbed home environment, 
repeated periods of illness and hospital admissions all contribute to developmental 
delay and motor deficits (Ultmann et al, 1985).  
2.5.4 Predisposing Factors to Encephalopathy 
Risk factors for paediatric CNS involvement include the timing of infection, advanced 
maternal disease at delivery, rapid progression with early advanced immune 
suppression, high plasma viral load in infancy, and factors such as home environment 
and socioeconomic status (Robertson et al, 2008). In the absence of HAART, children 
with fast progression and more aggressive disease are likely to die before reaching 
the age of two years (Newell et al, 2004; Taha et al, 2000).  
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Those children with AIDS-defining illnesses in the first two years of life display very 
severe neurological and neurodevelopmental abnormalities (Chase et al, 2000; 
Pearson et al, 2000; Belman et al, 1996; Nozyce et al, 1994). The presence of 
hepatomegaly, splenomegaly, or lymphadenopathy in the first three months of life 
increases the likelihood of HIV encephalopathy and the risk of death 28-fold (Laufer et 
al, 2000).  
 
2.5.4.1 Immunological Factors 
A lower CD4 count and higher viral ribonucleic acid (RNA) load are associated with 
increased severity of disability, growth failure and slower attainment in milestones in 
infants and children with vertically transmitted HIV (Pearson et al, 2000; Belman et al, 
1996; Pollack et al, 1996; Chase et al, 1995).  
 
The risk of encephalopathy is higher among HIV infected children born to mothers 
with more advanced disease as measured by CD4 count and viral load at the time of 
delivery (Blanche et al, 1990). Children with more advanced degrees of immune 
suppression early in life and those with a high-plasma viral load in infancy also have 
higher rates of encephalopathy (Nozyce et al, 1994). Other virological factors 
associated with HIV-associated CNS disease are a detectable p24 antigen in mothers 
and infants (Tardieu et al, 2000), elevated plasma HIV RNA loads in the first year of 
life (Cooper et al, 2004), and, for later-onset encephalopathy, high HIV RNA loads in 
cerebrospinal fluid (CSF) (Tardieu et al, 2000; Sei et al, 1995). In general, higher CD4 
cell counts, lower CD8+ cell counts, and higher CD4:CD8 ratios have been associated 
with better neurobehavioural functioning (Marcotte et al, 2003). Tardieu et al (2000) 
found that encephalopathy in the first year of life was associated with normal or high 
levels of CD4+ T-lymphocytes in contrast to later-onset encephalopathy, in which 
CD4+ T-lymphocytes were deficient. HIV infected infants with low percentages of 
activated CD8+ T-cells at ages one and two months had a better neurodevelopmental 
prognosis during the first three years of life than infants with high percentages of 
activated CD8+ cells, and this association was independent of several variables that 
predict outcome of HIV infection, as well as overall clinical prognosis. The implication 
of these findings is that the activation state of CD8+ cells is important for the effects of 
HIV infection on CNS development in infants. Efforts to influence this activation may 
have preventive or therapeutic effects (Mekmullica et al, 2009). 
The Development of a Screening Tool to Evaluate Infants who are HIV Positive  
 20 
2.5.4.2 Environmental Risk Factors 
Many social and clinical factors may also affect functional status and quality of life for 
HIV infected children. HIV infected children are exposed to and live with altered family 
dynamics, in foster homes or homes with ill parents who may also have poor access 
to care, or in child-headed households. The medications used to slow disease 
progression have many potential toxicities and side effects. In addition, both poor 
nutritional status and growth are common (Arpadi et al, 2000; Mckinney et al, 1998). 
 
The cumulative effect of recurrent, frequent and severe episodes of opportunistic 
infections is also known to contribute to delayed motor development amongst HIV 
infected infants (Drotar et al, 1997). The motor skills of infants living with HIV are often 
delayed due to the child’s decreased ability to interact with his/her environments 
during periods of illness. Increased hospital admissions and length of hospital stay 
may lead to developmental delay in these children (Cooper et al, 2004; Fiser et al, 
2000). The most common reasons for hospital admissions in children with HIV are 
pneumonia and gastroenteritis (Meyers et al, 2000).  
 
Two hundred million children in developing countries fail to reach their potential in 
cognitive development because of poverty, poor health and nutrition, and deficient 
care (Grantham-McGregor et al, 2007). This has far reaching implications for 
education, and potential earning power, and therefore may result in transmission of 
poverty to upcoming generations in subsequent years.  
 
2.5.4.3 Timing of Infection 
Between 20 and 40% of HIV-positive women transmit infection to their babies in utero 
and intrapartum periods in the absence of antiretroviral therapy, as well as postpartum 
via breast-feeding (Peckham and Gibb, 1995).  
 
Vertically infected children are more likely to experience CNS disease, and children 
with intra-uterine infection are more likely than those with peri- or post-partum vertical 
infection to develop early onset, rapidly progressive and severe encephalopathy 
(Smith et al, 2000; Wolters et al, 1995). A positive culture result within the first 48 
hours of life (indicating in-utero infection) is associated with a more rapid decline in 
neurobehavioural function, compared with perinatally infected children (Smith et al, 
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2000). McGrath et al (2006a) found that children who tested positive between birth 
and 21 days of life had the poorest development over the first 18 months of life.  
 
The impact of the timing of HIV-1 infection on neurodevelopment is related to the 
stage of brain development (Davis et al, 1992). Early interference with myelination 
could affect projection fibres, as well as association and commissural connections 
resulting in global patterns of deficits with motor abnormalities. In contrast, later 
interference would largely affect the commissural connections and the connections 
with poles of the cerebral lobes affecting cognitive functions (Gendelman et al, 1994). 
Another possible mechanism of neurodevelopmental injury is HIV-enhanced 
apoptosis.  
2.5.5 Encephalopathy in sub-Saharan Africa 
It may be difficult to apply results from studies in developed countries to the 
populations in resource-poor settings, where there is also a high prevalence of 
malnutrition, malaria, opportunistic infections, as well as different child-rearing 
environments and a higher incidence of poverty.  
 
Studies on neurodevelopment in HIV infected children in Africa have revealed that a 
large proportion of children have moderate to severe delay in mental, motor, and 
language development (Ferguson and Jelsma, 2009; Potterton et al, 2009b; Van Rie 
et al, 2009; Baillieu and Potterton, 2008; McGrath et al, 2006a; Drotar et al, 1997; 
Msellati et al, 1993). Young HIV infected children also demonstrate more frequent and 
severe delays in mental and motor development compared with older HIV infected 
children (Van Rie et al, 2009).  It has also been shown that motor function is more 
severely affected than other components of neurodevelopment (Ferguson and 
Jelsma, 2009; Baillieu and Potterton, 2008; McGrath et al 2006a; Tindyebwa et al, 
2004; Drotar et al, 1997). Contrasting results were found by Van Rie et al (2008) on a 
population of children in Kinshasa, in the Democratic Republic of the Congo, where 
mental and not motor delay was most severely affected by HIV infection. These 
children were aged 18-72 months, which indicates that cognitive function may be 
more severely impaired in older children. The high prevalence of delay in cognitive 
development may be due to differences in child-rearing practices and lack of exposure 
to educational toys. This was supported by the high frequency of severe delay in 
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mental development among healthy control children in their study. Van Rie et al 
(2008) found in the same study that motor development improved after 
commencement of HAART, most likely due to the positive effects on muscle strength.  
2.5.6 Neurodevelopment in School-age Children 
From the beginning of the epidemic, there have been consistent findings of significant 
neurological, developmental, cognitive, and language deficits in HIV infected infants 
and younger children (Coplan et al, 1998; Belman et al, 1996). Unfortunately, less is 
known about these children as they age. In general, the severity of neurological and 
neuropsychological deficit increases with the severity of HIV-related illness (Jeremy et 
al, 2005). 
 
With the advent of antiretroviral treatment, a large number of HIV infected children are 
reaching adolescence (Brackis-Cott et al, 2009). Studies indicate that school-aged 
perinatally infected children present with significant learning problems, which affect 
their ability to perform in school, achieve appropriate developmental milestones, and 
function independently (Martin et al, 2006). Advances in the medical treatment of 
children with HIV not only have prolonged survival, but have also improved quality of 
life (Smith et al, 2006). Despite these advances, many children experience both the 
direct and indirect effects of HIV infection, which affect their ability to achieve at a 
school-level. Brackis-Cott et al (2009) found that a large proportion of HIV positive 
children were held back a grade in school, and eventually need to be placed in special 
education classes. The high rate of developmental delay in HIV infected children as 
compared with healthy controls underscores the need for screening for and prevention 
of neurodevelopmental delay at an early age and calls for access to early 
interventions, nutritional and care programs (Van Rie et al, 2007; Jin et al, 2007; 
Bridge et al, 2006; Powell et al, 2004; Eickmann et al, 2003).  
 
Children with HIV infection who experienced an early AIDS-defining illness exhibit 
significant impairment in their overall cognitive and motor ability, relative to their HIV 
infected, but relatively healthy counterparts and non-infected peers (Abubakar et al, 
2008a; Nozyce et al, 1994). Findings reported by Tardieu et al, (1995) suggest that 
other health markers, such as circulating CD4+ lymphocyte counts during the first year 
of life are predictive of cognitive functioning among vertically infected school-aged 
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children. Children who experience an AIDS-defining illness early in life score 
significantly lower on verbal, perceptual performance, quantitative abilities, and 
memory subtests than do either infected children with no AIDS-defining illness or non-
infected children (Abubaker et al, 2008a).  
 
The prevention of early AIDS-defining illnesses among young children with HIV 
infection is crucial for preventing poor neurodevelopmental outcomes (Abubakar et al, 
2008a). With early, appropriate antiretroviral therapy, not only does the child stand a 
better chance of survival, but may also avoid significant developmental impairment 
due to decreased chances of an early AIDS defining illness. In the meantime, HIV 
infected children of school-going age may need additional educational and 
psychosocial resources in the classroom and regular re-evaluation of their progress 
and learning needs (Smith et al, 2006). 
2.6 Socioeconomic Effects on Neurodevelopment  
Poverty is associated with inadequate food, poor sanitation and poor hygiene which 
lead to increased infections and stunting in children. Poverty is also associated with 
poor maternal education, increased maternal stress and depression, and inadequate 
stimulation in the home (Bradley and Corwyn, 2002). All these factors detrimentally 
affect child development (Grantham-McGregor et al, 2007; Olness, 2003). Risk factors 
related to poverty frequently occur together, and the increased number of risk factors 
increases the developmental deficit (Gorman and Pollitt, 1996). Many children in 
developing countries are exposed to multiple risk factors for poor development 
including poverty, poor health and nutrition. A conservative estimate is that more than 
200 million children under five years of age in developing countries are not developing 
to their full potential due to poverty and the associated health, nutrition and social 
factors (Grantham-McGregor et al, 2007; Walker et al, 2007). Walker et al (2007) have 
identified four key risk factors affecting development in children in resource-poor 
settings which warrant urgent intervention: stunting, inadequate cognitive stimulation, 
iodine deficiency, and iron deficiency anaemia.  
 
Anaemia is a common condition in HIV infected children and contributes significantly 
to morbidity. The prevalence in HIV infected infants is determined to a large extent by 
the prevalence of other conditions that cause anaemia, such as malaria and 
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helminthic infections (Tindyebwa et al, 2004). The prevalence of malnutrition,  
especially micronutrient malnutrition, also contributes significantly to the prevalence of 
anaemia. HIV infected children have an equal prevalence of anaemia compared with 
uninfected children but have a higher case fatality rate (Tindyebwa et al, 2004). Other 
developmental risk factors include malaria, intrauterine growth restriction, maternal 
depression, exposure to violence, and exposure to heavy metals (Walker et al, 2007). 
Infants born to HIV infected women are more likely to suffer from congenital malaria 
than children born to uninfected women. Likewise, an increased frequency of malaria 
has been noted in HIV infected children, with associated higher levels of parasitaemia 
than in other children (Tindyebwa et al, 2004). Additionally HIV infected children are 
more likely to be anaemic during an episode of malaria compared with uninfected 
children (Tindyebwa et al, 2004). Children living in resource-poor settings in South 
Africa are at risk for all of the above-mentioned issues. Those children infected with 
HIV are at added risk due to immune factors, and the social factors surrounding the 
condition.  
 
Developmental research has clearly established that both socioeconomic status and 
aspects of the home environment account for a significant proportion of the variance 
in cognitive functioning of healthy and preterm children (Brooks-Gunn et al, 1996; 
Bradley et al, 1989). Aspects of a child’s home environment and their associations 
with CNS factors may explain some of the variability in the cognitive functioning of 
children with HIV-1 infection. That is, despite CNS pathology, protective mechanisms 
may promote cognitive development in children with HIV-1 infection or, conversely, 
risk factors may result in greater vulnerability to cognitive dysfunction (Coscia et al, 
2001). As the child matures, the effect of poverty begins to snowball and there may be 
a decline in mental, motor and social/emotional development. Higher family income is 
associated with a more cognitively stimulating home environment, less maternal 
emotional stress and more positive parenting practices, which in turn are associated 
with higher cognitive outcomes (Linver and Brooks-Gunn, 2002). The length of time 
that a child is exposed to poverty may impact on the degree of developmental 
impairment (Duncan et al, 1994),  The timing of exposure to poverty is important, with 
children born into a poor household being at greater risk than those exposed to 
poverty at a later stage of their childhood (Burgess et al, 2004).  
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Parents are central to child-care (Schor et al, 2003). The health and well-being of 
children are linked to their parents’ physical, emotional and social health as well as 
their social circumstances and child rearing practices. Environmental stress is a 
known ‘neurotoxin’. Children from homes with higher numbers of environmental risk 
factors have been shown to achieve lower scores on measures of cognitive 
performance (Hochhauser et al, 2008; Gutman et al, 2003; Bennett et al, 2002). A 
family which is preoccupied with life crises is less able to provide the stimulating and 
varied experiences which foster cognitive growth (McLoyd, 1998). The lack of items 
such as toys geared to teaching about shapes and colours has been shown to be 
associated with reduced Intelligence quotient (IQ) scores in children (Bradley et al, 
1989). Decreases in emotional support and in cognitive stimulation have been shown 
to account for 33-50% of the decreases in academic performances in children under 
conditions of chronic poverty (Korenman et al, 1995). Socioeconomic disadvantage 
has been shown to have a negative educational effect on language and reading skills, 
as well as on the motor skills of children (McPhillips and Jordan-Black, 2007). Poor 
development leads to poor school achievement, and children who do poorly in school 
are likely to transfer poverty to the next generation.  This loss of human potential is 
associated with more than a 20% deficit in adult income and has implications for 
national development (Grantham-McGregor et al, 2007).  
 
Research from developed countries has identified three aspects of parenting that are 
consistently related to young children’s cognitive and social-emotional competence: 
cognitive stimulation, caregiver sensitivity and responsiveness to the child, and 
caregiver affect (emotional warmth or rejection of child) (Walker et al, 2007). These 
child-rearing dimensions affect children from developed and developing countries in 
similar ways (Bradley and Corwyn, 2005). All these aspects of parenting are likely to 
be affected in the context of HIV, due to maternal stress and depression (Potterton et 
al, 2007).  
 
Effective interventions are available that may reduce the developmental loss currently 
estimated to affect more than 200 million children under five years of age in 
developing countries (Engle et al, 2007). The most effective interventions are 
comprehensive programmes for younger and disadvantaged children and families that 
are of adequate duration, intensity, and quality, and are integrated with health and 
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nutrition services. Providing services directly to children and including an active 
parenting and skill-building component is a more effective strategy than providing 
information alone (Engle et al, 2007). This may be difficult to achieve in the South 
African context due to lack of resources, understaffing, and high patient case loads, 
especially in the HIV context. Interventions may need to be preventative in terms of 
providing information, adequate nutrition, and parental support.  
2.7 Paediatric HIV and Growth 
In the formative years of development, malnourishment affects all dimensions of 
health and development (Spurr, 1983). For children growing up in poverty, physical 
and mental development are intertwined. Measures such as weight, height, and head 
circumference are predictors of cognitive abilities, whilst morbidity is negatively 
associated with cognitive test scores (Bhargava, 1998).  
 
HIV infected children in developing countries show a decline in length and weight 
within the first months of life, and eventually manifest a picture of chronic malnutrition 
(Tindyebwa et al, 2004). This may result from HIV infection itself, underlying disease 
such as tuberculosis, inadequate macro/micronutrient intake or a combination of any, 
or all of the above. At least 90% of HIV infected children experience wasting and 
nutritional depletions during the course of their illness. A high viral load in children is 
associated with increased risk of failure to thrive, while infections such as pneumonia, 
diarrhoea, and tuberculosis further exacerbate growth failure (Tindyebwa et al, 2004). 
 
In 2006, the World Health Organisation (WHO 2006a) released two sets of child 
growth standards to replace the National Centre for Health Statistics References 
(Dibley et al, 1987) as a tool for growth monitoring, nutrition screening, and 
surveillance, as a clinical tool to assist with the diagnosis of malnutrition, and as a tool 
for nutrition research (Van den Broek et al, 2009; WHO, 2006a). These new standards 
were developed in accordance with the idea that children born in any region of the 
world and given an optimum start in life all have the potential to grow and develop to 
within the same range of height- and weight-for-age. The new WHO child growth 
standards, which will be used worldwide, provide a common basis for the analysis of 
growth data (WHO, 2006a). 
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Moderate malnutrition is defined as a weight-for-age between -3 and -2 standard 
deviations (SD) below the median of the WHO child growth standards (WHO, 2006a), 
similarly, moderate wasting and stunting are defined as weight-for-height and height-
for-age respectively, between -3 and -2 SD (WHO, 2006a). Wasting can have a very 
rapid onset, but can also recover very quickly under favourable circumstances (WHO, 
2006a). Stunting is an indication of slow skeletal growth and is often associated with 
poor socioeconomic conditions, chronic or repeated infections as well as inadequate 
nutrition. Stunting takes a long time to correct once adverse circumstances have been 
corrected as skeletal growth is a slower process than growth in body mass (WHO, 
2006a). Children with growth failure may have decreased weight-for-height (wasting) 
and decreased height-for-age (stunting). Malnutrition initially causes wasting, while 
stunting is associated with prolonged malnutrition (Chantry and Moye, 2005).  
 
Severe acute malnutrition (severe wasting and/or oedema) or severe stunting is 
defined as weight-for-age less than -3 SD (WHO, 2006a). Mid-upper-arm- 
circumference-for-age scores below -2 SD are associated with wasting which is an 
indication of acute malnutrition and severe growth disturbance (Abubakar et al, 
2008b).  
 
Childhood malnutrition is high among HIV infected children and the magnitude is even 
higher in developing countries where it is already endemic. Malnutrition may occur as 
a result of reduced calorie intake due to poverty or poor feeding practices, or may be 
due to the effect of the HIV on the gastrointestinal system which results in 
malabsorption (Winter and Miller, 1994). HIV infected children are at increased risk of 
malnutrition for many reasons, including: decreased food intake because of anorexia 
associated with illness, mouth ulcers, oral thrush, increased nutrient loss resulting 
from malabsorption, diarrhoea or HIV enteropathy (after deterioration of immune 
function from malnutrition or HIV, enteric pathogens may injure the intestinal mucosa 
causing malabsorption) (Bachou et al, 2006; Tindyebwa et al, 2004). Prolonged 
malabsorption leads to malnutrition which causes immunodeficiency, more rapid 
progression to AIDS, and increased infection by opportunistic pathogens (Winter and 
Miller, 1994). Certain antiretroviral drugs may contribute to malnutrition by causing 
diarrhoea and vomiting (Bachou et al, 2006). Increased metabolic rate because of 
infections, opportunistic infections, and the HIV infection itself, release cytokines 
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(tumour necrosis factor [TNF] alpha and cachetin) into plasma or tissues and may 
mediate weight loss in HIV infected children (Tindyebwa et al, 2004). The effect of 
malnutrition is compounded by the high burden and recurring infections and 
infestations in HIV infected children. In addition, HIV-positive mothers have higher 
rates of low-birth-weight babies and premature birth, which are risk factors for 
malnutrition and failure to thrive (Tindyebwa et al, 2004).  
 
When formally assessed, growth hormone (GH) levels in HIV infected children, even 
in those with growth failure, are usually normal (Lepage et al, 1991; Laue et al, 1990). 
Potential causes of altered growth in HIV infected infants may be due to decreased 
peripheral sensitivity to GH, decreased levels of insulin-like growth factors (Matarazzo 
et al, 1994), or the release of cytokines secondary to HIV-1 infection which may then 
lead to ineffective action of growth hormone (Pollack et al, 1996). Cytokines are 
especially attractive as mediators of decreased growth because of their rapid 
appearance during active HIV infection. Interleuken-6 (IL-6) and macrophage 
inflammatory protein-1a (MIP-1a) have both been shown to be elevated during periods 
of rapid viral replication and also to have effects on bone activity (Cocchi et al, 1995; 
Fuller et al, 1995; Udagawa et al, 1995).  
 
Regular monitoring of weight, height and head circumference is recommended in all 
HIV infected children (Chantry and Moye, 2005; Nachman et al, 2002; Coovadia and 
Meyers et al, 2001; Bobat et al, 1998). Chronic malnutrition has been associated with 
decreased intellectual capacity, and therefore decreased earning capacity in later life, 
which perpetuates the cycle of poverty (Bridge et al, 2006). In a child who is not 
meeting his growth milestones, vitamin and micronutrient deficiencies should be 
considered as well (Mintz, 1999). 
 
A number of studies have investigated growth deficiencies in children infected with 
HIV. Nathan et al (2003) reported stunting, but not wasting in a sample of 
institutionalised HIV positive African children. Spira et al (1999) found that failure to 
thrive in the first few months of life was associated with increased risk of death or 
progression to AIDS in HIV infected infants in Rwanda. Bobat et al (2001) investigated 
the growth of HIV infected children born in Durban, South Africa. They found that HIV 
positive infants exhibited early and sustained low mean length-for-age and weight-for-
The Development of a Screening Tool to Evaluate Infants who are HIV Positive  
 29 
age z-scores but weight-for-length was within normal limits. The authors of this study 
concluded that HIV infected children have early and sustained stunting, but not 
wasting, although children with rapidly progressing disease are stunted and wasted 
and therefore have a very poor prognosis. In the European Collaborative Study 
(2003), growth faltering in terms of both weight and height was associated with 
vertically acquired HIV infection at least up to 10 years of age, extending previous 
findings from the European Collaborative Study (1995) and others (Arpadi, 2000) 
which were limited to early childhood. Differences in growth patterns between infected 
and exposed but uninfected children not only persisted but also significantly increased 
with age (Arpadi, 2000).  
2.7.1 Growth and Neurodevelopment 
There is an association between growth and neurodevelopmental delay in HIV 
positive children especially in children with advanced stages of the disease (Pollack et 
al, 1996). Infants with the most severe growth delay have significant cognitive and 
motor delay even if this only becomes apparent later (Pollack et al, 1996). Wiznia et al 
(1996) report a strong correlation between poor weight-for-age and decreased 
cognitive function and a low CD4 count. Similarly, Potterton et al (2009b) showed that 
poor weight-for-age was a predictor for both poor motor and cognitive function. 
Missmer et al (2000) found that a decreased height-for-age z-score is a strong 
predictor of decreased functional status, suggesting that height may be used as an 
indicator of disease severity. The delays in linear growth and neurodevelopment occur 
at different times suggesting that they represent two separate effects of high HIV viral 
burden or load (Pollack et al, 1996).  
 
Stunting in early childhood has been associated with diminished adult human capital, 
including poorer cognitive development, behavioral problems, and lower schooling 
attainment, even after controlling for confounding factors such as parental schooling 
and socioeconomic status (Victora et al, 2008). The critical period for the effect of 
undernutrition on cognitive development is early in infancy (Emond et al, 2007). It has 
been found that weight gain from birth to two years had the strongest relationship with 
schooling outcomes followed by birthweight; weight gain from 24 to 48 months has a 
weak or no relationship to schooling outcomes. The magnitudes of the relationships 
are of economic and public health importance (Martorell et al, 2010). Head-
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circumference-for-age is sensitive to the effects of chronic undernutrition, but is more 
closely related to genetic factors and may be influenced by perinatal insults such as 
birth asphyxia (Silva et al, 2005; Gale et al, 2004). One of the primary targets of HIV-1 
infection is brain tissue, which also commonly results in reduced brain growth 
(Macmillan et al, 2001). Acquired microcephally has been noted by a number of 
authors and is usually due to impaired brain growth and cerebral atrophy secondary to 
encephalopathy (Mitchell, 2001; Macmillan et al, 2001; Mintz, 1999). Cortical atrophy 
is associated with disease progression and neurodevelopmental delay (Llorente et al, 
2003; Pearson et al, 2000). Overall, the size of the head predicts the size of the brain, 
which is associated with Intelligence Quotient (IQ) – i.e. a bigger brain denotes better 
IQ (Wickett et al, 2000). The brain doubles its birth weight in the first year and triples it 
by age six (Gale et al, 2003). Head circumference at this age is about 93% of its final 
size, so measurements of head circumference made in adults are largely a reflection 
of brain growth during the first few years of postnatal life. The results of this study 
suggest that brain development during infancy and early childhood is more important 
than foetal growth in determining how well cognitive abilities are preserved in old age. 
Factors that promote brain growth during this period may help to protect against 
cognitive decline (Gale et al, 2003). Head growth in the first nine months of life and 
head growth between nine months and nine years of age are also related to cognitive 
function, regardless of head size at the beginning of these periods. Postnatal head 
growth is significantly greater in children whose mothers are educated to degree level 
or of higher socio-economic status (Gale et al, 2004).  
2.8 The Link between Socioeconomic Status and Growth 
One of the links between the effect of environmental risk and poor developmental 
outcome is sub-optimal physical growth (Bradley and Corwyn, 2002). The most 
vulnerable group of children with the highest prevalence of growth restriction are those 
under five years of age (WHO, 1995). Growth restriction in the early years of life 
increases the risk of mortality (Black et al, 2003), morbidity (Nannan et al, 2007), and 
leads to developmental delay and impairments (Siegel et al, 2005). Restricted social 
and economic resources have been associated with poor growth (Walker et al, 2000) 
and with poor developmental outcome (Bradley and Corwyn, 2002; 1996). Abubakar 
et al (2008b), and Walka and Pollitt (2000) report a significant relationship between 
socioeconomic status (SES) and height-for-age, and that the attainment of motor skills 
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is related to the child’s anthropometric measurments. The psychomotor performance 
of children experiencing poor physical growth ranges from moderate delay for 
stunting, being underweight and small mid-upper-arm-circumference-for-age, to 
severe delay for those with poor head growth (Abubakar et al, 2008b). SES therefore 
has a significant effect on psychomotor development through its influence on height-
for-age, weight-for-age and mid-upper-arm-circumference-for-age. This observed 
relationship can be interpreted by Bronfenbrenner’s (1977) framework. This states that 
a child grows up in layered environments, ranging from proximal factors (in this case 
anthropometric status) to distal factors (in this case SES). Distal factors define the 
context for proximal factors (SES impacts on anthropometric status); and proximal 
factors have more impact on developmental outcome than distal factors 
(anthropometric status has stronger association with psychomotor development 
compared with SES). These findings by Abubakar et al (2008b) suggest that the 
relationship between SES and psychomotor outcome is mediated by anthropometrics.  
 
There is no significant relationship between head-circumference-for-age and SES 
which may be explained by the large contribution of genetic factors to variance in 
head size. The association may mean that head circumference is the anthropometric 
measure that is less susceptible to influences of social and economic factors 
(Abubakar et al, 2008b). These findings therefore highlight the importance of 
monitoring growth in an infant population due to the impact of poor growth on 
psychomotor development (Abubakar et al, 2008b). Problems with psychomotor 
development in the early years may negatively impact on other aspects of child 
development since motor skills lead to developments in other areas such as social 
and communication skills (Giagazoglou et al, 2005). This is supported by earlier 
studies which indicate that the effect of undernutrition on locomotor development is 
the main pathway to other developmental deficits (Gardner et al, 1999).  
 
Research indicates that the negative effects of poor growth can be reversed or at least 
minimised through early intervention (Gardner et al, 2005; Powell et al, 2004; Pollitt et 
al, 1997). Abubakar et al (2008b) suggest that in resource-limited contexts, 
interventions aimed at facilitating physical growth in children with poor growth 
outcomes will potentially have a significant effect on psychomotor development. 
Interventions among infants in resource-limited settings should address both physical 
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health and motor as well as psychosocial functioning (Engle et al, 2007; Walker et al, 
2005; Pelto et al, 1999).  
2.9 Highly Active Antiretroviral Therapy (HAART)  
Guidelines for the treatment of HIV infection in children recommend the use of highly 
active antiretroviral therapy (HAART). This should include two nucleoside reverse-
transcriptase inhibitors (NRTIs) and either a protease inhibitor (PI) or a non-
nucleoside reverse transcriptase inhibitor (NNRTI) (Working Group on Antiretroviral 
Therapy, 2009; DOH, 2008, WHO, 2006b, Sharland et al, 2002). In HIV infected 
adults, combination therapy which includes a PI is associated with suppression of viral 
load, increased CD4 + T-lymphocyte counts, and lower mortality (Li et al, 1998). 
Several studies have demonstrated sustained increases in CD4+ T-cells in adults, 
even when virological failure has occurred after PI therapy (Deeks et al, 2000). 
Studies in HIV infected children also have found evidence of improvement in 
immunological status following therapy which included a PI (Wiznia et al, 2000).  The 
proportion of children with virologic suppression to undetectable levels is generally 
smaller than the corresponding proportion of adults (Nadal et al, 2000; Nachman et al, 
2000; Wiznia et al, 2000). This is due to the fact that the immune system is developing 
during childhood, and therefore the effects of treatment may differ between children 
and adults and between children of different ages.  
2.9.1 Initiation Criteria for Antiretroviral Therapy  
Eligibility for antiretroviral therapy (ART) is currently assessed on either clinical or 
immunological grounds. Treatment is started either when an individual’s clinical 
condition deteriorates to moderate or severe disease (WHO category three or four) or 
when their immunological levels drop to a level indicating severe immune deficiency 
(WHO, 2006c). CD4 percentage is the most appropriate immunological criterion to 
screen HIV- infected children from birth to 12 years for ART eligibility (WHO, 2006b), 
as it identifies the highest proportion of children in the early stages of 
immunosuppression. On the other hand, CD4 count and Total Lymphocyte Count 
(TLC) may be less appropriate as they tend to fluctuate more (WHO, 2006b). Where 
access to CD4 percentage assays is not available, CD4 percentage obtained with a 
simple formula based on total white blood count, lymphocyte percentage and total 
CD4 count may improve the identification of children in need of treatment in resource 
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poor settings (Callens et al, 2008).  
 
In developed countries the decision of when to initiate ART in children is based on 
clinical symptoms and assessment of CD4+ T-cell count or percent and HIV RNA viral 
load (Sharland et al, 2002). However, in many resource-limited settings these 
laboratory tests are not available. Therefore there is increasing interest in using 
alternative markers, such as total lymphocyte count (TLC) (Little et al, 2007). The 
WHO clinical staging system has also been widely used to initiate ARV’s in resource-
limited countries, particularly in the African region, and has proved useful in all levels 
of care (WHO, 2007). An evaluation of the Zambian guidelines revealed 20-fold higher 
mortality rates in children classified as being in WHO clinical stage four compared with 
those children in stages one and two, which confirms the association of clinical stage 
with prognosis (Walker et al, 2006). The WHO recommendations for assessment of 
stage three and four disease may require confirmatory diagnosis (WHO, 2005). One 
of the indicators of clinical stage four disease is HIV encephalopathy, which is a 
condition where clinical diagnosis can be made on the basis of signs or simple 
investigations. This indicates that a simple developmental assessment tool may be 
sufficient to diagnose this condition, and where laboratory testing is not available, 
ARV’s could be started on this basis. The criteria for staging (WHO, 2005) are shown 
in Table 2.1 below:  
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WHO 2005 Interim WHO Clinical Staging of HIV/AIDS , page 30  
 
 
Treatment for HIV in low-income and middle-income countries (LMICs) is at present 
driven by a public health approach, where the primary goal is to provide ART to as 
broad a population as possible, in settings in which individualised management of 
patients by specialised physicians is not feasible (Bartlett and Shao, 2009). The issue 
of when to start HAART in perinatally HIV infected children is topical (Prendergast et 
al, 2007). Results of a clinical trial investigating the impact of early HAART on African 
Table 2.1 WHO Paediatric Clinical Staging System  
 Condition Diagnosis 
Clinical 
Stage 1 
Asymptomatic 
Persistant Generalised lymphadenopathy 
Clinical 
Clinical  
 
Clinical 
Stage 2 
Hepatosplenomegaly 
Papular pruritic eruptions 
Seborrhoeic dermatitis 
Fungal nail infections 
Angular cheilitis 
Lincal gingival erythema 
Human papilloma virus infection 
Molluscum contagiousum infection 
Recurrent oral ulceration 
Parotid enlargement 
Herpes zoster 
Recurrent respiratory tract infection 
Clinical  
Clinical 
Clinical 
Nail scrape 
Clinical 
Clinical 
Clinical 
Clinical  
Clinical 
Clinical 
Viral culture 
Clinical and x-ray 
 
Clinical 
stage 3 
Unexplained moderate malnutrition  
Unexplained persistent diarrhoea (>14 days) 
Unexplained persistent fever (>month) 
Oral candidiasis (outside first 6 weeks of life) 
Oral hairy leukoplakia 
Pulmonary TB 
Severe recurrent presumed bacterial pneumonia 
Acute necrotising gingivititis, or stomatitis, or acute necrotising periodontitis 
Systemic lymphoid interstitial pneuomonitis 
Chornic HIV-associated lung disease (including bronchiectasis) 
Unexplained anaemia or neutropenia 
Documentation and 
monitoring 
Clinical  
Clinical  
Microscopy or culture 
Clinical 
x-ray and sputum 
clinical  
clinical  
x-ray, oxygen saturation 
x-ray 
lab testing 
 
Clinical 
stage 4 
Unexplained severe wasting or severe malnutrition 
Pneumocystis pneumonia 
Recurrent severe presumed bacterial infection  
Chronic herpes simplex virus infection 
Oesophogeal candidiases 
Extrapulmonary TB 
Karposi’s sarcoma 
Cytomegalovirus retinitis and infection of organs other than lymph nodes, liver or 
spleen 
CNS toxoplasmosis 
Cryptococcal Meningitis 
HIV encephalopathy 
 
 
Disseminated mycosis 
Candidiasis of the trachea, bronchi or lungs 
Disseminated mycobacteriosis other than TB 
Cryptosporidiosis  
Isosporiasis 
Cerebral or B cell non-Hodgkins lymphoma 
Progressive multifocal leukoencephalopathy 
Acquired HIV-Associated rectal fistula including recto-vaginal fistula 
HIV-associated nephropathy 
HIV-associated cardiomyopathy 
Documentation and 
monitoring 
Sputum and chext x-ray 
Clinical  
Histology or culture 
Clinical  
Blood culture 
Biopsy  
Histology 
CT scan and CSF culture 
CSF culture 
Clinical and recommendation 
of CT scan to exclude other 
causes 
Microscopy or histology 
Microscopy or histology 
Stool, blood, body fuid culture 
Microscopy  
Response to therapy 
CNS imaging 
MRI or CT scan 
Clinical  
Urine testing 
Echocardiography  
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children have recently been reported where early initiation of HAART resulted in a 
76% reduction in mortality, and decreased disease progression by 75% at a 10 month 
follow-up (Violari et al, 2008). Rapid control of HIV infection is especially important in 
resource-limited countries with high rates of opportunistic infections. Therapy initiation 
guidelines would be useful for South African physicians while awaiting the results of 
ongoing trials of different CD4 count thresholds for therapy initiation (Walensky et al, 
2009).  
2.9.2 Treatment Initiation in Developed Countries 
Based on the European (Sharland et al, 2002) and US guidelines (Working group on 
ARV Therapy, 2009), children with clinical or immunologic deterioration should receive 
ART. Controversy remains regarding early treatment in infants with no or 
mild/moderate signs or normal immunologic status. The risk of disease progression is 
higher in children than in adults, with15-20% of HIV-1 infected children progressing to 
AIDS or death within the first year of life (HIV Paediatric Prognistic Markers 
Collaborative Study Group 2003; Gray et al, 2001; Tovo et al, 1992). The 
commencement of combined ART within the first six months of life in HIV-1 perinatally 
infected children has been shown to result in avoidance of clinical manifestation, 
preserved CD4+ T-lymphocyte percentage, and no increase in CD8+ T-lymphocyte 
percentage, at least for the first years of life. Clinical benefits from early ART were 
also shown (Chiappini et al, 2006). However, in children under two years of age 
neither CD4+ T-lymphocyte percentage nor viral load can identify those at higher risk 
of disease progression, supporting the universal treatment strategy (Dunn, 2003). 
 
Early ART has been recently proposed for the treatment of asymptomatic or 
moderately symptomatic infants with HIV-1 infection (Working group on ARV Therapy, 
2009). As the rate of viral replication during the first months of life is correlated with 
disease outcome, early therapeutic intervention, which keeps the virus at low levels 
during primary infection, may lead to a better long-term viral suppression and 
preserved immune system function (Working group on ARV Therapy, 2009). 
Moreover, one possible goal of early ART is the prevention of HIV-mediated damage 
of the developing nervous system which is particularly frequent in infants (Sanchez-
Ramon et al, 2003).  
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2.9.3 Treatment in Developing Countries 
ART has been available in South Africa since 2004, although strict guidelines for 
initiating treatment have had to be followed due to a shortage of funding for drugs 
(DOH, 2008). Children, like adults, are eligible for ART on the basis of clinical 
symptoms or signs, or of immunological status (Dabis et al, 2000), but disease 
progression in children is more complex than in adults, and starting treatment at an 
appropriate time to ensure efficacy is often difficult. Where ART can be provided to 
children as they progress to moderate or severe disease it has been shown to 
significantly and substantially improve their chances of survival. In developing 
countries the rollout of a comprehensive paediatric care package encompassing 
regular monitoring, ART, prophylaxis and other supportive therapy is therefore likely to 
cause a ballooning of the demand for ART (Little et al, 2007). In developing countries, 
the commencement of HAART along with the frequent problems of advanced disease, 
poor access to healthcare services, lack of infrastructure, inadequate nutrition and 
poor living standards may result in poorer outcomes compared with developed regions 
(Cowburn et al, 2007; Feucht et al, 2007). Despite these challenges, HAART has 
been shown to decrease mortality and morbidity in poorly-resourced settings (Violari 
et al, 2008; Cowburn et al, 2007; Reddi et al, 2007). 
 
In order to facilitate the rapid scale-up of paediatric antiretroviral treatment (ART), the 
World Health Organisation (WHO) published revised paediatric ART guidelines for 
resource-poor settings in 2006 (WHO, 2006b). The eligibility criteria for infants and 
children rely on clinical and/or immunological thresholds and aim to identify those 
children with poor prognosis if ART initiation is delayed. The WHO guidelines are as 
follows: The threshold CD4 levels for severe immunodeficiency are <25% for infants 
<11 months, <20% for children aged 12-35 months, or <15% for children aged 3 years 
and above (WHO, 2006b).  
 
In comparison with World Health Organisation Guidelines, the South African 
guidelines have slightly lower CD4 thresholds, and therefore initiation of ART would 
commence later. In South Africa, children are eligible for ARV’s based on the following 
criteria from 2008 (DOH, 2008):  
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Clinical Criteria 
- Confirmation of diagnosis of HIV-infection AND 
- Recurrent (>2 admissions per year) hospitalisations or prolonged hospitalisation 
(>4 weeks) for HIV-related illness OR 
- The patient satisfies the WHO Stage III/IV disease OR 
- For relatively asymptomatic patients, one can consider CD4 percentage <20% if 
under 18 months or <15% if over 18 months. 
 
Social Criteria 
These criteria are extremely important for the success of the programme and need to 
be adhered to – the principle is that adherence to treatment must be at least probable. 
- At least one identifiable caregiver who is able to supervise the child for the 
administration of the medication.  
- Disclosure to another adult living in the same house is encouraged so that there is 
someone else who can help with the child’s ART. 
 
The DOH goals for HAART therapy are as follows:  
• To increase survival and decrease HIV-related morbidity and mortality.  
• The child’s CD4 count should rise and remain above the baseline count.  
• The child’s viral load should become undetectable <25 copies/ml and should 
remain undetectable on ART (DOH, 2008). 
 
On the second of December 2009, President Jacob Zuma announced revised 
guidelines for ARV initation in South Africa in certain vulnerable groups of people. The 
most significant changes, which will commence as from the first of April 2010 are: 
pregnant women living with HIV will qualify for ARV’s if their CD count falls below 350 
cells/mmÚ; and pregnant women with higher CD4 counts will be given treatment from 
14 weeks of pregnancy to attempt to prevent mother-to-child transmission. All HIV 
positive children under the age of one year will be eligible for treatment regardless of 
their CD4 count. For children aged between one and five years, those with clinical 
stage three or four signs, or a CD4 percentage of ≤ 25 are eligible to commence ART. 
Children eligible to be fast tracked are those under one year of age, those with signs 
of stage four disease, and those with multidrug resistant tuberculosis. This will allow 
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children to access treatment earlier, and for many, as soon as they are diagnosed 
(Department of Health, 2010).  
 
WHO immunological thresholds for total CD4+ T-lymphocyte count (CD4 count) and 
CD4 percentage are associated with improved prognosis, and correspond to a five 
percent decrease in annual mortality risk in children from the United States and 
Europe aged one year or older (HIV Pediatric Prognostic Makers Collaborative Study, 
2005). The same level of immunosuppression in children living in resource poor 
settings may not have the same prognosis due to differences in environmental factors 
such as opportunistic infections or malnutrition (Bachou et al, 2006; Lugada et al, 
2004). Embree et al (2001), found that CD4 percentage and CD4 count in healthy 
Kenyan children was markedly lower than European, American and West African 
children. Therefore the thresholds established through longitudinal studies in the 
United States and Europe may not be extrapolated to other regions in the world.  
 
In the pre-HAART era, African children experienced rapid and more aggressive HIV 
disease with higher mortality (Obimbo et al, 2004). As programmes providing HAART 
scale up in Africa, survival of HIV-1 infected children is expected to improve, based on 
what has been observed in Western settings (Gortmaker et al, 2001). In a review of 30 
studies done in sub-Saharan Africa, which described the treatment of HIV infected 
children (Sutcliffe et al, 2008), it was found that children are entering treatment 
programmes at older ages in sub-Saharan Africa. Most children in these studies were 
older than five years when they started antiretroviral therapy. In a pooled analysis of 
mortality among HIV infected treatment-naive African children, an estimated 35% and 
53% died within one and two years, respectively (Newell et al, 2004). By age five 
years, other studies have estimated that 62–89% of children have died (van der Loeff 
et al, 2003). Only a few studies reported on how children came to be enrolled in the 
antiretroviral therapy programmes: most were identified as HIV infected and clinically 
in need of treatment through health-care services, rather than in infancy through 
Prevention-of-Mother-to-Child-Transmission (PMTCT) or voluntary counselling and 
testing programmes, when children are often asymptomatic (Wamalwa et al, 2007). 
Therefore, older children with slower disease progression are more likely to gain 
access to antiretroviral therapy in sub-Saharan Africa. By contrast, nearly two-thirds of 
HIV infected children who would have benefited from life-prolonging treatment before 
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reaching age five years are not being diagnosed and treated (Wamalwa et al, 2007).  
 
By definition, children eligible for treatment by CDC or WHO guidelines have 
moderate to severe immunosuppression (WHO, 2006b). However, with a median 
CD4+ T-cell percentage of less than 10% in most studies, children in sub-Saharan 
Africa are starting antiretroviral therapy at more advanced stages of disease (CD4 T-
cell percentage of approximately five to ten percent lower) than children in high-
income countries, thereby putting them at an increased risk for treatment failure, and 
poor immunological response (Resino et al, 2006). 
2.9.4 Regimens of ART 
Antiretroviral regimens including Protease Inhibitors (PI’s) have been shown to 
increase CD4 cell counts, even for children with advanced disease (Storm et al, 2005; 
Nachman et al, 2000; Wiznia et al, 2000), and studies are now beginning to document 
their effects on clinical outcomes. Baseline and treatment-mediated changes in 
immunologic and virologic markers were independent predictors of survival in a meta-
analysis of paediatric antiretroviral clinical trials, and virologic markers predicted 
weight, growth and cognitive failure among children one year of age (Lindsey et al, 
2000). The use of PI therapy has been found to reduce morbidity and mortality rate 
among HIV infected children and adolescents (Gortmaker et al, 2001), and has been 
shown to increase height and weight growth (Verweel et al, 2002; Buchacz et al, 
2001).  
 
In a study by Lindsey et al (2007), PI-based HAART was shown to have a positive but 
limited impact on neurodevelopmental trajectories and the rate of significant cognitive 
and motor impairment in HIV-positive infants and young children during the first three 
years of life, despite substantial effects on survival and immunologic status. This 
limited positive effect of HAART may be partly because infants and young children 
with a compromised CNS now survive the more severe early manifestations of the 
disease but may have persistent neurobehavioral difficulties. The effects of HAART 
may become more apparent as the children reach school age and beyond and as 
differential and characteristic patterns of strengths and weakness in domains of 
development are identified.  
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2.9.5 ART in sub-Saharan Africa 
Resource-limited settings pose unique challenges to the implementation, 
effectiveness, and sustainability of HAART programs (Cowburn et al, 2007; Feucht et 
al, 2007). Limited availability of paediatric formulations of antiretroviral drugs, weak 
healthcare infrastructure and the widespread conviction that paediatric specialists are 
needed to initiate and monitor HAART due to its perceived complexity serve as 
barriers to comprehensive implementation (Kim and Gilks, 2005). Threats to 
effectiveness and sustainability in the paediatric population include morbidity and 
mortality of primary caregivers due to rising HIV prevalence rates, and although the 
expectation of poor adherence in this setting leading to widespread "antiretroviral 
anarchy" has not been met, treatment failure and exhaustion of available regimens are 
ongoing risks (Harries et al, 2001). Children are entering treatment programmes at 
older ages in sub-Saharan Africa, as many mothers have no access to PMTCT or 
voluntary counselling and testing programmes, and therefore children are only 
identified as being HIV-positive and clinically in need of treatment when they become 
symptomatic (Sutcliffe et al, 2008). Therefore, older children with slower disease 
progression are more likely to gain access to antiretroviral therapy in sub-Saharan 
Africa (Sutcliffe et al, 2008).  
2.9.6 The Effects due to Timing of Initiation of ART 
Soh et al (2003) found that improvements in CD4 percentage were greater in younger 
children, than in older children on PI-based therapy, which may substantiate the 
argument to initiate ART’s. Early deaths occurred in children with advanced HIV 
disease within five months of treatment initiation. This suggests that a greater effort 
should be made to identify and treat HIV-positive children at an earlier stage of their 
infection, and that children with advanced disease should be closely monitored and 
supported at the onset of HAART (Reddi et al, 2007). 
 
Although long-term HAART allows restoration of CD4+ cell percentages and control of 
viral loads in HIV-1 infected children, HAART initiation after severe 
immunosuppression may be less effective for restoration or maintenance of a normal 
CD4+ cell percentage. These data argue in favour of not delaying initiation of HAART 
in young children (Resino et al, 2006). 
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2.9.7 Effects of ART on Growth  
Growth seems to be one of the most sensitive indicators of disease progression in 
children with acquired immunodeficiency syndrome (AIDS), with the absence of 
growth indicating a poor prognosis, even in children who are treated with antiretroviral 
regimes (Lindsey et al, 2000). HIV-1 infected children show a trend towards an 
increase in height and weight after the initiation of HAART, although in children with a 
better virologic response to therapy, these increases are greater (Verweel et al, 2002). 
 
Increasing CD4+ T-cell counts favourably influence weight and body mass index 
(BMI). BMI z-scores increase more in children with an advanced clinical stage of 
infection at initiation of HAART due to the fact that the energy expenditure previously 
needed to combat infection was possibly used for catch-up growth (Verweel et al, 
2002). Height increases after weight, which is a normal reaction to the correction of a 
growth-retarding disorder: catch-up growth first affects weight followed by height. 
Sustained low viral loads, and higher CD4 counts help to support this (which are 
dependent on successful application of HAART) (Verweel et al, 2002).  
 
At the initiation of HAART, viral loads correlate negatively with height z-score change 
in the previous year and the clinical stage of infection correlates negatively with BMI z- 
score and weight z-score (Verweel et al, 2002). Although the number or percentage of 
CD4+ T-cells has a larger influence on prognosis, increasing growth rates also 
contribute to a better prognosis (Carey et al, 1998). The positive effects of HAART on 
growth can be sustained for at least 96 weeks (Verweel et al, 2002), and the effect on 
growth lasts longer in patients receiving HAART than in patients receiving mono or 
duo reverse transcriptase inhibitor therapy. There seems to be a relation between the 
time that antiretroviral therapy is successful in the suppression of viral load and the 
time that the positive effect on growth by this therapy can be maintained (Verweel et 
al, 2002).  
 
Malnutrition is associated with disease progression and death in untreated children 
(Obimbo et al, 2004), and is associated with an increased risk of mortality among 
children receiving treatment (Reddi et al, 2007). In all studies that assessed this issue, 
nutritional status improved after antiretroviral therapy; however, the effect of 
malnutrition on virological success and immune reconstitution has not been fully 
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explored. Treatment programmes need to address malnutrition and micronutrient 
deficiencies through an integrated model of care or by partnering with organisations 
that have the resources to provide nutritional supplementation (Agnarson et al, 2007).  
2.9.8 Effects of ART on the CNS and Neurodevelopment 
Studies of cerebrospinal fluid (CSF) from children with HIV encephalopathy found 
active and persistent brain infection with HIV suggesting a need for antiretrovirals that 
penetrate the blood–brain barrier (Epstein et al, 1987). To aid clinicians in 
antiretroviral therapy decision-making for patients with neurological symptoms, this 
information has recently been used to develop a drug ranking system based on a 
drug’s ability to penetrate the CNS (Patel et al, 2009). To rank antiretroviral regimens 
according to their ability to penetrate the CNS, a modified version of the CNS 
penetration-effectiveness rank developed by Letendre et al, (2008) has been created.  
 
A scale of one (lowest penetration) to three (highest penetration) has been used to 
rank each antiretroviral drug. A CNS-penetration score is calculated for each 
antiretroviral regimen by summing the individual ranks of each antiretroviral drug 
included in the regimen. Antiretroviral regimens with scores of less than four are 
classified as low CNS-penetrating regimens, scores of four to five are classified as 
medium CNS-penetrating regimens, and scores greater than or equal to six are 
classified as high CNS-penetrating regimens. The score allocated to each drug by 
Patel et al (2009) is shown in Table 2.2 below:  
 
Table 2.2 CNS Penetration Classification  
1 (lowest penetration) 
 
2 (medium penetration) 3 (highest penetration) 
Didanosine (ddl) 
Tenofovir (TFV) 
Zalcitabine (ddC) 
Nelfinavir (NFV) 
Saquinavir (SQV) 
Saquinavir/ritonavir (SQV-r) 
Tipranavir/ritonavir (TPV-r) 
Enfuvirtide (T-20) 
 
Emtricitabine (FTC) 
Lamivudine (3TC) 
Stavudine (d4T) 
Efavirenz (EFV) 
Amprenavir (APV) 
Atazanavir (ATV) 
Foasamprenavir (f-APV) 
Indinavir (IDV) 
Abacavir (ABC) 
Zidovudine (ZDV) 
Delavirdine (DLV) 
Nevirapine (NVP) 
Amprenavir/ritonavir(APV-r) 
Atazanavir/ritonavir (ATV-r) 
Fosamprenavir/ritonavir(f-APV) 
Indinavir/ritonavir (IDV-r) 
Lopanavir/ritonavir (LPV-r) 
(Patel et al, 2009 Impact of HAART and CNS-penetrating antiretroviral regimens on HIV 
encephalopathy among perinatally infected children and adolescents.  AIDS 23: 1 – 9 (page 3). 
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A ten-fold decrease in the incidence of HIV encephalopathy among a large 
prospective cohort of perinatally infected children enrolled over a 14-year period, 
1993–2006 was found (Patel et al, 2009). This dramatic decline in incidence occurred 
with a concurrent increase in the use of HAART, proposing an association between 
HAART use and risk of HIV encephalopathy. HAART use was found to decrease the 
risk of HIV encephalopathy by 50% compared with no HAART use (Patel et al, 2009). 
Children who were on a high CNS penetrating regimen had a 41% decrease in the 
incidence of encephalopathy compared with those children on a low CNS penetrating 
regimen (Patel et al, 2009). 
 
HAART may therefore inhibit or delay HIV dissemination in the CNS and may also 
decrease viral replication if an active and persistent infection is already established in 
the brain (Patel et al, 2009). One study found a significant decrease in CNS viral load 
with increasing numbers of CNS-penetrating antiretroviral drugs independent of 
HAART alone (DeLuca et al, 2002). Optimal levels of antiretroviral drugs within the 
CNS, over what some HAART regimens provide, are needed to stop the active 
replication of HIV within the brain that can lead to further neurological decline and 
eventually death (Cysique et al, 2004). Further research is required to assess the 
impact of antiretroviral CNS-penetration effectiveness on the various pathogenic 
mechanisms leading to neurological deterioration and disease. Highly CNS-
penetrating regimens result in a substantial survival benefit to children with HIV 
encephalopathy compared with low CNS-penetrating regimens (Van Dyke et al, 
2008).  
2.10 Developmental Screening and Surveillance 
Developmental screening is the administration of a brief standardised tool that aids 
the identification of children at risk for a developmental disorder. Developmental 
screening does not result in either a diagnosis or treatment plan but rather identifies 
areas in which a child’s development differs from same-age norms. Screening is a 
brief assessment procedure designed to identify children who should receive more 
intensive diagnosis or assessment (Dworkin, 1993).  
 
Developmental screening has been shown to improve the accuracy with which 
children’s developmental delays are identified when compared with decisions based 
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only on clinical judgment (Dearlove and Kearney, 1990). Previous studies indicated 
that the most common developmental screening technique used in the primary care 
setting is informal clinical assessment and that few health care practitioners use 
standardised developmental screening tests routinely (Rydz et al, 2006). The 
performance characteristics of screening tools demonstrate their accuracy to be well 
above that of informal methods (Glascoe, 1997). Unfortunately, clinical assessment 
alone detects less than 30% of children with developmental disabilities (Rydz et al, 
2006). In contrast, standardised developmental screening instruments have been 
reported to have sensitivities and specificities of 70% to 90% (Glascoe, 1997). 
 
Surveillance is a continuous process which is performed by skilled professionals, and 
involves observations of children during the provision of health care. The components 
of developmental surveillance include attending to parental concerns, obtaining a 
relevant developmental history, making accurate observations of children, and sharing 
opinions and concerns with other relevant professionals (Dworkin, 1993). 
Paediatricians often use age-appropriate developmental checklists to record 
milestones as part of developmental surveillance.  
 
Surveillance and screening have limitations due to the dynamic nature of development 
(American Academy of Paediatrics [AAP], 2006). Repeated and regular screening is 
more likely than a single screening to identify problems, especially in later-developing 
skills such as language (AAP, 2006). Waiting until a young child misses a major 
milestone such as walking or talking may result in late rather than early recognition, 
increasing parental dissatisfaction and anxiety and depriving the child and family of 
the benefits of early identification and intervention (AAP, 2006).  The advantages of 
standardised developmental screening instruments are that they provide a set of 
norms against which to measure development, serve as a reminder to the 
paediatrician to observe development, are efficient ways to record observations, and 
identify children with delays. The major disadvantage is that they take time to 
administer and interpret. Therefore, developmental screening instruments are not 
widely used in paediatric practice (AAP, 2006; Glascoe, 2001). Although the use of 
screening tests would improve the rate and accuracy of identification, a recent survey 
demonstrated that only 23% of primary care clinicians used a standardised screening 
tool (Sand et al, 2005).  
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2.10.1 The use of Standardised Assessment Tools in sub-Saharan Africa 
The adequate monitoring of disease effects and intervention among children in rural 
communities in Africa is hampered by a lack of appropriate assessment tools (Holding 
and Kitsao-Wekulo, 2004). Instruments developed in one culture cannot be readily 
transferred to another, despite evidence that cognitive abilities of children do not vary 
across cultures (van de Vijver, 1997).  The shortage of personnel with a background in 
child assessment within an African context has been identified as another limitation to 
the use of tests that require prior experience in child development and extensive 
training (Olness, 2003). 
 
Other challenges to the application of Western instruments in a non-Western context 
arise from a lack of familiarity with test demands, incomparability of samples and poor 
translation of test items (Holding and Kitsao-Wekulo, 2004; van de Vijver, 1997). 
Problems with applying and adapting standardised assessment techniques in Africa 
begin with the often prohibitively high price of Western materials (Aina and Morakinyo, 
2001) and are compounded by the shortage of trained and qualified test 
administrators (Olness, 2003; Haataja et al, 2002). The numerous challenges 
described highlight the need to develop culture-appropriate items, administration 
procedures and the establishment of culture-specific norms for the interpretation of 
score levels (Abubakar et al, 2007).  
 
In the absence of existing tests there are different approaches that have been applied 
to the production of new assessment measures (van de Vijver and Tanzer, 2004). The 
most common approach is translation of existing measures, but this may constrict the 
within-population variance and mask true group differences (Connolly and Grantham- 
McGregor, 1993). On the other hand, the production of a novel assessment limits the 
comparability of outcomes across different cultural settings (Sternberg et al, 2001). A 
third option is to assemble a selection of activities into a new measure, and to ensure 
that items included are not only acceptable to the target population but also evaluate 
constructs common to those measured by published tests (Abubakar et al, 2007). This 
is potentially important as it enables the comparison of disease effects across sites 
and contexts (Holding and Kitsao-Wekulo, 2004).  
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2.10.2 Properties of Acceptable Screening Tools 
The best screening instruments have good psychometric properties, including 
adequate sensitivity, specificity, validity, and reliability, and have been standardised 
on diverse populations (American Academy of Pediatrics, 2001).  
● Reliability is the ability of a measure to produce consistent results.  
● Validity of a developmental screening test relates to its ability to discriminate 
between a child at a determined level of risk for delay (ie, high, moderate) and the rest 
of the population (low risk).  
● Sensitivity is the accuracy of the test in identifying delayed development.  
● Specificity is the accuracy of the test in identifying individuals who are not delayed 
(AAP, 2006) 
 
For developmental screening tests, scoring systems should minimise both under-
referrals and over-referrals. Trade-offs between sensitivity and specificity occur when 
devising these scoring systems in order to achieve this (AAP, 2006). None of the 
above properties of screening tests can be used in isolation to assess the 
effectiveness of a test, but together they provide the multiple perspectives for 
evaluating a test’s validity (Meisels, 1989). 
2.11 Development and Statistical Properties of Screening Tools 
Aylward (2009) proposed that there is no real ‘gold standard’ in developmental 
evaluation due to the level of variation in the tests, testee, and tester. Development, 
when assessed using a developmental test, may be a moving target, due to two 
factors: (1) the Flynn effect (Flynn, 1999) and (2) revisions of developmental 
assessment instruments. With the former, the mean of a test increases 0.3-0.5 points 
per year, this roughly equating to five points per decade. Therefore, it may be better to 
update norms with minimal alterations in test content. This raises conceptual and 
financial issues and the argument that changes in knowledge of development should 
be reflected by changes in tests (Aylward, 2009). Regardless, clinicians should not 
unquestioningly accept a test as being the gold standard. Knowledge of the test’s 
strengths, weaknesses, and relationships to other tests is critical. In the literature 
reviewed on the development of screening tools, a certain sequence of steps may be 
followed when developing a new tool or adapting an existing tool. These include item 
selection or generation, validation and reliability testing, and standardisation.  
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2.12 Item Selection 
In a review of the literature on the development of screening tools, item selection is 
largely based on the following:  ‐ Review of the literature (Kirby et al, 2010; Bart et al, 2010; Martin et al, 2009; 
Bayley, 2006a; Bayley 2006b; Bayley 2006c; Harris et al, 2003; Beckung, 2000) ‐ Review of similar screening tools (Kirby et al, 2010; Harris et al, 2003) ‐ Items taken from an existing assessment tool (Gladstone et al, 2008; Bayley, 
2006c; Aylward, 1995) ‐ Interviews with people who have the relevant condition (Bart et al, 2010) ‐ Clinical experience (Bayley, 2006a; Harris et al, 2003; Beckung, 2000) 
2.13 Statistical Properties of Screening Tools 
Screening tools should have the following statistical attributes (American 
Psychological Association, 1985): 
2.13.1 Validity 
There are a number of tests that an assessment tool should undergo in order to 
determine validity. Validity is defined as “the degree to which a useful (meaningful) 
interpretation can be inferred from a measurement” (Rothstein et al, 1991, pg 597). 
According to the Standards for Measurement in Physical Therapy these include 
criterion-based validity, construct validity, and content validity (Rothstein et al, 1991).  
 
2.13.1.1 Criterion Validity 
Criterion Validity consists of three aspects: concurrent validity, predictive validity and 
prescriptive validity. Rothstein et al (1991) define these as follows:  
 
2.13.1.2 Concurrent validity  
The interpretation is justified by comparing the new measurement to be validated with 
another validated measurement at approximately the same time.  The measurement 
of concurrent validity should be provided when the new test claims to be able to give 
information about the current status of a person at the time that the measurements are 
obtained (Rothstein et al, 1991). Concurrent validity is the degree to which outcomes 
on one test correlate with outcomes on a criterion test, when both tests are given at 
the same time (Portney and Watkins, 2000). Correlations of 0.6 or greater should be 
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obtained (American Psychological Association, 1985). Other values which can be 
obtained following studies for concurrent validity are sensitivity, specificity, positive 
predictive value and negative predicitive value.  
 
2.13.1.3 Predictive Validity 
Predictive validity examines the justification of using a measurement to say something 
about future events or conditions (Rothstein et al, 1991). Information about predictive 
validity should be provided when a measurement claims to be able to provide 
information about future status (Rothstein et al, 1991). Marks et al (2008) express 
concern at conducting predictive validity studies on developmental screening tools, as 
by design, screening tools are developed to provide information on the current status 
of a child, and not give an indication of future outcome. The American Academy of 
Pediatrics (2006) state that a screening tool should generate a referral to early 
intervention, where the child may receive more in-depth assessment, or monitoring 
through surveillance.  
 
2.13.1.4 Prescriptive Validity 
Prescriptive validity refers to the validity of a test when the results are used to 
determine what treatment the person will receive (Rothstein et al, 1991), information 
regarding prescriptive validity should be provided when the the results of a 
measurement will be used to determine treatment options.  
 
2.13.1.5 Construct Validity  
This is the theoretical basis for using a measurement for a specific purpose (Rothstein 
et al, 1991). Evidence for construct validity is through logical argumentation based on 
evidence from theory and research.  
 
2.13.1.6 Content Validity 
Content validity is an essential step in the development of new measuring devices as 
it represents a beginning mechanism for linking abstract concepts with observable and 
measurable indicators (Wynd et al, 2003).  Content validity is often the first step in 
examining the validity of a newly developed tool and is not determined by statistical 
analyses, but by practical considerations (McEwan et al, 2003; American 
Psychological Association, 1985). This is often carried out in consultation with a panel 
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of experts to obtain consensus on each item, as well as the consensus on the scale 
as a whole (Dunn et al, 2005; Harris et al, 2003; Harris and Daniels, 1996). Specifying 
the objectives of the test and providing the rationale for item selection enhance the 
content validity of a test. A theoretical basis should be provided, as well as the source 
of items and proof of systematic and logical analysis of item development (American 
Psychological Association, 1985). When assessing content validity, it is necessary to 
define the domain of content of the concept being measured and then to determine 
whether this is adequately covered by the instrument. The more elements within the 
concept that are actually assessed by the instrument, the greater the instrument's 
content validity (Sim and Arnell, 1993).  
  
Content validity is largely a matter of judgement, involving two distinct phases: the 
scale developer should enhance content validity through careful conceptualisation and 
domain analysis prior to item generation, and the relevance of the scale’s content 
through expert assessment (Polit and Beck, 2006; Mastaglia, et al, 2003; Beck and 
Gable, 2001). Expert assessment can be carried out in a number of ways: These 
include averaging experts’ ratings of item relevance and using a pre-established 
criterion of acceptability (Beck and Gable, 2001); using coefficient alpha to quantify 
agreement of item relevance by three or more experts, and computing a multirater 
kappa coefficient (Wynd et al, 2003), having a team of experts indicate whether each 
item on a scale is congruent with (or relevant to) the construct, computing the 
percentage of items deemed to be relevant for each expert, and then taking an 
average of the percentages across experts (Polit and Beck, 2006). A validity 
questionnaire may be drawn up, and responses to questions are rated on a likert 
scale (Parks et al, 2007; Harris and Daniels, 1996).  
 
Other methods to obtain consensus include the Delphi Technique and Nominal Group 
Technique. The Delphi technique is a method for the collection of opinion on a 
particular topic. It is based on the premise that ‘pooled intelligence’ enhances 
individual judgement and captures the collective opinion of experts (Jones et al, 
2000). It typically involves 15-30 participants (de Villiers et al, 2005). The conventional 
Delphi technique uses a series of questionnaires to aggregate expert opinion in an 
anonymous fashion. This takes place over a series of ‘rounds’. Communication can 
take place by post or by electronic exchange (Jones et al, 1992). A question is 
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formulated and expanded upon in a set of assumptions, solutions or options. 
Secondly, an expert panel is identified and invited to provide opinions. The responses 
are analysed and ranked, using predetermined criteria for agreement and 
disagreement. A second questionnaire is developed using the results and feedback 
from the first round. Participants again record their opinions, which are collated and 
assessed for consensus (Jones and Hunter, 1995). The process terminates when an 
acceptable degree of consensus is reached. Three rounds are usually sufficient to 
achieve consensus with the largest adjustments occurring between rounds one and 
two (Bellamy et al, 1991).  
 
Another method to achieve consensus is the Nominal Group Technique (NGT) (Potter 
et al, 2004), and has been recommended by the authors as a technique to achieve 
consensus amongst experts in the development and review of outcome measures. 
The NGT has been shown to be a reliable method to establish the content validity of 
new instruments (Hyrkas et al, 2003). The aim of the NGT is to generate information 
in response to a focused issue, and to facilitate discussion around this. This is done 
during a focused meeting, which lasts up to two hours, and consists of five to nine 
participants. There are a number of advantages to this technique: minimal preparation 
is required by participants, and participants input is limited to a single meeting lasting 
up to two hours. Task completion and immediate dissemination of results to the group 
lead to greater satisfaction amongst participants due to quick dissemination of 
information; and researcher-bias is minimised due to the highly structured nature of 
the process (Potter et al, 2004). The NGT protocol follows a number of steps as 
outlined below:  
 
1. Introduction and explanation: the participants should be welcomed, and an 
explanation of the purpose and procedure of the meeting should be given. 
 
2. Generation of ideas: each participant should be provided with a sheet of paper with 
the question to be addressed and participants are then asked to write down all ideas 
that come to mind when considering the question. During this period, participants are 
asked not to consult or discuss their ideas with others. Approximately ten minutes are 
allowed for this. 
 
The Development of a Screening Tool to Evaluate Infants who are HIV Positive  
 51 
3. Sharing of ideas: participants should be invited to share the ideas they have 
generated. The process continues until all ideas have been presented. There is no 
debate about items at this stage and participants should write down any new ideas 
that may arise from what others have shared. This process ensures that all 
participants get an opportunity to make an equal contribution and provides a written 
record of all ideas generated by the group.  
 
4. Group discussion: participants are invited to ask for further explanation and detail 
about any of the ideas that colleagues have produced.  
 
5. Voting and ranking: this involves prioritising the recorded ideas in relation to the 
original question. Immediate results are available to participants so that the outcomes 
are reached by the time the meeting concludes. It is recommended that the process is 
recorded on videotape or audiotape (Potter et al, 2004).  
 
A modified version of the NGT was successfully used during the content validation 
process of the Gross Motor Function Classification Measure in order to facilitate group 
decision-making with clearly focused outcomes (Palisano et al, 2008), and consensus 
was defined as agreement with a question by at least 80% of participants (Palisano et 
al, 2008). It has been used in a number of other studies to evaluate the content 
validity of new tools (Dyrbye et al, 2010; Shea et al, 2007; van der Camp et al, 2006). 
2.13.2 Evaluation of Diagnostic Tests 
A diagnostic test is used to screen for the presence or absence of a disease or 
abnormal condition. The quality of a screening test therefore should be evaluated 
against the findings obtained by a test which is considered to be the ‘gold standard’ 
(Portney and Watkins, 2000). The validity of a diagnostic test is therefore evaluated in 
terms of its ability to accurately assess the presence or absence of a specific 
condition, which is done through the evaluation of the sensitivity and specificity of the 
test:  
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2.13.2.1 Sensitivity, Specificity, Positive Predictive Value and Negative 
Predictive Value 
The sensitivity, specificity, positive predictive value, and negative predictive value can 
be used to analyse the criterion validity of a screening test (Glascoe, 1997). Sensitivity 
and specificity of developmental screening tools are measured by comparing the test 
results to that of gold-standard developmental evaluation tools (Glascoe, 1997).  
 
Sensitivity is a measure of validity of a screening procedure based on the probability 
that someone who has the condition will test positive (Portney and Watkins, 2000). 
Sensitivity is computed as: (the number of children with delays who were 
identified)/([those identified] + [children with delays who were not identified by the 
screening test]). Glascoe (1997) recommends that a screening test should have 
sensitivity levels of 70-80% due to the nature and complexity of measuring the 
continuous process of child development. Meisels (1989) suggested that more 
conservative criteria should be used with sensitivity levels of no less than 80% in order 
to avoid too many over-referrals. The value of 80% is also recommended by the 
American Psychological Association (1985).  
 
Specificity is a measure of validity of a screening procedure based on the probability 
that someone who does not have the condition will test negative (Portney and 
Watkins, 2000). It is computed as (the number of normal children who also scored 
‘normal’ on the test)/(normal children + normal children identified by a test as having 
delays) (Glascoe, 1991). There often is a trade-off in specificity if the sensitivity of a 
measure is very high. Again, Glascoe (1997) recommends that a screening test 
should have specificity levels of 70-80% due to the nature and complexity of 
measuring the continuous process of child development. Meisels (1989) suggested 
that more conservative criteria should be used with specifity levels of no less than 
80% to avoid under-referrals. The recommendation by the American Psychological 
Association, (1985) is 90%. This indicates that there is a wide variation in acceptable 
levels of specificity, but when combining the above recommendations, it should be 
between 70-90%.  
 
Positive predictive value is an estimate of the likelihood that a person who tests 
positive actually has the condition (Portney and Watkins, 2000). The lower the 
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prevalence of a disorder, however, the lower will be the positive and negative 
predictive values. A positive predictive value of 50% would be acceptable in 
developmental screening, although 30% and above is often found, because some of 
the low average children will be over-referrals (Aylward, 1997). The negative 
predictive value is the proportion of patients who are correctly diagnosed by the test 
as not having the condition (Altman and Bland, 1994). This result is less commonly 
presented.  
2.13.3 Reliability 
A test should be reliable – that is, it should be consistently free from error (Portney 
and Watkins, 2000). There are a number of types of reliability which a test should 
possess:  
 
2.13.3.1 Interrater Reliability 
Interrater reliability is the degree to which two or more raters can obtain the same 
ratings for a given variable (Portney and Watkins, 2000), and should be 0.8 or greater 
(American Psychological Association, 1985). Interrater reliability is best measured 
when all raters are able to measure a response during a single trial (Portney and 
Watkins, 2000). If interrater reliability has not been established, it cannot be assumed 
that other raters would have obtained the same results, which therefore limits the 
application of the findings (Portney and Watkins, 2000). Studies should have been 
conducted in a clinical context consistent with the intended use of the measurements 
(Rothstein et al, 1991). A number of raters may evaluate reliability, and may range 
from two to multiple numbers of raters. Videotapes may be useful in allowing multiple 
raters to view and rate the same performance (Smits-Engelsman et al, 2008; Bodkin 
et al, 2003; Portney and Watkins, 2000; Gowland et al, 1995), although this may be 
problematic, as it is difficult to capture all aspects of a performance, or all body parts 
on a video, and some studies have found that higher reliability coefficients have been 
found during observations rather than assessing a videotaped performance (Gowland 
et al, 1995). 
 
2.13.3.2 Test-retest Reliability 
Test-retest reliability is the degree to which an instrument is stable, based on repeated 
administrations of the test to the same individuals over a specified time period (during 
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which individuals are not expected to change) (Portney and Watkins, 2000) and 
should be at least 0.8 (American Psychological Association, 1985). Within-day and 
between-day studies should have been conducted in a clinical context consistent with 
the intended use of the measurements (Rothstein et al, 1991).  
 
In the reviewed literature on developmental screening and performance tests, the time 
between testing for test-retest reliability differed significantly, and ranged from two 
days to thirty days (Thomas-Stonell et al, 2010; Bayley, 2006a; Saigal et al, 2005; 
Harris and Daniels, 2001; Squires et al, 1997; Coster, 1995; Frankenberg et al, 1992). 
Portney and Watkins (2000) state that the interval between tests should be considered 
very carefully: they should be far enough apart to avoid fatigue, learning or memory 
effects, but close enough to avoid changes in the variable to be measured. They state 
that the primary criteria for choosing an appropriate interval are the stability of the 
response variable, and the purpose of the test. In addition, they also state that 
measurements of infant development might need to be taken over a short period to 
avoid the rapidly occurring changes of early infancy. Caution should be given to carry-
over effects, which may occur with repeated measurements, and concepts such as 
motor learning, which may result in improvements in the first test score (Portney and 
Watkins, 2000).  
 
2.13.3.3 Intrarater Reliability 
This refers to the stability of data recorded by one individual over two or more tests. 
This is usually assessed using trials with short intervals in-between where carryover 
effects are not an issue (Portney and Watkins, 2000). In a test-retest situation, when a 
rater’s skill is relevant to the accuracy of the test, intrarater and test-retest reliability 
are essentially the same estimate (Portney and Watkins, 2000).  
2.14 Standardisation Sampling 
Normative tables should be drawn up after administering the test to a large number of 
normal children, whose performance becomes the test’s norms. The standardisation 
sample should be determined by the country’s census using racial, geographic, and 
socioeconomic distributions.  At least 100 children per age interval, which is usually 6-
12 months should be included (American Psychological Association, 1985).  
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2.15 Comparison of Screening Tools 
In order to illustrate the variability in development and validation of screening tools, six 
commonly used screening tools have been selected, and their properties have been 
compared.  
 
The following discussion attempts to compare and contrast the development and 
psychometric properties of the following developmental screening tests:  The Ages 
and Stages Questionnaire (ASQ) (Squires et al, 1997); The Alberta Infant Motor Scale 
(AIMS) (Piper et al, 1992); Denver II (DDST) (Frankenberg et al, 1992); Harris Infant 
Neuromotor Test (HINT) (Harris, 1991); Bayley-III Screening Test (Bayley, 2006c), 
and the Bayley Infant Neurodevelopmental Screener (BINS) (Aylward, 1995).   
2.15.1 Description of the Screening Tools 
The Ages and Stages Questionnaire (ASQ) (Bricker et al, 1995) is a parent-completed 
child monitoring system, which was first published in 1995, and was a revision of the 
infant/child-monitoring questionnaire from the 1980’s. The ASQ evaluates gross 
motor, fine motor, communication, problem-solving, and personal-social domains of 
development of children aged 4-48 months, and takes 10 to 20 minutes to complete.  
 
The Alberta Infant Motor Scale (AIMS) (Piper et al, 1992) is a motor observational 
assessment requiring minimal handling of the infant, and can be administered in 10 to 
20 minutes by any health professional with a background in infant motor development. 
The AIMS was developed to provide a valid and reliable measure of motor 
development for infants at high risk of motor delay (Piper et al, 1992). Unlike previous 
standardised developmental assessments, the AIMS focuses on the motor 
requirements to attain each milestone, rather than looking only at when the milestone 
was achieved.  
 
The Denver Developmental Screening Test (DDST) was first standardised and 
published in 1967, and is used to assess multiple aspects of child development. In the 
early 1990’s, the DDST underwent revision and re-standardisation and has since been 
known as the Denver-II (Frankenberg et al, 1992). The Denver-II items are assessed 
by observation, parental report, or direct elicitation in the following domains: personal-
social, fine motor adaptive, language, and gross motor. The administration time is 10 
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to 20 minutes (Frankenberg et al, 1992).  
 
The Harris Infant Neuromotor Test (HINT) is a screening test that was first developed 
in 1991 to identify neuromotor, cognitive, or behavioral concerns in infants between 
the ages of 2.5-12.5 months. The administration time is about 30 minutes. The test’s 
reliability, validity and standardisation were completed over the following decade 
(Harris et al, 2003). 
 
The Bayley Infant Neurodevelopmental Screener (BINS) (Alyward, 1995) was 
developed for children ages 3–24 months and is based on the Bayley Scales of Infant 
Development, second edition (BSID-II) (Bayley, 1996). It assesses basic neurological 
function/intactness, receptive function, expressive function, and cognitive processes, 
and takes about 10 minutes to administer.  
 
The Bayley-III Screening Test (Bayley, 2006c) is an individually administered 
instrument designed to briefly assess the cognitive, language and motor functioning of 
infants and young children between the ages of 1-42 months of age.  
2.15.2 Standardisation Samples of the Six Tests  
The standardisation samples of the tests are compared and contrasted below. The  
numbers in the standardisation samples and the stratification of each sample are 
shown in Table 2.3 below:  
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Table 2.3 Standardisation Samples of the Six Tests 
Tool Standardisation sample 
 
BINS 600 infants with both clinical and nonclinical concerns and was stratified according to 
age, sex, ethnicity, region, and parent education 
 
ASQ 2008 children from Oregon, Hawaii, and Ohio. Included children at risk for 
developmental delay due to medical or environmental risk factors (81%) and children 
who were typically developing with no known risk factors (19%). Diverse ethnic and 
socioeconomic backgrounds were represented  
 
Denver-II 2096 children from Colorado; stratified by age, gender, socioeconomic status, maternal 
education, culture 
 
HINT 412 children from British Columbia, Canada. The normative sample was stratified by 
gender, maternal education, and ethnicity.   
 
AIMS Normative sample of 2202 from Alberta, Canada, Stratified by age and gender only 
 
Bayley-III 
Screening 
Test 
1675 children ages 16 days to 43 months 15 days who were demographically 
representative according to the United States Census, as well as children with 
specifically chosen conditions.  
 
The standardisation sample for the ASQ was 2008 children from Oregon, Hawaii, and 
Ohio (Bricker et al, 1995). The sample included both children at risk for developmental 
delay due to medical or environmental risk factors (81%) and typically developing 
children with no known risk factors (19%). Diverse ethnic and socioeconomic 
backgrounds were represented, although the authors noted that the Hispanic 
population was underrepresented and the Native-American population was 
overrepresented (Bricker et al, 1995).  
 
The AIMS was standardised on a sample of 2202 infants who were recruited 
exclusively from the province of Alberta, Canada. The sample was stratified by age 
and gender, but ethnic and socioeconomic characteristics were not reported (Coster, 
1995), which could indicate that the test may not be suitable for use on all groups.  
 
The standardisation sample for the Denver-II was a sample of 2096 children from the 
state of Colorado, from birth to six years of age. This sample was stratified by gender, 
maternal education, ethnicity, and socioeconomic status (Frankenberg et al, 1992).  
 
Recent normative data for the HINT were collected for 412 Canadian infants from the 
provinces of British Columbia, Manitoba, Nova Scotia, Ontario, and Quebec (Harris et 
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al, 2003). The sample was stratified by gender, maternal education, and ethnicity.  
 
The standardisation sample for the BINS consisted of 600 infants with both clinical 
and non-clinical concerns and was stratified according to age, sex, ethnicity, region, 
and parent education (Aylward, 1995).  
 
The standardisation of the Bayley-III Screening Test consisted of 1675 children from 
all over the United States, between the ages of 16 days and 43 months, 15 days who 
were demographically representative of the US population (Bayley, 2006c). Children 
were excluded from participating if they had any history of medical complications, and 
were not currently diagnosed with mental, physical or behavioural difficulties (Bayley, 
2006c). A number of special group studies were conducted in order to determine its 
suitability for use on these groups. The groups included children at high-risk for 
developmental delays due to a variety of conditions (Bayley, 2006c). 
 
As can be seen from the above, the standardisation samples for the six tools vary in 
size, stratification, and time that standardisation was carried out as compared with 
when the tool was developed. Only the Denver-II meets all the criteria outlined for 
standardisation samples in terms of size and stratification, which is outlined in 2.14 
above (American Psychological Association, 1985).  
2.15.3 Validity of the Tests 
Concurrent and preditictive validity of the six tests are described below. The values for 
each test are shown in Table 2.4 below: 
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2.15.3.1 Validity of the ASQ 
For the ASQ, concurrent validity was calculated by comparing the results of 1511 
assessments using the ASQ and the results obtained on the Revised Gesell and 
Amatruda Developmental and Neurologic Examination, the Bayley Scales of Infant 
Development II (<3 years), the Stanford-Binet Intelligence Test-4th edition and the 
McCarthy Scales of Children’s Abilities (>3 years) (Bricker et al, 1995). The 
assessments were administered within 29 days of ASQ completion by parent or 
Table 2.4 Validity of the Tests 
Tool Predictive Validity Concurrent Validity 
 
Bins Assessed against BSID II and 
has been found to be predictive 
of outcome at 36 months 
Mental Developmental Index of the BSID II (r = 0.40) 
Motor Scale of the BSID II (r = 0.35) 
Sensitivity: 75 – 86% 
Specificity: 75 – 86% 
 
ASQ Not assessed Compared  results of 1511 ASQ assessments and  
results on: Revised Gesell and Amatruda Developmental  
and Neurologic Examination and BSID (<3 years). For >3 
years,  
The Stanford-Binet Intelligence Test-4th edition and the 
McCarthy Scales  
of Children’s Abilities Assessment administered within 29 
days of  
ASQ completion by parent or caregiver. Sensitivity:75%  
Specificity: 85% PPV 46% 
 
Denver-II Not assessed Suspect w/normal group Sensitivity=56% Specificity=80% 
PPV= 37%  
Suspect w/abnormal group Sensitivity=83% Specificity=43% 
PPV=23%  
 
HINT Administered between 2.5 and 
12.5 months, and compared to 
scores on the BSID II Mental 
and Motor Scales at 17 to 
22mnths.Correlation between  
HINT and the  Bayley Motor 
Scale=-0.49(p < 0.01), 
predictive validity of the HINT 
and the Bayley Mental Scale 
was poor (r=-0.11) 
 
With Bayley  II Mental:r= -0.73 Motor: r= -0.89 
Sensitivity and specificity testing underway 
AIMS 164 high-risk infants recruited 
from Edmonton, Alberta. 
Correlation between AIMS, and 
MAI, and PDGMS at 4 months 
compared with evaluation by 
paediatrician at 18 months. At 8 
months: sensitivity: 86.4% 
Specificity:93% 
PPV: 65.5% 
 
120 infants from 0 to 13 months of age on the Motor Scale of 
the  
Bayley Scales of Infant Development (r=0.98) and the  
Peabody Developmental Motor Scales (r=0.97) 
Bayley-III 
Screening 
Test 
Not assessed Against the BSID III on 1657 children 
At-Risk: moderate (41.82% - 65.91%) 
Emerging: accurate (63.87% - 77.78%) 
Competent: very accurate (83.84% - 92.11%) 
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caregiver. The sensitivity and specificity of the ASQ across all age intervals were 
determined to be 75% and 85% respectively, with a positive predictive value of 46%. 
In the second edition of the ASQ, published in 1999, two additional questionnaires 
were added for the age intervals 10, 14, 16, 22, 33, 42, 54, and 60 months (Bricker 
and Squires, 1999). Neither reliability nor concurrent validity of the second edition has 
been examined, nor has predictive validity been examined for either the first or second 
edition.  
 
2.15.3.2 Validity of the AIMS 
In evaluating the AIMS’s concurrent validity, the authors assessed 120 infants from 
birth to 13 months of age on the Motor Scale of the Bayley Scales of Infant 
Development II and the Peabody Developmental Motor Scales. Concurrent validity 
was measured using the Pearson product-moment correlation. Correlation coefficients 
were r=0.98 for the Motor Scale of the Bayley Scales of Infant Development II and 
r=0.97 for the Peabody Developmental Motor Scales (PDMS) (Piper and Darrah, 
1994). 
 
The predictive validity of the AIMS was assessed in a sample of 164 infants at high 
risk recruited from two neonatal intensive care units in Edmonton, Alberta (Darrah et 
al, 1998). The predictive validity of the AIMS was compared with the predictive validity 
of the Movement Assessment of Infants (MAI) and the Peabody Developmental Gross 
Motor Scale (PDGMS). A physiotherapist administered the AIMS, MAI, and PDGMS to 
each infant at four and eight months of age and was blinded to the infants’ medical 
history. At 18 months of age, a follow-up assessment was conducted by a 
developmental paediatrician who classified the infants as normal, suspect, or 
abnormal in terms of motor development. The paediatrician’s evaluation was based on 
the following criteria: postural control, muscle tone, reflexes, and achievement of 
motor milestones. At 18 months, 78% of the infants were classified by the 
paediatrician as normal, 8.5% as suspect, and 13.4% as abnormal in their motor 
development. For predictive validity analyses, infants at 18 months receiving a 
suspect outcome were either grouped with those classified as normal or with those 
receiving an abnormal classification. Predictive values were determined for all three 
measures initially administered at four and eight months. When grouping infants with 
suspected delay with normal infants at the 18-month outcome assessment, the AIMS 
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and MAI showed similar sensitivity at four months but the MAI provided greater 
specificity (Darrah et al, 1998). When infants were assessed at eight months, 
however, the AIMS demonstrated greater specificity than the MAI for the 18-month 
outcomes. The PDGMS did not show an acceptable combination of sensitivity and 
specificity until its cutoff score was set at the 16th percentile rank at four months. 
When infants suspect for delay were grouped with abnormal classifications, a 
grouping proposed by Glascoe et al (1992), the sensitivity of the AIMS and MAI 
decreased for assessments at both four and eight months while the sensitivity of the 
PDGMS was poor at four months and its specificity was poor at eight months. 
Grouping suspect with abnormal outcomes maximised both the sensitivity and 
specificity of the AIMS: 77.3% and 81.7% at four months and 86.4% and 93.0% at 
eight months, respectively. The positive predictive value for the AIMS was 39.5% at 
four months and 65.5% at eight months. 
 
2.15.3.3 Validity of the Denver-II 
Although the revision and re-standardisation of the DDST attempted to address 
previous inadequacies, the Denver-II was published and distributed prior to studying 
its concurrent validity or predictive accuracy (Harris et al, 2005). In 1992, a study 
evaluating the accuracy of the Denver-II in identifying children with atypical 
development was published (Glascoe et al, 1992). This consisted of 17 examiners 
who assessed five children each. One hundred and forty one items had 100% 
agreement, seven had 90-99% and one had 83%. To examine the test’s concurrent 
accuracy, Glascoe et al (1992) assessed the correspondence of categorical 
classifications on the Denver-II with categorical classifications on other reference 
screening tests in order to determine the sensitivity, specificity, and positive predictive 
value of the Denver-II. One hundred and four children, ranging in age from three to 72 
months, were recruited. All children were assessed initially using the Denver-II. Within 
seven days of that assessment, each child was assessed on a battery of standardised 
assessments, including the Vineland Adaptive Behavior Scale, the Kaufman 
Assessment Battery for Children Achievement Subtests, the Fluharty Preschool 
Speech and Language Screening Test, and one of the following cognitive tests: the 
Bayley Scales of Infant Development II, the Stanford- Binet Intelligence Scale, 4th 
edition, or the Kaufman Assessment Battery for Children. By applying the results from 
this battery of tests to criteria for special education eligibility, the presence or absence 
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of developmental delay was determined and these classifications were compared with 
those from performance on the Denver-II. When questionable scores were grouped 
with normal scores, the Denver-II yielded a sensitivity value of 56%, specificity of 80%, 
and a positive predictive value of 37%. When grouping abnormal scores with suspect 
scores, the sensitivity of the Denver-II was 83%, specificity was 43%, and positive 
predictive value was 23%. Based on these findings, the American Academy of 
Pediatrics (2001) noted that ‘‘the Denver-II screening test is used widely but has 
modest sensitivity and specificity depending on the interpretation of questionable 
results.’’ Despite attaining the desired level of sensitivity by using this recommended 
grouping, more than 50% of typically developing children would then be classified as 
suspect for developmental delay. As a result, developmental screening with the 
Denver-II could lead to further diagnostic examination of about 60% of the children 
tested. Such low specificity of a screening test produces concern for an unnecessarily 
high referral rate. 
 
A study published by Glascoe and Byrne (1993) examined the relative accuracy of the 
Denver-II, the Developmental Profile II, and the Battelle Developmental Inventory 
Screening Test when compared with scores on a battery of standardised 
assessments. Specificity for the Denver-II was unacceptably low (46%) when grouping 
questionable with abnormal scores, although sensitivity was 83%. Using this grouping, 
the positive predictive value was only 28%, however, when grouping questionable 
scores with normal scores, specificity increased to 80% but sensitivity fell to 56%. The 
positive predictive value using this grouping was 42%. Glascoe and Byrne (1993) 
concluded that the Denver-II ‘‘produced more incorrect than correct classifications.’’ 
Although revision and re-standardisation represented an improvement over the 
original DDST, the failure to address the revised test’s accuracy based on standard 
criteria for the development of new tests is a major shortcoming, and the suggested 
validity studies have not yet been undertaken.  
 
2.15.3.4 Validity of the HINT 
Concurrent validity was assessed by comparing HINT total scores with raw scores on 
the Mental and Motor Scales of the BSID II for 54 infants at high risk (Harris et al, 
2005). Both tests were administered at the same assessment session. The Pearson r 
was used to calculate the relationship between the HINT and the BSID-II scales. For 
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the HINT and the Bayley Mental Scale, the concurrent validity was r= -0.73, whereas 
for the HINT and the Bayley Motor Scale, the relationship was r= -0.89.The predictive 
validity of the HINT, administered between 2.5-12.5 months, was assessed by 
comparing those scores to scores on the Bayley Mental and Motor Scales at 17 to 22 
months. The predictive correlation (Pearson r) between the HINT and the later Bayley 
Motor Scale was -0.49 (p < 0.01). However, the predictive validity of the HINT for the 
Bayley Mental Scale was r= 0.11. Interestingly, the predictive correlation for the HINT 
to the later Bayley Motor Scale was stronger than the relationship between the early 
Bayley Motor Scale and the later Bayley Motor Scale (0.49 and 0.34). Sensitivity and 
specificity analyses of the HINT’s predictive accuracy with the Bayley-II at 17–22 
months are currently in progress and involve a sample of 119 infants, approximately 
half of whom were at high risk and half of whom were at low risk for developmental 
delays (Harris et al, 2003).  
 
2.15.3.5 Validity of the BINS 
Concurrent validity of the BINS was assessed against the BSID II, on 199 infants at 
four age groups. Pearson correlations were calculated in order to evaluate the 
agreement between the BINS and the BSID II Mental Developmental Index (MDI), and 
results ranged from 0.43 to 0.82 (Aylward, 1995). For agreement between the BINS 
and the BSID II Psychomotor Developmental Index (PDI) score, results ranged 
between 0.39 to 0.58. All correlations were low to moderate apart from the result of 
0.82 for the 24 month age group against the BSID II MDI (Reid and Rigby, 1997). For 
the BINS, validity as a screening tool has been evaluated by examining sensitivity, 
specificity, and positive predictive value (PPV). The sensitivity of the test is 80%, and 
the specificity of the test is 89% (Aylward, 1995). Aylward (1995) did not report the 
ranges obtained during the sensitivity and specificity studies, and specificity is thought 
to lie between 50 and 70% (Reid and Rigby, 1997), which indicates that the BINS may 
overidentify children as having developmental problems. In terms of predictive validity, 
the BINS has been highly correlated with the BSID II at 36 months (Aylward, 2000). 
More validity studies need to be conducted in order to clarify all the different results 
obtained, and establish more precise values for validity of the BINS (Reid and Rigby, 
1997).  
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2.15.3.6 Validity of the Bayley-III Screening Test 
Validity was assessed against the BSID III on 1657 children (Bayley, 2006c). For 
children who obtained scores in the At-Risk category of the Bayley-III Screening Test, 
classification was moderate (41.82%-65.91%) – none were identified as proficient. For 
children who obtained scores in the Emerging category of the Bayley-III Screening 
Test, classification was accurate (63.87%-77.78%), with 0.82%-5.21% being identified 
as At-Risk. For children in the Competent category of the Bayley-III Screening Test, 
classification was very accurate (83.84%-92.11%), with no children being misidenitifed 
as At-Risk (Bayley, 2006c).  
2.15.4 Reliability 
Reliability of the six tests are compared and contrasted for the following: interrater 
reliability, intrarater reliability and test-retest reliability, which were the most commonly 
reported reliability properties of the tools. The values for each test are shown in Table 
2.5 below:  
 
Table 2.5 Reliability of the Tests 
Tool Interrater 
reliability 
 
Intrarater reliability Test-retest reliability 
BINS .79 to .96 
 
Not described .71 to .84 
ASQ 94% (SEM = 
0.12)  
 
94%  
 
94%  
Denver-II 141 items had 
100% 
agreement, 7 
had 90 – 99% 
and one had 
83%.  
 
Not assessed Excellent agreement for 
59% of items (k≥ 0.75), 
23% of items:  fair to 
good agreement (k≥ 
0.40). 
HINT 0.99.  
 
 0.98 to 0.99 0.98.  
AIMS 0.996 and 
above 
 
0–18mo (n=195) 
ICC=0.9915  
 
3–18mo (n=45) 
ICC=0.98–0.9952  
 
0.86 to 0.99  
Bayley-III 
Screening Test 
Not described Cognitive 0.85 
Receptive Communication 0.88 
Expressive Communication 0.88 
Fine motor 0.82 
Gross motor 0.86 
0.80 – 0.83 
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2.15.4.1 Reliability of the ASQ  
For the ASQ, test-retest (n=175) and interrater reliability (n=112) were based on 
parent-completed questionnaires (Squires et al, 1997). To evaluate test-retest 
reliability, scores on two identical questionnaires completed by parents at two-week 
intervals were compared. Based on the percentage of agreement between the 
outcomes of the two completed questionnaires, test-retest reliability was reported to 
be 94% (standard error of the mean [SEM]=0.10).  Interrater reliability was determined 
by evaluating the percentage of agreement between the classification of children as 
assessed by parent-completed questionnaires and by professional examiners. Inter-
rater reliability was found to be 94% (SEM=0.12). The percent of agreement will often 
overestimate true reliability because it fails to account for chance agreement. The 
Kappa statistic would have been preferable for calculating the test-retest and interrater 
reliability of the ASQ (Portney and Watkins, 2000).  
 
2.15.4.2 Reliability of the AIMS 
Interrater reliability was assessed through simultaneous administration by two different 
examiners where one examiner actively scored the test while the other observed, and 
scored the test independently. The scores obtained for the 221 infants included in this 
correlation analysis resulted in an interrater reliability coefficient of > 0.996 (Piper et al, 
1992). Test-retest reliability was analysed by administering the AIMS to 253 infants on 
two occasions, within seven days of each other. The test-retest reliability across all 
ages on the AIMS ranged from 0.86 to 0.99 but the authors do not report the statistic 
used to calculate the reliabilities (Coster, 1995).  
 
2.15.4.3 Reliability of the Denver-II 
For the Denver-II, test-retest reliability at seven to 10 days was found to show 
excellent agreement for 59% of the Denver-II items (k≥0.75), whereas 23% of items 
demonstrated fair to good agreement (k≥0.40). Interrater reliability was (≥0.75) 
(Frankenberg et al, 1992). Interrater relibaility was assesed using 17 examiners, who 
each assessed five children. One hundred and forty one items had 100% agreement, 
seven items had 90-99% and one item had 83%.  
 
2.15.4.4. Reliability of the HINT 
Interrater reliability of the HINT was examined by five paediatric physical or 
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occupational therapists for 28 infants at high risk (Harris and Daniels, 2001). One 
therapist served as the primary examiner and administered the test, while a second 
therapist observed and scored the test independently. For the total HINT score, the 
interrater reliability intra-class correlation coefficient (ICC) was 0.99. To evaluate test-
retest reliability, the primary examiner re-administered the HINT within nine days of 
the initial screening for 20 of the infants. The test-retest reliability ICC=0.98. Intrarater 
reliability was examined by videotaping the assessments of 20 infants, scoring the 
videotapes, and then rescoring them at least one month later. For the five therapists, 
the intrarater reliability and intra-class correlation coefficients (ICCs) ranged from 0.98 
to 0.99 (Harris and Daniels, 2001).  
 
2.15.4.5 Reliability of the BINS 
For the BINS, test-retest reliability was conducted by correlating BINS scores for 150 
infants who were tested twice, the time interval being one week apart (Aylward, 1995). 
The reliability coefficient scores ranged from 0.71-0.84 depending on the child’s age. 
Interrater reliability was conducted on 90 infants, and the number of examiners ranged 
from 15 to 18. For each infant, one examiner assessed the child, while the other 
observed and scored at the same time. Reliability coefficient results ranged from 0.79-
0.96 (Aylward, 1995).  
 
2.15.4.6 Reliability of the Bayley-III Screening Test 
Internal consistency of the items was tested resulting in the following scores: 
Cognitive=0.85, Receptive Communication=0.88, Expressive Communication=0.88, 
Fine Motor=0.82 and Gross Motor=0.86, which reflects a high degree of internal 
consistency in the items (Bayley, 2006c). Test-retest reliability was tested using 203 
children who were tested twice (range of 2-30 days between tests), with stability 
coefficients of between 0.80-0.83 revealing that the Bayley-III Screening Test provides 
consistent measurements (Bayley, 2006c).  
 
It is difficult to compare the reliability results of the screening tools, as different 
methods and statistical calculations have been used, Only the HINT meets the 
recommended reliability requirements for screening tests (Rothstein et al, 1991), as 
none of the other tools reported on intrarater reliability.   
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As can be seen from the above review of the screening tests, none of the tests 
reviewed satisfies the criteria of having a representative standardisation sample as 
well as acceptable levels of reliability, validity, sensitivity, specificity, and positive 
predictive values (Harris et al, 2005). The AIMS is the strongest with regards to 
reliability, concurrent validity, and predictive validity, but is limited in comparison with 
the other tests in that it assesses only gross motor development. Although the AIMS’ 
standardisation sample is large (n=2202) and was randomly selected and stratified by 
age and gender, concerns exist about the failure to report ethnic and socioeconomic 
variables (Harris et al, 2005).  
 
The Denver-II has questionable accuracy in concurrently identifying typical children 
when compared with other standardised developmental assessments. In spite of 
having been published more than a decade ago, the predictive validity of the Denver-II 
has yet to be evaluated. Furthermore, the normative sample for the Denver-II was 
limited to children from the state of Colorado. Similar to the Denver-II, no predictive 
validity studies have been conducted for the ASQ, although this was not the intended 
goal. The HINT has strong reliability as well as acceptable concurrent validity with the 
Bayley-II. The predictive relationship of the HINT to the Bayley Motor Scale was 
modest, albeit stronger than the early Bayley Motor Scale’s relationship to the later 
Bayley Motor Scale. Compared with the other tests, the HINT’s normative sample is 
the smallest but its age range is also the narrowest. The normative sample is, 
however, diverse and representative of a variety of ethnic groups and maternal 
education levels. The Bayley-III Screening Test’s accuracy improves with the 
classification category, which is problematic, as the lowest scores are in the At-Risk 
group – therefore the sensitivity of this screening test is poor. In light of the fact that 
each of the screening tests reviewed has identified strengths and weaknesses, 
practicing clinicians should use stringent criteria in determining which test to use 
within their own setting (Harris et al, 2005).  
2.16 Test Manual 
The following information should be outlined in the test manual:  
The purpose of the screening test, as stated (Rothstein et al, 1991).  The desired 
qualifications of the examiner or assessor should be outlned. The age range that the 
test covers should be stated. The time needed to administer and score the test should 
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be described, and is especially important where time constraints may apply. The 
developmental domains encompassed by the screening test should be outlined to 
ensure that the correct aspects of development are being assessed (Rothstein et al, 
1991). The comparability between the standardisation sample used to determine 
normal values of the test (eg, ethnicity, gender, demographic characteristics) and 
those of the infants or children being screened should be discussed (Rothstein et al, 
1991). Lastly, the traditional psychometric properties of the test (eg, reliability, validity) 
and/or the clinical epidemiological characteristics (eg, sensitivity, specificity) should be 
outlined in order to determine whether the test has been well-developed and will 
ascertain what it was developed for (Harris et al, 2005).  
2.17 Conclusions 
Paediatric HIV remains a major health challenge in South Africa. HIV is known to 
cause neurological damage through a number of pathological mechanisms. This 
results in a well described encephalopathy which causes developmental complications 
early on in childhood, and affects all facets of development, most notably gross motor 
development. Children use motor skills to interact with their peers and to maintain 
levels of confidence and independence in daily activities. Cognitive growth and social 
maturation have both been associated with motor skill development (Heller, 1997). 
Evaluation of motor skills in children with HIV infection requires the establishment of a 
descriptive base of motor performance levels for this population (Smith et al, 2002). 
With the advent of antiretroviral therapy, many children are now living longer, but often 
with severe developemental delay or disability due to HIV encephalopathy.  
 
In developed countries, HIV positive children are routinely assessed for 
developmental problems, and are timeously referred for intervention. In South Africa, 
due to under-staffing, and high patient case loads, routine developmental screening 
has not been incorporated into routine paediatric HIV care, despite being a 
recommendation in the National Strategic Management Plan for HIV/AIDS for 2007- 
2011 (NSP, 2007). This is due to a number of factors including a lack of awareness, a 
lack of trained staff, a lack of time, and most of all, a lack of suitable outcome 
measures within this context.  
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There is therefore a need for a suitable screening tool, which is able to identify those 
children at risk for developmental delay, who may then be referred on for 
comprehensive developmental assessment and treatment. The screening tool should 
posess the following properties recommended by Rothstein et al (1991): the tool 
should be culturally sensitive, reliable, valid, and have high levels of sensitivity and 
specificity. As stated in chapter one this study therefore undertakes to evaluate an 
existing screening tool to determine its suitability for use in the South African context, 
and should this not prove to be suitable, a new screening tool will be developed, in 
order to address the need for identification and referral of those children with 
developmental problems.  
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Chapter 3 
MEASURING INSTRUMENTS  
In this chapter the measuring instruments used in this study will be discussed. Issues 
of reliability and validity are highlighted.  
3.1 Bayley Scales of Infant and Toddler Development III (BSID III) 
The Bayley Scales of Infant Development (BSID) were first published in 1969 and 
have long been considered the gold standard in developmental assessments (Harris 
et al, 2005; Tieman et al, 2005). Three versions of the BSID exist. The Bayley Scales 
of Infant and Toddler Development have been found to be sensitive to developmental 
changes in the first two years of life of infants who are medically fragile (Niccols and 
Latchman, 2002), and these findings support the clinical validity of the scale, which 
can be applied to those with HIV.  
 
Like its predecessors (Bayley Scales of Infant Development I and II), the Bayley 
Scales of Infant Development III (BSID III) is an individually administered instrument 
which assesses developmental functioning of infants and young children aged 
between one and forty-two months. The primary purpose of the  BSID III is to identify 
children with developmental delay and to provide information for intervention planning 
(Bayley, 2006a). The BSID III is a revision of the BSID II, and the revision was 
undertaken to improve the quality and enhance the utility of the instrument. The 
separate areas of Expressive and Receptive Communication, and Fine and Gross 
Motor function are able to be analysed individually in the BSID III. The BSID III was 
standardised on a national sample of 1,700 children in the United States of America 
who were stratified by age, sex, race/ethnicity, parent education level and region 
(Bayley, 2006b). The BSID III is reliable and valid, and is predictive of later 
developmental outcome (Bayley, 2006b). Internal consistency coefficients range from 
r=0.86 (Fine Motor) to r=0.91 (Cognitive, Expressive Communication and Gross 
Motor), to Receptive Communication which is r=0.87.The test-retest reliability ranges 
between r=0.63-0.87.  The interrater reliability coefficient is r=0.82. The concurrent 
validity between the BSID II and BSID III ranged between r=0.41-0.71 (Bayley, 
2006b). The BSID III is not an appropriate tool to use in busy HIV clinics in South 
The Development of a Screening Tool to Evaluate Infants who are HIV Positive  
 71 
Africa, as the administrator needs to be trained in the use of the tool and the 
assessment is lengthy.  
 
The Bayley Scales of Infant Development II (Bayley N, 1993), has been extensively 
used in HIV/AIDS research worldwide, and has also been used in South Africa in 
order to be able to compare results with worldwide studies (Potterton et al, 2009a; 
Potterton et al, 2009b; Baillieu and Potterton, 2008; McGrath et al, 2006a; Aina and 
Morakinyo, 2005; Chase et al, 2000; Drotar et al, 1997; Gay et al, 1995). The BSID I 
was normed on over 700 South African children taken from both urban and rural 
areas, and was found to be suitable for use on South African infants (Richter et al, 
1992; Richter and Griesel, 1988). The South African infants scored above the test 
norms up to 10 months of age on both the Mental and Motor scales, and from 10 
months up to the middle of the second year the groups obtained very similar scores. 
The trend across the whole age range in the South African sample was for urban 
children to score higher than rural children on both the Mental and Motor scales, 
although this was not statistically significant across the age range (Richter and 
Griesel, 1988). Based on these findings, the authors recommended that the BSID be 
used without adaptation on South African children. A study was also done in Uganda, 
examining normative data for the BSID II on infants between eight weeks and 30 
months (Aina and Morakinyo, 2005). They determined that the infants scored above 
the normal values in both the Mental and Motor scale of the BSID II, and furthermore, 
their scores in the motor scale were significantly higher, especially in the lower age 
groups of eight, 16 and 32 weeks when compared with data from the Western world 
(Aina and Morakinyo, 2005).   
 
The BSID III has been tested on normal black African infants (0-18 months) in 
Johannesburg who come from similar socioeconomic backgrounds to this study 
population, and results showed that the infants did well, and were often above 
average, which indicates that the BSID III is suitable for use on this population 
(Rademeyer, 2010; Brown, 2009). The procedure for training and interrater reliability 
testing is outlined in chapter four.  
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3.2 Bayley-III Screening Test 
The Bayley-III Screening Test was developed using items from the BSID III. It is 
designed to assess briefly the cognitive, language and motor functioning of infants 
and young children between one and forty-two months. The primary purpose is to 
determine whether a child shows competence in age-appropriate tasks, shows 
evidence of emerging age-appropriate skills, or shows evidence of being at-risk for 
developmental delay. It was standardised on a sample of 1,675 children in the United 
States of America and included representative proportions of infants according to 
selected demographic variables. It has been shown to be reliable and valid (Bayley, 
2006c). Internal consistency ranges between r=0.82-0.88, and test-retest reliability 
ranges between r=0.73-0.89. Validity was examined through test content, and 
classification accuracy against the BSID III. Classification accuracy ranges between 
41.82% to 92.11% (Bayley, 2006b) Due to the fact that this tool was developed 
directly from the BSID III, which has long been considered to be the ‘gold standard’ in 
infant developmental assessment (Harris et al, 2005; Tieman et al, 2005), and the 
BSID I and II have shown to be suitable for use on a South African population, it was 
concluded that the Bayley-III Screening Test would be the most appropriate screening 
test to evaluate for use  in the screening of infants infected with HIV.  
3.3 Household Economic and Social Status Index (HESSI) 
The Household Economic and Social Status Index (HESSI) was used to collect 
demographic information in this study. The HESSI was developed and standardised in 
Soweto, South Africa (Barbarin and Khomo, 1997).  
 
 The HESSI has the following characteristics:  
 Simplicity in administration; ease of calculation;  
 Scaled to be sensitive to variations in economic status at the low end of the 
economic scale;  
 Reliance on information which is accessible to the informant;  
 High correlations with widely used methods for assessing economic well-being; 
and  
 Dimensions which have cross-cultural, cross-regional and cross-national 
reliance (Barbarin and Khomo, 1997).  
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Barbarin and Khomo (1997) recognised that financial resources alone are not an 
accurate measure of poverty in developing countries, and therefore rather than relying 
on self-reported income, the scale focuses on hunger, housing, utility expenses, 
possession of durable consumer goods, and accumulation of assets, social status and 
education (Barbarin and Khomo, 1997). Although these indicators may lack the 
financial specificity for studies of economic development, they are useful for studies of 
individual behaviour and child development (Barbarin and Khomo, 1997).  The HESSI 
has been used in longitudinal studies in Soweto in order to evaluate socioeconomic 
status on a similar population (Potterton et al, 2009a; Potterton et al, 2009b; Barbarin 
and Richter, 2001; Barbarin and Khomo, 1997).  
3.4 Conclusion 
Based on the literature reviewed it was determined that the BSID III was the most 
appropriate developmental assessment tool for use in this study. The Bayley-III 
Screening Test was developed directly from the BSID, and it was therefore 
determined that this would be the most suitable screening tool to evaluate HIV- 
infected infants. The HESSI was considered to be an appropriate tool for assessing 
socioeconomic status in this study population as it was developed in Soweto, South 
Africa and focuses on socioeconomic factors which may impact on a child’s 
development.   
The Development of a Screening Tool to Evaluate Infants who are HIV Positive  
 74 
Chapter 4 
STUDY ONE: THE EVALUATION OF THE BAYLEY-III SCREENING 
TEST AGAINST THE BAYLEY SCALES OF INFANT AND TODDLER 
DEVELOPMENT III 
 
Study one consisted of the testing of the Bayley Scales of Infant and Toddler 
Development III (BSID III), against the Bayley-III Screening Test, to evaluate whether 
the Bayley-III Screening Test was suitable for use on this study population. The 
methodology and results for this stage will be presented in this chapter.  
 
The objectives of this study were to:  
• Test the Bayley-III Screening Test against the Bayley Scales of Infant and 
Toddler Development III in order to determine its suitability for use in South 
Africa 
• Analyse demographic, anthropometric, and immunologic data in order to 
describe the health and socioeconomic status of the sample  
4.1 Location 
This study was conducted at the Harriet Shezi Children’s Clinic, which is a public 
sector paediatric HIV clinic at Chris Hani Baragwanath Hospital in Soweto, South 
Africa. This is an outpatient clinic, which provides a variety of services for HIV positive 
children. Children are managed by a multi-disciplinary health team including 
paediatricians, medical officers, primary health care sisters, professional nurses, lay 
counsellors, dieticians, psychologists and pharmacists. Children are referred to the 
Harriet Shezi Children’s clinic as soon as they are diagnosed with HIV. They are 
followed up at 3-6 monthly intervals depending on how well they are, and may be 
seen more regularly if they are ill.  
 
The doctors at the clinic see over 100 HIV positive patients per day, ranging in age 
from birth to 16 years. Harriet Shezi clinic is an example of a relatively well-staffed, 
well-resourced urban clinic, and children who attend this clinic have access to many 
more services than are available in most other clinics in South Africa. In outlying 
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clinics, due to a shortage of doctors, children may be seen by nurses, who may be in 
charge of administering antiretrovirals, as well as making complex clinical decisions.  
All clinics, regardless of services offered, are understaffed due to the high numbers of 
children who attend the clinics each day. Harriet Shezi clinic was chosen as the 
location for data collection, as it is representative of a paediatric clinic in South Africa 
in terms of patient characteristics and volumes.  
4.2 Ethical Considerations 
Ethical clearance was obtained from the Committee for Research on Human Subjects 
at the University of the Witwatersrand (Clearance certificate M070817) (See Appendix 
I).  
 
Permission to conduct the study was obtained from the hospital Chief Executive 
Officer at Chris Hani Baragwanath Hospital, as well as the head of the Harriet Shezi 
Clinic (See Appendix II and III).  
 
Informed, written consent for the child was obtained from his/her primary caregiver 
prior to him/her being enrolled in the study. The study was explained to the caregiver 
and a written information sheet was provided. Caregivers were given the opportunity 
to ask questions before giving their consent (See Appendix IV).  
 
The results of the assessment were discussed with the primary caregiver, and where 
the child was found to be delayed and in need of therapy, appropriate referrals were 
made. Home advice was also given to each caregiver regarding appropriate activities 
to do with the child in order to facilitate development.  
4.3 Study Design  
The design for study one was a cross-sectional study. 
4.3.1 Subjects 
Consecutive subjects were recruited from the Harriet Shezi Children’s Clinic at Chris 
Hani Baragwanath hospital, Soweto. The caregivers of all children who met the 
inclusion criteria were asked to participate in the study. 
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4.3.2 Sample Size 
For study one, the sample size calculation was performed as follows: the expected 
proportion of successes was 0.8 and testing was at the 0.05 level of significance. A 
sample size of 112 had a 90% power to detect a kappa of 0.75 (H1: kappa > 0.75) 
when testing the null hypothesis that kappa was 0.4 (Ho: kappa = 0.4). The sample 
size when comparing the Bayley Scales of Infant Development III with the Bayley-III 
Screening Test was therefore 112 infants. 
 
Inclusion criteria: 
• HIV positive infants aged between six and 18 months 
 
Exclusion criteria: 
• Infants who had severe enough physical and/or sensory impairments, which 
would not allow a norm-referenced score to be obtained on the Bayley Scales 
of Infant and Toddler Development III as outlined in the manual (Bayley, 2006a) 
4.4 Materials and Measurements 
4.4.1 Bayley Scales of Infant and Toddler Development (3rd version)(BSID III) 
The Bayley Scales of Infant and Toddler Development III (Bayley, 2006a) have been 
found to be suitable for use on infants who are medically fragile (Niccols and 
Latchman, 2002). The BSID III assesses Cognitive function, Expressive and 
Receptive Communication, and Fine and Gross Motor function (Bayley, 2006a).  
4.4.2 Bayley-III Screening Test 
The Bayley-III Screening Test items are a subset of items of the Bayley Scales of 
Infant and Toddler Development, Third Edition (Bayley, 2006a; Bayley, 2006c). The 
test is designed to briefly assess the cognitive, language and motor functioning of 
infants and young children between 1-42 months of age and to determine whether a 
child shows competence in age-appropriate tasks, shows evidence of emerging age-
appropriate skills, or shows evidence of being at-risk for developmental delay (Bayley, 
2006c). 
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4.4.3 Household Economic and Social Status Inventory (HESSI) 
The HESSI was used to give an indication of socioeconomic status in this population. 
This tool was developed in Soweto, South Africa (Barbarin and Khomo, 1997).  
4.4.4 Anthropometric Measurements 
Height/length and weight were measured routinely by the clinic nurses prior to the 
children seeing a doctor. Head circumference was measured in centimeters by the 
researcher, using a tape measure. The tape measure was placed just above the 
eyebrows and ears, and around the occipital bulge at the back of the child’s head. The 
measure was recorded to the nearest 0.1cm. 
 
Children who could stand independently had their height measured using a wall 
mounted scale (Hottain Ltd, Crymych, Dyfed). The children stood against the 
measure, bare foot or in socks, with their heels against the wall, and had the 
horizontal plate lowered until it rested on top of their heads. Height was recorded in 
centimeters. Infants who could not stand had their length measured in supine on a 
“Morena Baby Measuring Mat”. Their heads were placed against the vertical board 
and the measurement was taken at the heel. Length was recorded in centimeters. 
Children who could stand had their weight measured on a Standing Digital Scale 
(Seca). Infants were weighed on a Tanita 1584 Baby Scale. Weight was recorded in 
kilograms to two decimal places. 
4.4.5 Immunologic and Virologic Data 
The child’s clinical file was examined and the most recent CD4 count and viral load 
were noted, as well as their antiretroviral regimen and how long they had been on 
antiretroviral therapy.  
4.5 Procedure 
4.5.1 Training and Reliability 
The administration of the BSID III is not limited to specific professions, however, 
paediatric experience is recommended. The researcher and the two research 
assistants who participated in the study all have more than five years of paediatric 
clinical experience and are well versed in the administration of standardised 
assessments. The researcher and two research assistants went through the 
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assessment thoroughly, and each item was discussed. The BSID III was administered 
to two normal children in order to practice administration of the items. Prior to 
commencement of data collection, interrater reliability was conducted between the 
researcher and the two research assistants on both the Bayley Scales of Infant and 
Toddler Development III and the Bayley-III Screening Test. Ten children (just under 
ten percent of the sample size for the first stage of the study) were assessed by the 
researcher and the two research assistants (one administered the items and allocated 
scores, while the other two observed and allocated scores). The scores were 
compared, and results are depicted in Table 4.1 and Table 4.2 below:    
 
Table 4.1 Agreement between Researcher and Research Assistants on the 
BSID III (n=10) 
Domain Agreement between 
researcher and 
research assistant 1 
Agreement between 
researcher and 
research assistant 2 
Cognitive 100 % 100 % 
Expressive Communication 99 % 100 % 
Receptive Communication 100 % 99 % 
Fine Motor 100 % 100 % 
Gross Motor 100 % 100 % 
 
The agreement between the researcher and the research assistants on the BSID III 
was excellent. The main discrepancies occurred in the Language domains, and 
therefore the responses were examined, and the reasons as to the differing scores 
were discussed and consensus on scoring was reached.    
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Table 4.2 Agreement between Researcher and Research Assistants on the 
Bayley-III Screening Test (n=10) 
Domain Agreement between 
Researcher and 
Research Assistant 1 
Agreement between 
Researcher and 
Research Assistant 2 
Cognitive 100 % 100 % 
Expressive Communication 100 % 99 % 
Receptive Communication 99 % 98 % 
Fine Motor 100 % 100 % 
Gross Motor 100 % 100 % 
 
Again, agreement between the researcher and research assistants on the Bayley-III 
Screening Test was excellent, and only small discrepancies in scores were 
encountered in the Language domain. The results and responses were discussed, 
and consensus was reached as to what the correct responses from the child should 
be. The agreement between the researchers was excellent, and therefore data 
collection could proceed following the reliability testing.  
4.6 Data Collection 
The files for each child attending the clinic that day were laid out as soon as the 
caregiver registered at reception. The files were screened to determine the ages of 
the infants who were registered for the clinic, and all infants between the ages of six 
and 18 months were selected. The caregivers of the children who met the inclusion 
criteria were approached, and the caregiver was given a letter of information regarding 
the study. Where the caregiver could not speak or understand English, a counsellor or 
nurse was asked to translate. Once the caregiver agreed to participate, he/she was 
asked to give written informed consent for the child and his/herself (see Appendix IV). 
The researchers waited for the children to be weighed and measured before taking 
the child and caregiver to a quiet room to be assessed. The caregiver was asked to 
complete the HESSI form (and again where English was not understood, a counsellor 
or nurse was asked to translate for the assessment). The child’s height, weight, CD4 
count and viral load were noted from the file, as well as the combination of 
antiretroviral drugs the child was on, and length of time that they had been on 
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treatment. The child’s head circumference was measured by the researcher with a 
tape measure – this procedure is described in 4.4.4 above. 
 
The child was assessed on the BSID III and the Bayley-III Screening Test according to 
the guidelines outlined in the manuals. Once the assessments had been scored, the 
results were given to the caregiver, and the child’s developmental status was 
discussed, along with the impact of HIV on neurodevelopment. When the child 
obtained a low score, he/she was appropriately referred, and where home intervention 
was appropriate, activities and advice were given to the caregiver. One hundred and 
twelve (112) infants between the ages of six and 18 months were assessed, and the 
data were entered into Excel spreadsheets.  
4.7 Statistical Analysis  
Statistical analysis was performed in consultation with the Medical Research Council 
of South Africa using STATA (version 10). The agreement between the Bayley Scales 
of Infant and Toddler Development III and the Bayley-III Screening Test was analysed 
using a Kappa statistic for ordinal data.  
 
The Kappa scores were interpreted as follows:  
<0.4 = poor agreement 
≥ 0.4-0.74 = moderate agreement 
≥ 0.75 = excellent agreement (Landis and Koch, 1977) 
 
Demographic, anthromometric, immunologic and virologic data collected during study 
one were descriptively analysed using means, standard deviations and percentages. 
Z-scores were used for the following: height-for-age, weight-for-age, body mass index 
(BMI), head circumference, and weight-for-height.  
4.8 Results 
The results for this stage of the study will be presented and briefly discussed. 
Demographic information, anthropometric data, immunological data and 
developmental scores will be presented to give an indication of the health and 
socioeconomic status of the sample.  
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4.8.1 Demographic Information  
Demographic information was collected using the HESSI questionnaire. Means and 
standard deviations or percentages were used to summarise the data. The data are 
displayed in Table 4.3 below: 
 
Table 4.3 Demographic Information of the Sample (n=112) 
Age (months) 11.38 (±3.9) 
Primary Caregiver 
Mother 
Grandmother 
Father 
Aunt 
Other 
 
 
91 (81.3%) 
16 (14.3%) 
1   (0.8%) 
2   (1.8%) 
2   (1.8%) 
Education of primary caregiver 
<grade 5 
grade 5 – 6 
grade 7 – 9  
grade 10 – 11 
grade 12 
tertiary 
 
 
6   (5.3%) 
7   (6.4%) 
25 (22%) 
40 (35%) 
28 (25%) 
7   (6.3%) 
Total number of people living in the house 4.8 (±2.1) 
 
Total number of adults living in the house 3.1 (±1.3) 
 
Total number of children living in the house 2.1 (±1.2) 
 
Means of income 
1 adult bringing in income 
2 adults bringing in income 
Grant dependent families 
No income 
 
51 (45%) 
6   (5.3%) 
27 (24.7%) 
28 (25%) 
 
Housing 
Shack 
Room 
Flat 
Home shared with other family 
Own home 
 
51 (45%) 
9   (8%) 
6   (5.3%) 
32 (29.2%) 
14 (12.5%) 
 
The mean age of the sample was 11.38 (±3.9) months. Eighty-one percent of primary 
caregivers were mothers, with grandmothers taking on this responsibility where 
mothers were no longer alive. Most primary caregivers had not completed school, and 
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therefore maternal education levels were low. When taking the average number of 
people per household (4.8 people) together with the fact that 45% of the families lived 
in a shack, and in 45% of families there is only one adult bringing in an income, the 
socioeconomic status of the sample was determined to be low.  
4.8.2 Anthropometric Data 
The anthropometric data are presented below, and are represented by means and 
standard deviations of z-scores which were calculated using height, weight, head 
circumference, age and gender. The results are shown in Table 4.4 below: 
 
 
In 2006, the World Health Organisation released two sets of child growth standards to 
replace the National Centre for Health Statistics References as a tool for growth 
monitoring, nutrition screening, and surveillance, as a clinical tool to assist with the 
diagnosis of malnutrition, and as a tool for nutrition research (Van den Broek, 2009; 
WHO, 2006a). The summary statistics can be compared with the reference, which has 
an expected mean z-score of 0 and a SD of 1.0 for all normalised growth indices. 
 
Table 4.4 Anthropometric Data of the Sample (n=112) 
 6 – 8 m  
(n=38) 
9–11 m 
(n = 23) 
12 – 14 m 
(n = 21) 
15 – 18 m 
(n = 30) 
Total 
Group 
(n= 112) 
Head 
circumference   
-3.36(± 2.25) -2.66 (±1.4) -2.99 (±3.0) -2.84 (±2.1) -3.01 (±2.2) 
 
Height-for-age -2.26 (±1.5) -1.60 (±1.6) -1.82 (± 1.3) -2.87(± 2.0) -2.21 (±1.7) 
 
Weight-for-age 
 
-2.29 (±1.8) -1.46 (±1.6) -1.36 (±1.6) -1.94 (±2.0) -1.85 (±1.8) 
 
Weight-for-
height 
 
-1.10 (±1.99) -0.75 (±1.5) -0.64 (±1.6) -0.74(±1.9) -0.85 (±1.7) 
BMI -1.39 (±2.09) -0.73 (±1.4) -0.41 (±1.6) -0.35(±1.9) -0.79 (±1.8) 
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4.8.2.1 Malnutrition, Stunting and Wasting 
Moderate malnutrition is defined as a weight-for-age between -3 and -2 z-scores 
below the median of the WHO child growth standards (WHO, 2006a), similarly, 
moderate wasting and stunting are defined as a weight-for-height and height-for-age 
respectively, between -3 and -2 z-scores (WHO, 2006a). Severe acute malnutrition 
(severe wasting and/or oedema) or severe stunting is defined as height-for-age less 
than -3 z-scores (WHO, 2006a).  
 
All data used to determine whether there is malnutrition, wasting or stunting present in 
this sample are presented in Table 4.4 above. In terms of malnutrition in this sample, it 
can be seen that only the younger group (6-8 months) is affected, with a mean weight-
for-age of -2.29, which is indicative of moderate malnutrition.  
 
Stunting is a problem in this sample, and is most severe in the 6-8 month old age 
group, where there is moderate stunting (height-for-age =-2.26). The 15-18 month age 
group also shows moderate stunting (height-for-age =- 2.87).  
 
4.8.2.2 Body Mass Index (BMI) 
Body Mass Index (BMI) is a simple index of weight-for-height that is commonly used 
to classify underweight, overweight and obese children. It is defined as the weight in 
kilograms divided by the square of the height in metres (kg/m) (WHO, 2006a). The 
only group with a low body mass index is the 6-8 month age group, again, due to their 
low weight measurements.  
 
4.8.2.3 Head Circumference 
The children in this sample had head circumference z-scores of between -2 and -3, 
indicating that they are below the WHO average, when taking the cut-off score of less 
than -2. Head circumference is known to correlate closely with brain volume and can 
therefore be used to measure brain growth (Wickett et al, 2000).  It has been found 
that postnatal brain growth is more important than prenatal brain growth in 
determining higher mental function at the age of nine years (Gale et al, 2004). This is 
of concern for these children, as they may be affected cognitively when reaching 
school age.   
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4.8.3 Immunological and Antiretroviral Status 
The immunological status of the infants is consistently monitored at the clinic. 
Baseline laboratory tests including CD4 cell count, CD4 percentage (percentage of 
total lymphocyte count) and full blood count are performed for each child. Children not 
yet meeting the criteria for HAART initiation are followed up at varying intervals which 
are dependent on age, immune status and clinical disease category, until they meet 
the criteria for HAART. Prior to HAART initiation, a viral load test is performed and lay 
counsellors provide counselling and information on HAART and adherence. Children 
undergo a clinical examination at four and 12 weeks after HAART initiation, and are 
assessed at 12 weekly intervals thereafter. CD4 count, CD4 percentage, and viral 
load tests are performed 24 weeks after starting HAART, and are repeated every 24 
weeks thereafter.  
 
CD4 percentage and viral load are used by the clinic to monitor immune status and 
adherance or response to HAART. According to the South African Department of 
Health guidelines (DOH, 2008), treatment failure is defined as the following:  
- no improvement in CD4 percentage after 24 weeks of HAART 
- return of CD4 percentage (repeated after one month of treatment) to baseline or 
below, in the absence of concurrent illness 
- more than 50% decline in CD4 percentage from peak (confirmed within one 
month) in the absence of concurrent illness 
- rebound of viral load to baseline 
 
Immunological data including CD4 percentage and viral load were collected for each 
child in this study in order to assess their current immunological status. The latest 
available values were recorded from the file. The immunological and virological status 
of the sample is shown in Table 4.5 below: 
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The immunological status of this sample was rather varied, and no real conclusions 
could be drawn from it. The number of children overall who are receiving HAART is 
not optimal (68.8%). The mean viral load drops with increasing age, and the mean 
CD4 percentage increases with increasing age.  
4.8.5 BSID III Composite Scores 
The mean composite scores achieved by the sample are presented below. These 
scores give an indication of where the infant’s development lies relative to the average 
score (Bayley, 2006b). Composite scores have a range of 40 to 160, a mean of 100 
(which is the average), and a standard deviation of 15 (Bayley, 2006b) (See ‘Definition 
of Terms’ on page xviii for interpretation of the scores). The composite scores are 
presented as means with the standard deviation for each age group and for the total 
group in Table 4.6 below: 
 
 
 
 
 
 
 
 
Table 4.5 Immunologic and Antiretroviral Status of the Sample (n=112) 
Age  n Number of 
children on 
HAART 
Average length of 
time on HAART 
CD4% Viral Load 
6–8 m 
 
38 24 (63.2%) 6.3 weeks (±6.4) 19.6%(±9.6) 96262 (±26) 
 
 
9–11 m 
 
23 18 (78.3%) 16.8 weeks (±11.4) 23.0% (±12) 38037 (±75.2) 
 
 
12–14 m 
 
21 13 (61.9%) 15 weeks (± 17.2) 22.2%(±9.6) 11124(±116.7) 
 
15–18 m 
 
30 22 (73.3%) 15.9 weeks (±15.4) 28.0%(±0.5) 5568.6(±78.7) 
Total  112 77 (68.8%) 18 weeks (±2.8) 
 
23.0% (±9.9) 21823.2 (±3.5) 
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Table 4.6 BSID II Composite Scores and Interpretation (n = 112) 
Age n Cognitive Language  Motor 
6 – 8 months 38 85 (± 20.85) 95 (± 18.68) 76 (± 23.95) 
9 – 11 months 23 86 (± 14.20) 93 (± 15.47) 74 (± 20.59) 
12 – 14 months 21 75 (± 17.41) 81 (± 15.80) 71 (± 8.72) 
15 – 18 months 30 74 (± 15.22) 79 (± 14.19) 68 (± 15.59) 
Total Group 112 80 (± 18.04) 88 (± 17.68) 72(± 20.32) 
 
The composite scores give an indication as to the developmental status of the sample. 
Language function is the area which is least affected in the sample, although the only 
scores which fell into the Average range in the Language domain were those in the 
two younger age groups. Cognitive function is less affected than motor function in this 
sample, although the scores are low and fall into the ‘Low Average’ and ‘Borderline’ 
categories. Motor function is the area of development which is most consistently 
severely affected, and falls into ‘Borderline’ or ‘Extremely Low’ categories. In all 
domains, the scores worsen as the children get older. The percentage of infants in 
each classification category for Cognitive, Language and Motor function is shown in 
Table 4.7 below:  
 
In each area of development, there is a large percentage of infants who scored in the 
Extremely Low range (69 and below). This is most evident in the Motor facet, where 
Table 4.7 Percentage of Infants in each Classification Category for Cognitive, 
Language and Motor Development 
Composite Classification Cognitive Language Motor 
130 and above Very Superior 0.9% 0% 0% 
120 – 129 Superior 0.% 1.8% 0% 
110 – 119 High Average 3.6% 8% 2.7% 
90 – 109 Average 31.3% 41.1% 19.7% 
80 – 89 Low Average 17.9% 17.9% 17% 
70 – 79 Borderline 17% 16.1% 18.8% 
69 and below Extremely Low 28.6% 15.2% 42% 
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41.96% of infants obtained scores in the Extremely Low range. Within the Cognitive 
facet, infants most commonly obtained scores in the Average range, followed by the 
Extremely Low range. In the Language domain, infants most commonly obtained 
scores in the Average range.  
4.9 Agreement between BSID III and the Bayley-III Screening Test 
The scaled score of the BSID III represents the child’s performance on a subtest 
relative to his or her peers of the same age (Bayley, 2006b), and may be converted to 
the category obtained on the Bayley-III Screening Test (Bayley, 2006c) (See 
‘Definition of Terms’ on page xix for conversion of the scores).   
 
The data for each child were entered into Excel, and the results for the BSID III were 
converted to the same format as the Bayley-III Screening Test (At-Risk, Emerging, 
and Competent) for comparison. In order to enter the data in Excel, each category 
was assigned values as follows: the category ‘At-Risk’ was assigned a value of one, 
‘Emerging’ was assigned a value of two, and ‘Competent’ was assigned a value of 
three. Agreement between the results was tested using a Kappa statistic for ordinal 
data. The results are presented in Table 4.8 below: 
Table 4.8 Agreement between the Bayley Scales of Infant and Toddler 
Development III and the Bayley-III Screening Test (n=112) 
Age 
group 
n Cognitive  Expressive 
Communication 
Receptive 
Communication 
Fine 
motor  
Gross 
motor 
 
6–8 
months 
 
38 0.41  0.75  0.55 0.28  0.61  
9–11 
months 
 
23 0.51 0.48  0.86 0.50 0.43 
12–14 
months 
 
21 0.69 0.79  0.78  0.51 0.92 
15–18 
months 
 
30 0.70 0.89  0.87 0.49  0.41  
Total 
group 
 
112 0.58 0.82  0.76  0.44  0.57 
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The above scores were obtained when each child was assessed on the BSID III, and 
the Bayley-III Screening Test, and were analysed as follows: the BSID III scaled score 
was used to compare the result with the Bayley-III Screening Test. The figures in bold 
represent the Kappa scores which denote excellent agreement. The agreement in 
each area of development is presented below:  
4.9.1 Cognitive Development 
The agreement between the Bayley-III Screening Test and the BSID III in the 
Cognitive facet ranged between 0.41 and 0.70. None of the Kappa scores in the 
Cognitive facet were higher than 0.70, representing moderate agreement across the 
Cognitive facet. The overall agreement in the Cognitive facet was 0.58, which 
represents moderate agreement (≥0.4 -<0.75).  
4.9.2 Language Development 
The agreement between the Bayley-III Screening Test and the BSID III was better in 
the Language facet. The Expressive and Receptive Communication domains had 
excellent agreement in all age groups apart from the 9-11 month group for Expressive 
Communication, and the 6-8 month age group for Receptive Communication. The 
overall agreement between the tools in the Expressive Communication facet was 
0.82, and in the Receptive Communication facet was 0.76, representing excellent 
agreement (≥ 0.75). 
4.9.3 Motor Development  
The agreement between the Bayley-III Screening Test and the BSID III in the Motor 
facet ranged between 0.28 and 0.92. The agreement in the Fine Motor facet was poor 
to moderate for all age groups, ranging between 0.28 and 0.50. In the Gross Motor 
facet the agreement ranged between 0.41 and 0.92, with most age groups 
demonstrating moderate agreement (≥0.4 -<0.75). The overall agreement in the Fine 
Motor facet was 0.44, and in the Gross Motor facet, was 0.57 which represents 
moderate agreement in both (≥0.4 -<0.75).   
4.9.4 Agreement Compared with Bayley-III Screening Test Standardisation 
Sample 
The classification accuracy of the Bayley-III Screening Test with the BSID III is 
outlined in the Bayley-III Screening Test technical manual (Bayley, 2006c). In order to 
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establish whether the present study had similar trends in classification accuracy, the 
data were analysed in the same way as is outlined in the technical manual. The 
percentage of children correctly identified by the Bayley-III Screening Test was 
calculated, and could then be compared with the Bayley-III Screening Test 
standardisation sample. This was done for each possible category of the test namely 
At-Risk, Emerging, and Competent. The classification accuracy of the Bayley-III 
Screening Test with the BSID III for At-Risk cases is shown in Table 4.9 below:  
 
Table 4.9 Classification Accuracy of the Bayley III Screening Test with the 
BSID III for At-Risk Cases 
 No of 
Cases on 
BSID III  
No of Cases 
on Bayley-III 
Screening Test 
 
Percentage 
Identified by 
Screening Test 
Screener 
Classification of 
Outlying Cases  
Cognitive 36 28 77.8% 5=Emerging (13.9%) 
3=Competent (8.3%) 
 
Receptive 
Communication 
 
17 14 82.4% 3=Emerging (17.6%) 
Expressive 
Communication 
18 15 83.3% 2=Emerging (11.1%) 
1=Competent (5.6%) 
 
Fine Motor 34 20 58.8% 14=Emerging(41.2%) 
 
Gross Motor 56 35 62.5% 18=Emerging(32.1%) 
3=Competent (5.4%) 
 
Table 4.9 shows the classification accuracy for the children identified by the BSID III 
as being At-Risk. In the technical manual (Bayley, 2006c), it is stated that 
classification accuracy was “moderate” for children with scaled scores of 1-4. The 
range for the standardisation sample was 41.82% for Fine Motor function to 65.9% for 
Receptive Communication. None of the children in the standardisation sample were 
identified as Competent. In the present study, the range is 58.8% for Fine Motor 
function to 83.3% for Expressive Communication. The range is wider, and Expressive 
Communication had better accuracy than Receptive Communication, but only by one 
percent. There were a number of cases where children were identified as Competent, 
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which did not occur in the standardisation sample (Bayley, 2006c). The range in the 
present study for children misidentified as Competent was 5.4% for Gross Motor 
function to 8.33% for Cognitive Function. The classification accuracy of the Bayley-III 
Screening Test with the BSID III for Emerging cases is shown in Table 4.10 below: 
 
Table 4.10 Classification Accuracy of the Bayley III Screening Test with the 
BSID III for Emerging Cases 
 No of Cases 
on BSID III  
No of Cases 
on Screening 
Test 
Percentage 
Identified by 
Screening 
Test 
 
Screener  
Classification of 
Outlying Cases  
Cognitive 32 19 59.4% 9=Competent (28.1%) 
4=At-Risk (12.5%) 
 
Receptive 
Communication 
 
33 31 93.9% 2=Competent (6.1%) 
Expressive 
Communication 
 
19 13 68.4% 5=Competent (26.3%) 
1=At-Risk (5.3%) 
Fine Motor 30 17 56.7% 8=Competent (26.7%) 
5=At-Risk (16.7%) 
 
Gross Motor 28 20 71.4% 8=Competent (28.6%) 
 
 
Table 4.10 shows the classification accuracy for the chidlren identified by the BSID III 
as having Emerging skills. In the technical manual (Bayley, 2006c), it is stated that 
classification accuracy was “accurate” for children with scaled scores of 5-7. The 
range for the standardisation sample was 63.9% for Cognitive function to 77.8% for 
Receptive Communication (Bayley, 2006b). The percentage of children misidentified 
as being At-Risk was very low (0.8%-5.2%) (Bayley, 2006c).  In this study, the range 
is 56.7% for Fine Motor function to 93.9% for Receptive Communication. The range is 
wider, and Fine Motor function had the lowest percentage of classification accuracy, 
but this was only two percent lower than Cognitive function. There were a number of 
cases where children were identified as At-Risk, which did not occur in the 
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standardisation sample (Bayley, 2006c). The range in this study for children 
misidentified as At-Risk was 5.3-16.7% which is much higher than the standardisation 
sample. Conversely, the range for children misidentified as Competent in the present 
study was 6.1% to 28.6% which indicates that the problems with which these children 
present with may be missed. The classification accuracy of the Bayley-III Screening 
Test with the BSID III for Competent cases is shown in Table 4.11 below:  
 
 
Table 4.11 shows the classification accuracy for the children identified by the BSID III 
as having Competent skills. In the technical manual (Bayley, 2006c), it is stated that 
classification accuracy was “very accurate” for children with scaled scores of 8-19. 
The range for the standardisation sample was 84% for Cognitive function to 92.1% for 
Receptive Communication (Bayley, 2006c). None of the children in the standardisation 
sample were misidentified as being At-Risk (Bayley, 2006).  In the present study, the 
range is 68.8% for Fine Motor function to 94.7% for Expressive Communication. In 
this case, Expressive Communication was higher than Receptive Communication, and 
Fine Motor function had the lowest accuracy. There were a few cases (2.3%) where 
children were identified as At-Risk, which did not occur in the standardisation sample 
Table 4.11 Classification Accuracy of the Bayley III Screening Test with the 
BSID III for Competent Cases 
 No of 
Cases on 
BSID III  
No of Cases 
on Screening 
Test 
Percentage 
Identified by 
Screening Test 
 
Screener 
Classification of 
Outlying Cases  
Cognitive 44 34 77.3% 9=Emerging (20.5%) 
1=At-Risk (2.3%) 
 
Receptive 
Communication 
 
62 55 88.7% 7=Emerging (11.3%) 
Expressive 
Communication 
 
76 72 94.7% 4=Emerging (5.3%) 
Fine Motor 48 33 68.8% 15=Emerging (31.3%) 
 
Gross Motor 28 25 89.3% 3=Emerging (10.7%) 
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(Bayley, 2006c). Similarly, the range for children misidentified as having Emerging 
skills was 5.3-31.3%.  
4.9.4 Conclusion 
As can be seen from the above results, the Kappa scores are poor to moderate for 
most domains, apart from the Language facets, and therefore the Bayley-III Screening 
Test could not be considered optimal for clinical use, as Kappa scores of ≥0.75 are 
preferred for clinical suitability (Landis and Koch, 1977). The scores with the highest 
level of agreement are those in the Expressive and Receptive Communication 
domains, but since Motor and Cognitive function are more severely affected in HIV- 
infected children, the screening tool needs to be sensitive enough to detect these 
problems, which it did not.  
 
The Bayley-III Screening Test was therefore unsuitable for use in this context, as it did 
not sufficiently detect the main problems that occur in these children. A new screening 
tool therefore needed to be developed, which would be more suitable for use in this 
context.  The development of a new test is therefore reported on in chapter five.  
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Chapter 5 
STUDY TWO: DEVELOPMENT OF A NEW SCREENING TOOL 
5.1 Development of a New Screening Tool 
The Bayley Scales of Infant and Toddler Development III and the Bayley-III Screening 
Test did not correlate sufficiently for clinical use (Kappa <0.75), and therefore a new 
screening tool had to be developed. The objectives for study two were as follows:  
- To identify items which would be suitable for inclusion in a new screening tool 
- To categorise items into age group suitability 
- To develop a scoring system for each age group 
- To develop a new screening tool based on the above three objectives 
5.2 Initial Identification of Developmental Facets to be Included in a New 
Screening Tool 
Developmental scores from the original sample were analysed to determine which 
facets of development were most severely affected in this group, and therefore which 
facets of development should be included in a screening tool. Motor development was 
consistently the lowest score obtained in all age groups (see Table 4.5). The scaled 
scores obtained on the BSID III were also examined in order to distinguish between 
Gross and Fine Motor function, and Expressive and Receptive Communication 
function, which the composite scores do not. The scaled scores (means and standard 
deviations) are presented in Table 5.1 below:  
 
Table 5.1 Scaled Scores Obtained by the Sample on the BSID III (n=112) 
Age n Cognitive Expressive 
Communication 
Receptive 
Communication 
Fine 
Motor 
Gross 
Motor 
 
6–8m 38 7.07 (±4.2) 8.55 (±3.2) 9.81(±3.7) 7.26 (±4.6) 5.15(±3.7) 
9–11m 23 7.00(±2.7) 9.17(±3.2) 8.82(±2.4) 7.39(±2.6) 5.65(±4.2) 
12–14m  21 5.14(±3.4) 7.09 (±3.8) 6.47(±2.1) 6.14 (±3.2) 4.28 (±3.7) 
15–18m  30 4.96 (±3.0) 7.36 (±2.9) 5.70 (±2.3) 5.20 (±2.6) 4.33 (±2.9) 
Total   112 6.13 (±3.6) 7.88 (±3.4) 8.08 (±3.3) 6.52 (±3.6) 4.88(±3.6) 
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Gross Motor function was consistently found to be the developmental facet that was 
most severely affected, followed by Cognitive function. In order to evaluate cognitive 
function, a large range of equipment is required, which would be costly to produce, 
and would require more time during evaluation, as more subtle responses are 
required. A screening tool needs to fulfil the following criteria in a busy clinic in a 
developing country:  
a) It should identify those children who are experiencing developmental problems, 
so that they may be referred for further assessment 
b) It should be sensitive enough to distinguish between children who are 
experiencing problems and those who are not 
c) It should be quick and easy to administer due to time constraints 
d) It should not require profession specific training, so that counsellors and nurses 
may also administer it, should the need arise 
e) It should be inexpensive enough to reproduce, and should not require any 
special equipment 
 
After careful examination of the above data, it was evident that a gross motor 
screening tool should be developed. Gross motor function is relatively quick and easy 
to assess, as no equipment is needed, which is a major consideration for clinics in 
South Africa and other developing countries, as time is limited, and budgets cannot 
cater for expensive assessments requiring equipment. The identification of gross 
motor function as being the most severely affected facet of development is in line with 
results of studies done globally as well as in South Africa (Potterton et al, 2009a; 
Potterton et al, 2009b; Ferguson and Jelsma, 2009; Baillieu and Potterton, 2008; 
Drotar, 1997; Chase et al, 1995; Nozyce et al, 1994).  
5.3 Process of Development 
The process of development of the new screening tool is outlined in Figure 5.1 below: 
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Figure 5.1 Process of development of the new screening tool 
5.3.1 Item Analysis 
Data from the BSID III Gross Motor scale were entered into an Excel spreadsheet. 
The scores for each item on the BSID III were entered as follows:  
1 = credit 
0 = no credit 
2 = finished the facet (after obtaining five zero’s in a row)  
The data were entered according to age group and were grouped according to the 
score obtained on the BSID III namely ‘At-Risk’, ‘Emerging’, and ‘Competent’ (See 
Appendix V for example).  
 
Percentages obtained by the group for each item were obtained for each score group 
(At-Risk, Emerging and Competent), and six items were then selected for each age 
group according to the percentages obtained. This was done as follows and is 
illustrated in Table 5.2:  
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Table 5.2 Item Selection 
Item Percentage 
Obtained in the  
At-Risk Group 
Percentage Obtained in 
the Emerging Group 
Percentage Obtained in 
the Competent Group 
1 <20 100 100 
2 <20 100 100 
3 0 ≤50 100 
4 0 ≤50 100 
5 0 0 As close to 100% as 
possible 
6 0 0 As close to 100% as 
possible 
 
Two items which discriminated the At-risk, from Emerging and Competent groups 
(less than 20% in the At-Risk group, and 100% in the other groups) were selected. 
Then, items which discriminated between Emerging and Competent groups were 
selected (0-5% of children who were At-Risk obtained credit, 30-50% of the Emerging 
group obtained credit, and 100% of the Competent group obtained credit). Lastly, two 
items were selected which discriminated the Competent group from the other two 
groups (100% or as high as possible in the Competent group, and 0% in the other 
groups).  
 
The selected items were grouped according to the age groups for study one (6-8 
months, 9-11 months, 12-14 months, 15-18 months). Scoring was determined as 
follows: the oldest children in the group should obtain credits for all items to be 
considered Competent; and one less credit was needed by each subsequent age 
group to be considered Competent. This was done following a literature search to 
determine which activities were appropriate per age group, and therefore which items 
a child should get credit for to be placed in the Competent or At-Risk categories. The 
Emerging category was assigned a score in the middle of the other two. Table 5.3 
illustrates this with an example from the 6-8 month age-group:  
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Table 5.3 Scoring 
Age Score Obtained to 
be placed in the 
Competent category 
Score Obtained to be 
placed in the 
Emerging category 
Score Obtained to 
be placed in the At-
Risk category 
6 months 4 3 ≤2 
7 months 5 4 ≤3 
8 months 6 5 ≤4 
 
The initial outcomes of the new screening tool were similar to those used in the 
Bayley-III Screening Test, namely At-Risk, Emerging and Competent, so that 
comparisons between the tools could be made. The first version of the new screening 
tool was then tested against the data collected in study one using the motor section of 
the assessment form for the 112 infants. Only the Gross Motor facet of the BSID III 
data was used, as the new screening tool was a gross motor assessment tool only, 
and the new screening tool was scored against all 112 infants. The results are 
presented in chapter six.  
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Chapter 6 
STUDY THREE: TESTING OF THE NEW ASSESSMENT TOOL 
The objective for study three was as follows:  
• Testing and refinement of the first version of the screening tool until it satisfied 
statistical criteria (K≥0.75).  
6.1 Testing of the First Version of the New Assessment Tool 
Once the items had been assigned to age groups, and the scoring had been 
formulated, the first version was ready for testing against data collected for study one, 
using the assessment forms from the BSID III. This was done using the Gross Motor 
scale only, and the results from the new screening tool were compared with the scaled 
score obtained from the BSID III, which had been converted into categories (At-Risk, 
Emerging and Competent). One hundred and twelve BSID III assessments were 
scored against the new screening tool in the following age groups, which were 
stratified as outlined in Table 6.1 below:  
 
Table 6.1 Age Groups and Stratification for Testing of First Version of the New 
Screening Tool (n = 112) 
Age n 
 
6 – 8 months 38 
9 – 11 months 23 
12 – 14 months 21 
15 – 18 months 30 
6.1.1 Statistical Analysis 
The data were entered into an Excel spreadsheet, and the statistical analysis was 
done in consultation with a biostatistician from the Medical Research Council of South 
Africa, using Stata (version 10). Correlations between the new screening test and the 
items on the BSID III were carried out using a Kappa statistic for ordinal data. The 
results are presented in Table 6.2 below: 
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Table 6.2 Agreement between the BSID III and the First Version of the New 
Assessment Tool (n=112) 
Age Group Kappa Percentage of Children whose 
Scores Correlated on both 
Tools 
 
6 – 8 months 0.34 63.2% 
9 – 11 months 0.63 78.3% 
12 – 14 months 0.33 61.9% 
15 – 18 months 0.75 86.7% 
Total group 0.51 72.3% 
  
Agreement was poor in all age groups aside from the 15-18 month group where 
K=0.75 indicates excellent agreement (Landis and Koch, 1977). Therefore the data 
from age-groups 6-8 months, 9-11 months and 12-14 months needed to be analysed 
in order to determine where the scores did not agree and why this had occurred.  
6.1.2 Analysis of Results  
Once the data had been analysed to determine where the discrepancies lay, it was 
determined that the screening tool was not sensitive enough in terms of scoring for the 
middle age category in age-groups 6-8 months, 9-11 months and 12-14 months, and 
therefore scores were adjusted as follows:  
 
The two youngest age groups were combined for scoring in age-groups 6-8 months, 
9-11 months and 12-14 months in order to demand less of the infants in the middle 
age category in that age group (e.g. for seven month old, a score of five was required 
to denote competence in the first version, and in the second version, only four was 
required). This was done in age groups 6-8 months, 9-11 months and 12-14 months 
only, as the Kappa for the 15-18 month age-group was 0.75, which indicates excellent 
agreement (Landis and Koch, 1977). 
 
Following further data analysis, it was revealed that the last two items in the age group 
6-8 months were unsuitable for this age category, as they were too difficult for even 
the Competent infants, and did not differentiate between ‘Competent’ infants and 
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those with ‘Emerging’ skills. The last two items in the age group 6-8 months were 
therefore replaced with two items which were sourced from the item analysis. These 
two new items were better suited to the age category 6-8 months, and ensured that 
those children who were Competent could achieve all items. This is shown in Figure 
6.1 below; Omitted items are deleted, and the highlighted portions indicate where 
changes were made. The second version emerged through the changes outlined 
above, and was ready for testing against the BSID III.  
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Figure 6.1 Development of the second version of the new screening tool 
                                 FIRST VERSION 
6 - 8 months 
1) controls head at 90 degrees while lying on stomach 
2) Lifts chest while lying on stomach (with extended 
arms) 
3) plays with feet 
4) rolls from back to stomach 
5) makes stepping movements 
6) crawls on stomach 
 
6 months ≥4: Competent; 3: Emerging, ≤ 2: At-Risk 
7 months ≥5: Competent, 4: Emerging, ≤ 3: At-Risk 
8 months 6: Competent, 5: Emerging, ≤ 4: At-Risk 
 
9 - 11 months 
1) turns body while seated 
2) makes stepping movements 
3) moves from sitting to being on hands and knees 
4) crawls at least 1 ½ metres on hands and knees 
5) pulls up to standing position 
6) walks sideways with support 
 
9 months ≥4:Competent; 3: Emerging, ≤ 2: At-Risk 
10 months ≥5:Competent, 4: Emerging, ≤ 3: At-Risk 
11 months 6:Competent, 5: Emerging, ≤ 4: At-Risk 
 
12 – 14 months 
• pulls up to standing position 
• bounces while standing 
• sits down from standing in a controlled manner 
• stands independently 
• walks alone with coordination 
• squats without support 
 
12 months  ≥4:Competent; 3:Emerging, ≤ 2:At-Risk 
13 months ≥ 5:Competent, 4:Emerging, ≤ 3:At-Risk 
14 months = 6:Competent, 5:Emerging, ≤ 4:At-Risk 
 
15 – 18 months 
1) sits down from standing in a controlled manner 
2) stands independently  
3) stands up with no assistance 
4) walks alone with coordination (at least 5 steps) 
5) squats without support 
6) runs with coordination 
 
15 months ≥4:Competent; 3:Emerging, ≤2:At-Risk 
16 months ≥5:Competent, 4:Emerging, ≤3:At-Risk 
17 – 18 months 6:Competent, 5: Emerging, ≤ 4:At-Risk 
                          SECOND VERSION 
6 - 8 months 
1) controls head at 90 degrees while lying on stomach 
2) Lifts chest while lying on stomach (with extended 
arms) 
3) plays with feet 
4) rolls from back to stomach 
5) sits alone  
6) turns body while seated 
 
6 +7 months ≥4: Competent; 3: Emerging, ≤ 2: At-Risk 
8 months 6: Competent, 5: Emerging, ≤ 4: At-Risk 
 
 
9 - 11 months 
1) turns body while seated 
2) makes stepping movements 
3) moves from sitting to being on hands and knees 
4) crawls at least 1 ½ metres on hands and knees 
5) pulls up to standing position 
6) walks sideways with support 
 
9 +10 months ≥4: Competent; 3: Emerging, ≤ 2: At-Risk 
11 months 6: Competent, 5: Emerging, ≤ 4: At-Risk 
 
12 – 14 months 
1) pulls up to standing position 
2) bounces while standing 
3) sits down from standing in a controlled manner 
4) stands independently 
5) walks alone with coordination 
6) squats without support 
 
 
12 +13 months ≥4:Competent; 3:Emerging, ≤ 2:At-Risk 
14 months 6:Competent, 5:Emerging, ≤ 4:At-Risk 
 
 
15 – 18 months 
1) sits down in a controlled manner 
2) stands independently  
3) stands up with no assistance 
4) walks alone with coordination (at least 5 steps) 
5) squats without support 
6) runs with coordination 
 
15 months ≥4:Competent; 3: Emerging, ≤2: At-Risk 
16 months ≥5:Competent, 4: Emerging, ≤3: At-Risk 
17 – 18 months 6: Competent, 5: Emerging, ≤ 4: At-Risk 
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6.2 Testing of the Second Version of the New Screening Tool 
Once changes had been made to the first version, the second version was developed, 
and is shown in Figure 6.1. Testing of the second version was conducted against 
previous data collected for study one, using the BSID III Gross Motor facet. The same 
procedure that was outlined in 6.1 above was followed.  
6.2.1 Statistical Analysis 
Statistical analysis was carried out as described in 6.1.1. The results are presented in 
Table 6.3 below: 
 
Table 6.3 Agreement Between the BSID III Gross Motor Scaled Score and the 
Second Version of the New Screening Tool (n=112) 
Age group Kappa Percentage of Children whose Scores Correlated 
on both Tools 
6 – 8 months 0.56 73.7% 
9 – 11 months 0.85 91.3% 
12 – 14 months 0.84 90.5% 
15 – 18 months 0.88 93.3% 
Total group 0.76 85.7% 
 
The agreement in the age group 6-8 months was still not sufficient. All other age 
groups had excellent agreement between the BSID III and the new screening tool 
(k>0.75) (Landis and Koch, 1977). Therefore further analysis was undertaken to 
determine why the agreement in the 6-8 month age group was low.  
6.2.2 Analysis of Results 
It was determined that the scoring and items for this age group were not appropriate, 
and therefore were analysed and adjusted. The credits obtained by each child on the 
BSID III and the new screening tool were analysed to determine whether the child 
obtained credits for the same items on both tools, and was placed in the same score 
category by each tool (i.e. At-Risk, Emerging, or Competent).  Item number six (‘turns 
body while seated’) in the age group 6-8 months was too difficult, and therefore even if 
the child was Competent on the BSID III, he/she would not obtain a Competent score 
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on the screening tool, as he/she could not obtain six credits. Item six was removed, 
and the scores were adjusted as follows: an eight month old should obtain five credits 
in order to be classified as Competent, and a seven and six month old should obtain a 
score of four (illustrated in Figure 5.2 below).   
 
The last item was removed in the second age category “walks sideways with support” 
(9-11 months), and age groups were combined to form the following groups: 6-8 
months, 9-12 months, 13-16 months, and 17-18 months. This was done to avoid over-
penalising the older children (e.g. where a 14 month old was expected to obtain six 
credits in order to be deemed Competent through being the oldest in the group, the 
child now fell into the middle of the group and was only expected to obtain four 
credits). This was also done to ensure that items fell into clinically relevant age 
groups, as on the BSID III, items are not allocated to specific age groups, and 
therefore some of the items may have been too difficult for the groups they were 
allocated to on the new screening tool (illustrated in Figure 6.2 below). The item 
‘bounces while standing’ was removed, as most children tested in the 12-14 month 
age group had outgrown this activity. Once the above changes had been made, the 
third version was ready for testing against the BSID III. The third version is illustrated 
in Figure 6.2 below  
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                                    SECOND VERSION 
6 - 8 months 
1) controls head at 90 degrees while lying on stomach 
2) lifts chest while lying on stomach (with extended 
arms) 
3) plays with feet 
4) rolls from back to stomach 
5) sits alone  
6) turns body while seated 
6 +7 months ≥4: Competent; 3: Emerging, ≤2: At-Risk 
8 months 6: Competent, 5: Emerging, ≤ 4: At-Risk 
 
9 - 11 months 
1) turns body while seated 
2) makes stepping movements 
3) moves from sitting to being on hands and knees 
4) crawls at least 1 ½ metres on hands and knees 
5) pulls up to standing position 
6) walks sideways with support 
 
9 +10 months ≥ 4: Competent; 3: Emerging, ≤ 2: At-
Risk 
11 months 6: Competent, 5: Emerging, ≤ 4: At-Risk 
 
12 – 14 months 
1)   pulls up to standing position 
2) bounces while standing 
3) sits down from standing in a controlled manner 
4) stands independently 
5) walks alone with coordination 
6) squats without support 
 
12 +13 months ≥4: Competent; 3: Emerging, ≤ 2: At-
Risk 
14 months 6: Competent, 5: Emerging, ≤ 4: At-Risk 
 
 
15 – 18 months 
1) sits down from standing in a controlled manner 
2) stands independently  
3) stands up alone 
4) walks alone with coordination (at least 5 steps) 
5) squats without support 
6) runs with coordination 
 
15 months ≥4: Competent; 3: Emerging, ≤2: At-Risk 
16 months ≥5: Competent, 4: Emerging, ≤3: At-Risk 
17 – 18 months 6: Competent, 5: Emerging, ≤ 4: At-
Risk 
 
                               THIRD VERSION 
6 - 8 months 
1) controls head at 90 degrees while lying on stomach 
2) lifts chest while lying on stomach (with extended 
arms) 
3) plays with feet 
4) rolls from back to stomach 
5) sits alone  
 
6 +7 months ≥ 4: Competent; 3: Emerging, ≤ 2: At-Risk 
8 months 5: Competent, 4: Emerging, ≤ 3: At-Risk 
 
9 - 12 months 
1) turns body while seated 
2) makes stepping movements 
3) moves from sitting to being on hands and knees 
4) crawls at least 1 ½ metres on hands and knees 
5) pulls up to standing position 
 
 
9 +10 months ≥ 4: Competent; 3: Emerging, ≤ 2: At-
Risk 
11 +12 months 5: Competent, 4: Emerging, ≤ 3: At-Risk 
 
13 – 16 months 
1)   pulls up to standing position 
2) bounces while standing 
3) sits down from standing in a controlled manner 
4) stands independently 
5) walks alone with coordination 
6) squats without support 
13 months ≥3: Competent; 2: Emerging, ≤ 1: At-Risk 
14  months ≥4: Competent; 3: Emerging, ≤ 2: At-Risk 
15 + 16 months 5: Competent, 4: Emerging, ≤ 3: At-
Risk 
 
 
17 and 18 months 
1) sits down from standing in a controlled manner 
2) stands independently  
3) stands up alone 
4) walks alone with coordination (for at least 5 steps) 
5) squats with support 
6) runs with coordination  
 
17 + 18 months: 6: Competent, 5: Emerging, ≤ 4: At-
Risk 
 
 
Figure 6.2 Development of the third version of the new screening tool 
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6.3 Testing of the Third Version of the New Screening Tool 
Once the third version of the new screening tool had been developed as outlined 
above, it was tested against the BSID III Gross Motor facet as outlined in 6.1 above.  
6.3.1 Statistical Analysis 
The statistical analysis was carried out as outlined in 6.1.1 above. The results are 
presented in Table 6.4 below: 
 
Table 6.4 Agreement between the BSID III Gross Motor Scaled Score and the 
Second Version of the New Screening Tool (n = 112) 
Age group Kappa Percentage of Children whose Scores agreed on 
both Tools 
6 – 8 months 0.86 92.1% 
9 – 11 months 0.85 91.3% 
12 – 14 months 0.84 90.5% 
15 – 18 months 0.88 93.3% 
Total Group 0.87 92% 
 
After three rounds of refinement and further testing, the agreement between the BSID 
III Gross Motor facet and the new screening tool was excellent in all age groups 
(k≥0.75). Through the processes outlined in this chapter, the item selection for each 
age group and the scoring was refined and tested against the BSID III Gross Motor 
facet.  The new screening tool was refined as much as possible through the process 
outlined above, and at this stage needed external comment and further testing. The 
next step in the process was to invite a panel of experts in the field of paediatrics to 
evaluate the tool for content validity. This process is outlined in chapter seven.  
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Chapter 7 
STUDY FOUR: EXPERT PANEL 
 
The objectives for study four were as follows:  
• To have the new screening tool examined by a panel of experts for content 
validity 
• To adjust the new screening tool according to recommendations made by the 
expert group 
7.1 Procedure 
A panel discussion was conducted with seven experts in the field of paediatrics. A 
modified version of the Nominal Group Technique (NGT) was used in order to 
facilitate discussion and obtain consensus (Potter et al, 2004). Participants were 
considered to be experts if they met the following criteria:  
a) A minimum of 10 years of experience in paediatrics 
b) A medical/physiotherapy/occupational therapy degree 
c) Currently practicing in the field of paediatrics 
d) Preferably involved in research 
e) Familiar with the administration of standardised assessment tools  
 
A letter of invitation was sent to each person, outlining the proposed session, and 
asking whether they would like to participate in the session. The session was held in 
the staff room of the physiotherapy department at the University of the Witwatersrand, 
and was recorded using a dictaphone. The participants met all the criteria outlined 
above and were representative of the following professions: six paediatric 
physiotherapists and a developmental paediatrician. The physiotherapists were 
working in the following settings: one in a tertiary government hospital, two in private 
paediatric practice, and three in academia.  
 
The NGT protocol states that the steps below should be followed (as discussed in 
chapter two):  
1. Introduction and explanation: The participants should be welcomed, and an 
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explanation of the purpose and procedure of the meeting should be given. 
 
2. Generation of ideas: Each participant should be provided with a sheet of paper with 
the question to be addressed and are then asked to write down all ideas that come to 
mind when considering the question. During this period, participants are asked not to 
consult or discuss their ideas with others. Approximately ten minutes are allowed for 
this. 
 
3. Sharing of ideas: Participants should be invited to share the ideas they have 
generated. The process continues until all ideas have been presented. There is no 
debate about items at this stage and participants should write down any new ideas 
that may arise from what others have shared. This process ensures that all 
participants get an opportunity to make an equal contribution and provides a written 
record of all ideas generated by the group.  
 
4. Group discussion: Participants are invited to ask for further explanation and detail 
about any of the ideas that colleagues have produced.  
 
5. Voting and ranking: This involves prioritising the recorded ideas in relation to the 
original question. Immediate results are available to participants so that the outcomes 
are reached by the time the meeting concludes. It is recommended that the process is 
recorded on videotape or audiotape (Potter et al, 2004). 
 
This format was followed, and the following issues were addressed:  
1) Appropriateness of each item selected (the item itself, and item wording) 
2) Appropriateness of the age groups which had been selected 
3) Appropriateness of the items for the age-group in which they fell 
4) Appropriateness of scoring 
 
Each participant was provided with the proposal for the study, the methodology used 
in developing the new screening tool, and a copy of the new screening tool. 
Participants were given these documents on arrival, and were asked to look through 
them, so as to familiarise themselves with the process. The participants were 
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welcomed, introduced to one another, and a verbal explanation of the study, and the 
objectives to be addressed were given.  
 
This technique has been used in other content validity studies (Palisano et al, 2008), 
and consensus was defined as 80% of participants being in agreement. The same 
percentage of agreement was used in this study. All concerns were discussed and 
appropriate changes were suggested by participants. There was 100% agreement for 
objectives two, three and four, and 71.4% agreement for objective one. After 
discussion about appropriate changes to be made, and documenting these, 
agreement for objective one was 100%. Table 4.1 shows the agreement for each 
objective: 
 
Table 7.1 Agreement between Participants for Each Question 
Question Agreement Agreement after 
changes suggested 
 
Appropriateness of each item 
selected 
 
71.4% 100% 
Appropriateness of the age 
groups which had been 
selected 
 
100% n/a 
Appropriateness of the items 
for the age-group in which 
they fell 
 
100% n/a 
Appropriateness of scoring 
 
100% n/a 
 
The concerns raised about question one were discussed, and are outlined in 7.1 
below:  
7.1 Issues Emerging from the Panel Discussion 
During the panel discussion, two issues were raised: it was suggested by one member 
of the expert panel that item number two in the 6-8 month age group ‘lifts chest while 
lying on stomach (with extended arms)’ be replaced with a new item ‘pull to sit’. This 
was due to the concern that should a child have increased extensor tone, they would 
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appear to be able to elevate their trunk while lying in prone. It was concluded that this 
change should not be made for the following reasons:   
 
- ‘pull-to-sit’ did not differentiate as well between the groups during the item     
analysis: 13% of the ‘At-Risk’ group obtained a credit for ‘pull-to-sit’, whereas 0% 
of the ‘At-Risk’ group obtained a credit for  ‘elevates trunk while prone on 
extended arms’. ‘Pull-to-sit’ is often a difficult aspect to assess unless the 
assessor is skilled, as there are a number of compensatory strategies which the 
child may use.  
- The item ‘elevates trunk while prone on extended forearms’ is also used in the 
Gross Motor Function Measure (GMFM) (Rosenbaum et al, 1990; Russell et al, 
1989) which is specifically designed to assess children with cerebral palsy. This 
assessment tool is known as the ‘gold standard’ for assessment of children with 
cerebral palsy, and is a valid and reliable tool. This indicates that the item is 
reliable for use in children who have increased tone, and may be used on HIV- 
infected children who present with increased tone due to HIV encephalopathy.  
 
b) The wording for item number four in the 9-12 month age group was queried. The 
initial wording was ‘crawls forward at least 1½ metres on hands and knees’. It was 
suggested that the words “move forward” replace the word “crawls”, as children may 
do a number of different forms of crawling, which are all still normal. The revisions are 
presented in Figure 7.1 below:  
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                              THIRD VERSION 
6 - 8 months 
1) controls head at 90 degrees while lying on 
stomach 
2) lifts chest while lying on stomach (with extended 
arms) 
3) plays with feet 
4) rolls from back to stomach 
5) sits alone  
 
6 +7 months ≥ 4: Competent; 3: Emerging, ≤ 2: At-
Risk 
8 months 5: Competent, 4: Emerging, ≤ 3: At-Risk 
 
 
9 - 12 months 
1) turns body while seated 
2) makes stepping movements 
3) moves from sitting to being on hands and knees 
4) crawls at least 1 ½ metres on hands and knees 
5) pulls up to standing position 
 
 
9 +10 months ≥ 4: Competent; 3: Emerging, ≤ 2: 
At-Risk 
11 +12 months 5: Competent, 4: Emerging, ≤ 3: 
At-Risk 
 
13 – 16 months 
1)   pulls up to standing position 
2) sits down from standing in a controlled manner 
3) stands independently 
4) walks alone with coordination 
5) squats without support 
 
 
13 months ≥3: Competent; 2: Emerging, ≤ 1: At-
Risk 
14  months ≥4: Competent; 3: Emerging, ≤ 2: At-
Risk 
15 + 16 months 5: Competent, 4: Emerging, ≤ 3: 
At-Risk 
 
17 and 18 months 
1)   sits down from standing in a controlled manner 
2) stands independently 
3) stands up with no assistance 
4) walks alone with coordination  
5) squats with support 
6) runs with coordination  
 
 
17 + 18 months: 6: Competent, 5: Emerging, ≤ 4: 
At-Risk 
                                FOURTH VERSION 
6 - 8 months 
1) controls head at 90 degrees while lying on 
stomach 
2)lifts chest while lying on stomach (with extended 
arms) 
3) plays with feet 
4) rolls from back to stomach 
5) sits alone  
 
6 +7 months ≥ 4:Competent; 3: Emerging,≤ 2: At-
Risk 
8 months 5:Competent, 4: Emerging, ≤ 3: At-Risk 
 
9 - 12 months 
1) turns body while seated 
2) makes stepping movements 
3) moves from sitting to being on hands and 
knees 
4) crawls /moves forward at least 1 ½ metres  
5) pulls up to standing position 
 
 
9 +10 months ≥ 4: Competent; 3: Emerging, ≤ 2: 
At-Risk 
11 +12 months 5: Competent, 4: Emerging, ≤ 3: 
At-Risk 
 
13 – 16 months 
1)   pulls up to standing position 
2) sits down from standing in a controlled 
manner 
3) stands independently 
4) walks alone with coordination 
5) squats without support 
 
13 months ≥3: Competent; 2: Emerging, ≤ 1: At-
Risk 
14  months ≥4: Competent; 3: Emerging, ≤ 2: At-
Risk 
15 + 16 months 5: Competent, 4: Emerging, ≤ 3: 
At-Risk 
 
17 and 18 months 
1)    sits down from standing in a controlled 
manner 
2) stands independently 
3) stands up with no assistance 
4) walks alone with coordination 
5) squats with support 
6) runs with coordination  
 
17 + 18 months: 6: Competent, 5: Emerging, ≤ 4: 
At-Risk 
 
Figure 7.1 Development of the fourth version of the new screening tool 
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After the appropriate changes had been made following the expert panel discussion, 
the fourth and final version of the new screening tool was ready for preliminary testing 
to determine whether it was suitable for clinical use.  Preliminary testing of the 
screening tool against the Bayley Scales of Infant and Toddler Development-III Gross 
Motor facet was then carried out; this is outlined in chapter eight.   
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Chapter 8 
STUDY FIVE: PRELIMINARY TESTING OF THE FOURTH VERSION 
OF THE SCREENING TOOL 
 
Following the expert panel group, the new screening tool was ready for preliminary 
testing against the BSID III. The objective of study five was to determine whether 
there was acceptable agreement between the BSID III and the new screening tool.  
 
The objectives for study five were as follows:  
• To test the fourth version of the new screening tool against the Bayley Scales 
of Infant and Toddler Development III Gross Motor facet (n = 60) in order to 
establish concurrent validity 
• To establish diagnostic accuracy of the new screening tool through sensitivity 
and specificity values (n=60) 
• To establish interrater reliability, test-retest reliability and intrarater reliability for 
the new screening tool (n=15 for test-retest reliability, n=15 for interrater 
reliability) 
8.1 Concurrent Validity of the New Screening Tool against the BSID III 
8.1.1 Sample Size Determination for Evaluation of Concurrent Validity 
A minimum sample size of 60 infants is necessary to satisfy Nunnally and Bernstein’s 
(1994) requirements for complex statistical procedures.  The requirements state that 
the facet on the assessment tool which contains the highest number of items should 
be used, and that this number should be multiplied by ten to obtain the sample size. 
The highest number of items on the screening tool is six. Therefore 60 consecutive 
children between the ages of six and 18 months were tested. The sample was again 
drawn from Harriet Shezi Children’s Clinic. The age groups were stratified in order to 
ensure that sufficient data were obtained in all age groups, and therefore 15 children 
per age group were assessed. This is illustrated in Table 8.1 below:  
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Table 8.1 Stratification of Sample for Study Five (n=60) 
Age groups n per group 
6 – 8 months 15 
9 – 12 months 15 
13 – 16 months 15 
17 – 18 months 15 
Total  60 
 
8.1.2 Procedure  
The files for each child attending the clinic that day were laid out as soon as the 
caregiver registered at reception. The files were screened to determine the ages of 
the infants who were registered for the clinic, and all infants between the ages of six 
and 18 months were selected. The caregivers of the children who met the inclusion 
criteria were approached, and the caregiver was given a letter of information regarding 
the study (See Appendix VI). Where the caregiver could not speak or understand 
English, a counsellor or nurse was asked to translate. Once the caregiver agreed to 
participate, he/she was asked to give written informed consent for the child and 
his/herself (see Appendix VI). The child was assessed on both the Bayley Scales of 
Infant Development III Gross Motor facet, and the new screening tool.  
8.1.3 Statistical Analysis 
Once scores for both assessment tools were obtained, the results were entered into 
an Excel spreadsheet. Statistical analysis was done in conjunction with the Medical 
Research Council of South Africa using Stata. The agreement between the tools was 
analysed using Kappa. This was done twice: the first analysis used three possible 
scoring outcomes (At-Risk, Emerging and Competent) (shown in Table 8.2), and the 
second analysis used two (At-Risk and Emerging) (shown in Table 8.3). 
 
For conversion to two scoring outcomes, the following procedure was used: all the 
data (n=60) were analysed, and items for the children who fell into the ‘Emerging’ 
category on either the BSID III or the new screening tool were examined. After careful 
analysis, the BSID III scaled scores which translated into the ‘Emerging’ category 
were dealt with as follows:  
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• Scaled scores of 5 and 6 were classified as “At-Risk” 
• Scaled scores of 7 were classified as “Competent” 
This was done through thorough item analysis and the use of clinical judgement to 
determine whether a child who could not perform the items that they received a ‘no 
credit’ for on the BSID III Gross Motor scale would be considered to be 
developmentally competent, or at risk for developmental problems. On the new 
screening tool, the Emerging category was always converted to “At-Risk”. 
8.1.4 Results 
The agreement between the BSID III and the new screening tool was tested using a 
Kappa statistic for ordinal data. The results are presented below.  
 
Table 8.2 shows the agreement between the BSID III Gross Motor facet, and the 
fourth version of the new screening tool with three scoring outcomes. Table 8.3 shows 
the agreement between the BSID III Gross Motor facet, and the fourth version of the 
new screening tool with two scoring outcomes.   
 
Table 8.2 Results of the BSID III Gross Motor Facet versus the New Screening 
Tool with Three Scoring Outcomes (n=60) 
Age group 
 
n Percentage of Children whose 
Scores Correlated on both 
Tools 
Kappa  
6 – 8 months 
 
15 73.3% 0.56  
9 – 11 months 
 
15 80% 0.66 
 
12 – 14 months 
 
15 80% 0.51  
15 – 18 months 
 
15 86.7% 0.69  
Total group 60 80% 0.63  
 
 
The agreement for the version with three score categories was moderate in all age 
groups. The new screening tool assessed the children more conservatively than the 
BSID III, and therefore where there were discrepancies in scoring, the new screening 
tool score was always within one category of the BSID III, and was always one score 
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category below, indicating that it assesses children more strictly. For example, for a 
child whose scores differed on the two tools: where a score on the BSID III was in the 
Competent category, the new screening tool score would place the child in the 
Emerging category. Sensitivity, specificity, positive predictive value and negative 
predictive value cannot be calculated for three outcomes (Aylward, 2000).  
 
Table 8.3 Results of the BSID III Gross Motor Facet versus the New Screening 
Tool with Two Scoring Outcomes (n=60) 
Age group n Percentage of Children whose 
Scores Correlated on both Tools 
Kappa  
6-8 months 
 
15 86.7% 0.73 
9-12 months 
 
15 100% 1 
13-16 months 
 
15 100% 1 
17-18 months 
 
15 86.67% 0.60 
Total group 60 93.3% 0.85 
 
 
The overall Kappa for agreement between the BSID III and the new screening test 
with two scoring outcomes was excellent (0.85) (Landis and Koch, 1977). Within the 
age categories, there was 100% agreement in the 9-11 month group and the 12-14 
month group. Kappa was moderate in the 6-8 month group, and the 15-18 month 
group. Tables of symmetry for the 6-8 month group and the 9-11 month group are 
presented below in Table 8.4 in order to explain the slightly lower Kappa values: 
 
Table 8.4 Symmetry between the New Screening Tool and the BSID III for 6-8 
Months (n=15) 
Screening Tool                                           BSID III 
 At-Risk Competent Total 
At-Risk 6 1 7 
Competent 1 7 8 
Total  7 8 15 
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In Table 8.4, the agreement between the two tools is shown along the diagonal (i.e. 
both tools scored six children as being At-Risk, and both scored seven as being 
Competent). There were only two cases where the tools did not agree. In the first 
case, the BSID III scored the child as being Competent, and the new screening tool 
placed the child in the At-Risk category. In the second case, the new screening test 
placed the child in the Competent category, and the BSID III placed them in the At-
Risk category. Table 8.5 below shows the symmetry between the tools in the 17-18 
month age group.   
 
Table 8.5 Symmetry between the New Screening Tool and the BSID III for 17-18 
Months (n=15) 
Screening Tool                                           BSID III 
 At-Risk Competent Total 
At-Risk 11 2 13 
Competent 0 2 2 
Total  11 4 15 
 
In the Table 8.5 above, again the agreement is shown along the diagonal (both tools 
scored 11 children as being At-Risk, and both scored two children as being 
Competent). There were two cases where the tools did not agree. The BSID III scored 
the children as being Competent, and the new screening tool placed them in the At-
Risk category. This indicates that the new screening tool may be slightly more 
conservative in terms of scoring. Sensitivity and specificity were therefore tested in 
order to assess these capabilities of the new screening tool further.  
8.2 Evaluation of the Diagnostic Accuracy of the New Screening Tool 
The diagnostic accuracy of the new screening tool was evaluated by examining 
sensitivity, specificity, positive predictive value (PPV), and negative predictive value 
(NPV) against the BSID III.  
 
Sensitivity is defined as the proportion of children who are delayed and are correctly 
identified as delayed by the screening test, the ‘‘true positive’’ group. Specificity is 
defined as the proportion of children who are not delayed and are correctly identified 
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as not delayed by the screening test, the ‘‘true negative’’ group. The PPV is the 
probability that a child is truly developmentally delayed when results of the screening 
test are positive. Unlike the sensitivity and specificity of a screening test, which can be 
thought of as characteristics of the test itself, the PPV is dependent upon the 
prevalence of the disorder in the population tested (Frankenberg et al, 1992). 
Therefore, the sensitivity of the test may be a better measure to evaluate a screening 
tool for developmental delay than its PPV (Hess, 2004). The negative predictive value 
of a test is the proportion of patients with a negative screening result who do not have 
the condition   
8.2.1 Diagnostic Properties of the New Screening Tool 
The diagnostic properties of the new screening tool are presented in Table 8.6 below: 
 
Table 8.6 Diagnostic Properties of the New Screening Tool 
Sensitivity 97.4% 
Specificity 85.7% 
Positive predictive value 92.7% 
Negative predictive value 94.7% 
 
The sensitivity of the new screening tool is high, and indicates that the new screening 
tool identified 97.4% of the children who were delayed according to the BSID III. The 
specificity is also high, and the new screening tool identified 85.7% of children who 
were not delayed as being Satisfactory. The specificity is slightly lower than the 
sensitivity, as the new screening tool was slightly more conservative than the BSID III 
in classifying children as being At-Risk. The PPV is high at 92.7%, which indicates 
that there is a probability of 92.7% that children who were classified as having gross 
motor delay in this population were correctly diagnosed – the fact that gross motor 
delay in this population is very prevalent has to be taken into account, and therefore 
accounts for the high PPV.  The negative predictive value (NPV) overall is high at 
94.7%, which indicates that there is a probability of 94.7% that children who were 
classified as Competent do not have gross motor delays.  
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8.2.2 Diagnostic Properties per Age Group 
Table 8.7 illustrates the diagnostic properties of the new screening tool for the 6-8 
month age group 
 
Table 8.7 Diagnostic Properties of the New Screening Tool for 6-8 Months 
Sensitivity 85.7% 
Specificity 87.5% 
Positive predictive value 85.7% 
Negative predictive value 87.5% 
 
For the age group 6-8 months, the sensitivity of the new screening tool is adequately 
high, and indicates that the new screening tool identified 85.7% of the children that 
were delayed according to the BSID III. The specificity is also high, and the new 
screening tool identified 87.5% of children who were not delayed as being satisfactory. 
The specificity is slightly higher than the sensitivity, but only marginally so. The PPV is 
85.7%, which indicates that there is a probability of 85.7% that children who were 
classified as having gross motor delay in this population were correctly diagnosed.  
The NPV indicates that 87.5% of children who were classified as Competent do not 
have gross motor delay. Table 8.8 illustrates the statistical properties of the new 
screening tool for 9-12 month age group 
 
Table 8.8 Diagnostic Properties of the New Screening Tool for 9-12 Months 
Sensitivity 100% 
Specificity 100% 
Positive predictive value 100% 
Negative predictive value 100% 
 
For the age group 9-12 months, the sensitivity of the new screening tool is excellent, 
and indicates that the new screening tool identified 100% of the children that were 
delayed according to the BSID III. The specificity is also excellent, and the new 
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screening tool again identified 100% of children who were not delayed as being so. 
The PPV is also 100%, which indicates that there is a probability of 100% that children 
who were classified as having gross motor delay in this population were correctly 
diagnosed. Similarly, the NPV is 100%, which indicates that there is a probability of 
100% that children who were classified as Competent do not have gross motor delay.   
Table 8.9 illustrates the diagnostic properties of the new screening tool for the 13-16 
month age group: 
Table 8.9 Statistical Properties of the New Screening Tool for 13-16 Months 
Sensitivity 100% 
Specificity 100% 
Positive predictive value 100% 
Negative predictive value 100% 
 
For the age group 13-16 months, the sensitivity of the new screening tool is excellent, 
and indicates that the new screening tool identified 100% of the children who were 
delayed according to the BSID III. The specificity is also excellent, and the new 
screening tool again identified 100% of children who were not delayed as being so. 
The PPV is also 100%, which indicates that there is a probability of 100% that children 
who were classified as having gross motor delay in this population were correctly 
diagnosed.  Similarly, the NPV is 100%, indicating that there is a probability of 100% 
that children who were classified as being Competent do not have gross motor delay. 
Table 8.10 below illustrates the diagnostic properties of the new screening tool for the 
17-18 month age group: 
Table 8.10 Diagnostic Properties of the New Screening Tool for 17-18 Months 
Sensitivity 100% 
Specificity 50 % 
Positive predictive value 84.6% 
Negative predictive value 100% 
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For the age group 17-18 months, the sensitivity of the new screening tool is excellent, 
and indicates that the new screening tool identified 100% of the children who were 
delayed according to the BSID III. The specificity was low, and the new screening tool 
identified 50% of children who were not delayed as being so. This is due to the 
manner in which specificity is calculated: (the number of normal children who also 
scored ‘normal’ on the test)/(normal children +normal children identified by a test as 
having delays) (Glascoe, 1991).  
 
For this test, the calculation is as follows: (the number of normal children, who 
received a Competent score = 2)/(the number of normal children as identified by the 
BSID III [2]+the number of normal children who were identified by the new screening 
tool as having delays [2]) = 50%.  The PPV is 84.6%, which indicates that there is a 
probability of 84.6% that children who were classified as having gross motor delay in 
this population were correctly diagnosed.  The NPV is 100%, which indicates that 
there is a probability of 100% that children who were classified as being Competent do 
not have gross motor delay.  
8.3 Final Version of the New Screening Tool 
The two final versions (one with three scoring outcomes, and one with two scoring 
outcomes) of the new screening tool were taken to an expert in the field of paediatric 
HIV, in order to discuss which one would be more approriate for use in the HIV clinics. 
After careful analysis of both versions, it was concluded that a screening tool with only 
two possible scoring outcomes (“At-Risk” and “Satisfactory”) would be more 
appropriate, as an “Emerging” category may lead to loss to follow-up of children, and 
less vigilance in terms of sending those children with any risk of developmental delay 
for further assessment.  
8.4 Reliability of the New Screening Tool 
The reliabilty of the final version of the new screening tool was evaluated as follows:  
8.4.1 Test-retest Reliability and Intrarater Reliability 
Test-retest reliability was evaluted at Rahima Moosa Hospital in Johannesburg, 
Gauteng. Consent was obtained from the hospital CEO in order to carry out data 
collection (see Appendix VII). Fifteen infants (which is 25% of the sample size for 
study one) between the ages of 6-18 months who had been admitted to the wards as 
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in-patients were assessed twice within two days. The reasons for the use of this site, 
and the time interval were as follows: children attending HIV clinics as outpatients are 
scheduled for follow-up visits every three to six months, during which time their 
development would change considerably. Bringing the child back to the clinic within 
one to two weeks following their scheduled visits is very difficult for a number of 
logistical reasons: a) transport is costly to the patients, and therefore a transport fee 
would have to be given b) it is often difficult for the parent/caregiver of the child to 
attend more regularly due to work commitments. Inpatients are therefore easier to 
evaluate, and this is still within the intended context of use for the tool, as HIV positive 
infants who are inpatients will also be assessed using the tool. In terms of the time 
interval, due to the fact that the infants were inpatients, and were likely to be in varying 
stages of recovery, a short time period between assessments was selected to ensure 
that the infants did not change clinically. These patients were admitted with chronic 
conditions, and therefore no clinical improvement was expected. Once informed 
consent had been obtained from the child’s caregiver (see Appendix VIII), the 
assessment was carried out by a paediatric physiotherapist, who had undergone 
training on the new assessment tool, and worked at Rahima Moosa Hospital, so knew 
the ward routines and procedures well. The assessments for each child were carried 
out at the same time of the day in order to minimise effects by medication, and 
caregiving routines.   
 
In a test-retest situation, when a rater’s skill is relevant to the accuracy of the test, 
intrarater and test-retest reliability are essentially the same estimate (Portney and 
Watkins, 2000). In this study, the rater’s skill was relevant to the accuracy of the test, 
and therefore test-retest reliability and intrarater reliability are the same estimate. The 
results were entered into an Excel speadsheet, and the agreement between the score 
obtained on the first and second assessment was evaluated using the Pearson 
product-moment correlation coefficient, as the data is nominal data (Portney and 
Watkins, 2000). The results of the test-retest and intrarater reliability study are shown 
in Table 8.11 below:  
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Table 8.11 Test-retest and intrarater Reliability for the New Screening Tool 
(n=15) 
Test-retest and Intrarater reliability r = 0.98 
 
There were two cases where the scores differed by one point, and the score on the 
first assessment was higher than the second in both cases. The category in which the 
child was placed was not affected by the differences in scores, and in all cases, the 
developmental category (At-Risk or Satisfactory) was the same on the first and 
second assessments. The value of r=0.98 indicates excellent test-retest and intrarater 
reliability (Portney and Watkins, 2000), and shows that the new screening tool is 
stable, and obtains the same results with repeated administrations of the test, as well 
as stability of data obtained by one rater over two assessments (Portney and Watkins, 
2000).  
8.4.2 Interrater Reliability 
Interrater reliability was conduted at Harriet Shezi Clinic at Chris Hani Baragwanath 
Hospital on 15 consecutive infants (which is 25% of the sample size from study one) 
between the ages of 6 and 18 months. Once informed consent had been obtained 
from the caregiver of the child (see Appendix IX), two raters observed the gross motor 
behaviour of the infant and allocated scores similtaneously. One rater was the 
researcher, and the other a paediatric physiotherapist who had undergone training on 
the new screening tool. The results were entered into an Excel spreadsheet, and the 
agreement between the score obtained by the first rater and the second rater was 
analysed using the Pearson product-moment correlation coefficient, for nominal data 
(Portney and Watkins, 2000).  The results are shown in Table 8.12 below: 
 
Table 8.12 Interrater Reliability for the New Screening Tool (n=15) 
Interrater reliability r = 1 
 
The results for interrater reliability were excellent (r = 1) (Portney and Watkins, 2000), 
and indicates that both raters obtained the same score on each assessment.  
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8.5 Conclusion 
The results of this study indicate that children infected with HIV are at risk for 
developmental problems from an early age, This, along with the effects of HIV on 
growth, and the low socioeconomic status of this population present added risk factors 
for developmental delay. There is therefore a need for a screening tool which is able 
to detect these problems so that children may be referred on for more in-depth 
assessment and management. 
 
The findings of this study indicate that the results of the Bayley-III Screening Test and 
the BSID III do not correlate well, and therefore that the Bayley-III Screening Test is 
not suitable for use on HIV infected infants, as it does not adequately identify the 
children’s problems. A new screening tool was therefore developed, and the process 
has been outlined above. The preliminary testing for validity, reliability and diagnostic 
properties of the new screening tool were excellent. The implications of the above 
findings, as well as the development of the screening tool will be discussed in more 
detail in chapter nine.  
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Chapter 9 
DISCUSSION 
 
The results of this study will be discussed in more detail in this chapter. The main 
outcomes will be discussed as well as important clinical data which were collected. A 
number of suggestions for future research and clinical management will be put 
forward. The new screening tool will now be referred to as “The Infant Gross Motor 
Screening Test”. 
9.1 Classification Accuracy of the Bayley-III Screening Test 
One of the main objectives of this study was to examine the suitability of the Bayley-III 
Screening Test for use on HIV positive infants in South Africa. The need for 
developmental screening of HIV positive infants has been highlighted through many 
studies, which have been conducted in South Africa (Potterton et al, 2009b; Ferguson 
and Jelsma, 2009; Baillieu and Potterton, 2008). The development of a screening tool 
which is suitable for use in the paediatric HIV setting has been incorporated into the 
National Strategic Plan (NSP) for management of HIV for 2007-2011, and the South 
African government has made a commitment to ensuring that all HIV positive children 
under three years of age undergo developmental screening (NSP, 2007-2011). This 
has been reiterated in the South African Department of Health Antiretroviral Treatment 
Guidelines (2010), where developmental monitoring is recommended in order to 
assess children for ARV eligibility, as well as being one of the factors which is used to 
monitor response to treatment (DOH, 2010). The agreement between the Bayley-III 
Screening Test and the BSID III was not good enough (k< 0.75) for clinical use. The 
reasons for this will be outlined and discussed.  
9.1.1 Agreement between the Bayley-III Screening Test and the BSID III 
The Bayley-III Screening Test is designed to briefly assess the cognitive, language 
and motor function of infants and young children between 1-42 months of age (Bayley, 
2006c). The primary purposes are to determine whether a child is progressing 
according to normal expectations, to determine the degree of risk for developmental 
delay, and to determine if further, more comprehensive evaluation is needed. The 
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purpose of using a screening tool on this population of HIV positive infants would be 
similar – children with developmental problems who have been identified by the 
screening tool would need to be referred for more comprehensive testing. The 
characteristics of the sample population have been outlined in chapter four.  
 
The Bayley-III Screening Test was selected, due to the fact that it was developed from 
the Bayley Scales of Infant and Toddler Development (Bayley, 2006c), which has long 
been considered the ‘gold standard’ of infant developmental assessment (Harris et al, 
2005; Tieman et al, 2005). The BSID has been used in a number of studies in South 
Africa to evaluate the neurodevelopmental outcomes of HIV positive infants (Potterton 
et al, 2009b, Ferguson and Jelsma, 2009; Baillieu and Potterton, 2008), and the BSID 
III has been shown to be suitable for use on black South African infants from similar 
socioeoconomic backgrounds (Rademeyer, 2010; Brown, 2009). The Bayley-III 
Screening Test was therefore compared with the BSID III in order to determine its 
suitability for use in this population.  
 
The agreement between the Bayley-III Screening Test and the BSID III in the 
Cognitive facet ranged between K=0.41 and K=0.70. None of the Kappa scores in the 
Cognitive facet were higher than 0.70, representing moderate agreement across the 
Cognitive domain (Landis and Koch, 1977). The overall agreement in the Cognitive 
domain was K=0.58, which represents moderate agreement (≥0.4-<0.75) (Landis and 
Koch, 1977). When analysing the classification accuracy of the Bayley-III Screening 
Test for Cognitive function, the screening test identified 77.8% of At-Risk cases, 
59.4% of Emerging cases, and 77.3% of Competent cases.  
 
The agreement between the Bayley-III Screening Test and the BSID III was better in 
the Language facet. The Expressive and Receptive Communication domains had 
excellent agreement in all ages, groups apart from the 9-11 month group for 
Receptive Communication, and the 6-8 month age group for Expressive 
Communication. The overall agreement between the tools in the Expressive 
Communication facet was 0.76, and in the Receptive Communication facet 0.82, 
representing excellent agreement (≥ 0.75). When analysing the classification accuracy 
of the Bayley-III Screening Test for Language function, the screening test identified 
82.4% of At-Risk cases, 94% of Emerging cases, and 89% of Competent cases for 
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Receptive Communication, and 83.33% of At-Risk cases, 68.4% of Emerging cases, 
and 94.7% of Competent cases for Expressive Communication.  
 
The agreement between the Bayley-III Screening Test and the BSID III in the Motor 
facet ranged between K=0.28 and K=0.92. The agreement in the Fine Motor facet was 
poor to moderate for all age groups, ranging between K=0.28 and K=0.50. In the 
Gross Motor facet the agreement ranged between K=0.41 and K=0.92, with most age 
groups demonstrating moderate agreement (≥0.4 to <0.75). The overall agreement in 
the Fine Motor facet was K=0.44, and in the Gross Motor facet, was K=0.57 which 
represents moderate agreement in both (≥0.4 to <0.75).  When analysing the 
classification accuracy of the Bayley-III Screening Test for Motor function, the 
screening test identified 58.8% of At-Risk cases, 56.7% of Emerging cases, and 
68.8% of Competent cases for Fine Motor function, and 62.5% of At-Risk cases, 
71.4% of Emerging cases, and 89.3% of Competent cases for Gross Motor function.  
 
The agreement of the Bayley-III Screening Test with the BSID III is not optimal 
(K≤0.75) due to problems with classification accuracy. The Bayley-III Screening Test 
is more accurate for children who are classified as being in the Competent category, 
than for those in the At-Risk category, as stated in the manual (Bayley, 2006c). The 
population of children tested in this study are at high risk for developmental problems, 
especially for cognitive and motor function (Potterton et al, 2009b, Ferguson and 
Jelsma, 2009; Baillieu and Potterton, 2008), and therefore classification accuracy of 
the Bayley-III Screening Test will be moderate (Bayley, 2006c).  
9.1.2 Classification Accuracy of the Bayley-III Screening Test 
The trends in this study with regards to classification accuracy are similar to those in 
the Bayley-III Screening Test standardisation sample (Bayley, 2006c), and will be 
highlighted below. Bayley (2006c) stated that the Bayley-III Screening Test was more 
accurate in detecting those children classified as Competent, than those classified as 
At-Risk, and where the BSID III and Bayley-III Screening Test classified children 
differently, it was always within one category. For example, in the standardisation 
sample, children classified as At-Risk on the BSID III would be misclassified as 
Emerging by the Bayley-III Screening Test, but never as Competent (Bayley, 2006c). 
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9.1.2.1 Classification Accuracy of the Bayley-III Screening Test for Children 
Identified by the BSID III as At-Risk 
For children in the At-Risk category, classification accuracy of the Bayley-III Screening 
Test was ‘moderate’ in the standardisation sample (Bayley, 2006c). The range of 
correct classification of children as At-Risk by the Bayley-III Screening Test compared 
with the BSID III for the standardisation sample was 41.8% for Fine Motor function to 
66.9% for Receptive Communication. Not one of the children in the standardisation 
sample was misidentified as Competent on the Bayley-III Screening Test, and where 
the Bayley-III Screening Test and the BSID III did not agree, the Screening Test 
classified children in the Emerging category (Bayley, 2006c).   
 
In this study, the range of correct classification of children who are in the At-Risk 
category by the Bayley-III Screening Test as compared with the BSID III was 58.8% 
for Fine Motor function to 83.3% for Expressive Communication. The range in this 
study was wider than that of the standardisation sample (41.8%-65.9%), and 
Expressive Communication had better accuracy than Receptive Communication, but 
only by one percent. There were a number of cases where children were misidentified 
as Competent by the Bayley-III Screening Test, where the BSID III classified them as 
At-Risk, which did not occur in the standardisation sample (Bayley, 2006c), indicating 
that possibly on higher-risk populations such as HIV infected infants, the Bayley-III 
Screening Test is not sufficiently sensitive. The range in this study for children 
misidentified as Competent was 5.4% for Gross Motor function to 8.3% for Cognitive 
function. There were more children in this study who were correctly identified as being 
At-Risk (83.3% for Expressive Communication, as opposed to 65.9% for Receptive 
Communication in the standardisation sample), although the children in this study are 
all at high risk for severe developmental problems (Potterton et al, 2009b, Ferguson 
and Jelsma, 2009; Baillieu and Potterton, 2008), whereas the standardisation sample 
was healthy children, stratified by socioeconomics, ethnicity, gender, age and 
maternal education (Bayley, 2006c). The fact that despite the risk factors for the 
current study population, 5.4%-8.3% were misidentified as being Competent by the 
Bayley-III Screening Test, whereas the BSID III classified them as being At-Risk 
demonstrates the inherent problems with classification accuracy in the Bayley-III 
Screening Test. Due to the high risk nature of the HIV infected paediatric population 
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for developmental problems, a screening tool which is more sensitive would be 
necessary to detect those children who are At-Risk for developmental problems.  
 
9.1.2.2 Classification Accuracy of the Bayley-III Screening Test for Children 
Identified by the BSID III as Emerging 
For children in the Emerging Category, classification accuracy was ‘accurate’ for 
children with scaled scores of 5-7 in the standardisation sample (Bayley, 2006). The 
range of correct identification of children with Emerging skills as compared with the 
BSID III for the standardisation sample was 64% for Cognitive function to 77.8% for 
Receptive Communication (Bayley, 2006). The percentage of children misidentified as 
being At-Risk was very low in the standardisation sample (0.8%-5.2%) (Bayley, 
2006c).   
 
In this study, the range for correct identification of children with Emerging Skills as 
compared with the BSID III is 56.7% for Fine Motor function to 94% for Receptive 
Communication. This indicates that fewer children on the lower end of the range in 
this study were correctly identified as being in the Emerging Category (56.7% in this 
study as opposed to 64% in the standardisation sample, and there were a number of 
cases where children were misidentified as being in the At-Risk category, which did 
not occur in the standardisation sample (Bayley, 2006c). The range in this study for 
children misidentified as being in the At-Risk category by the Bayley-III Screening Test 
where the BSID III classified them as being in the Emerging category was 5.3% to 
16.7%, which is much higher than the standardisation sample (0.8%-5.2%). This 
indicates that a much higher percentage of children were misclassified in this study, 
which has important implications for the clinic. These children would have to be 
referred on for further assessment, which places an increased burden on already 
overloaded services. On the other hand, children misidentified as being in the 
Competent category by the Bayley-III Screening Test where they were classified as 
being in the Emerging category by the BSID III ranged from 6.1% for Receptive 
Communication to 28.6% for Gross Motor function, which indicates that at the upper 
end of the range, almost a quarter of children who should be monitored would be 
misclassified, and would no longer be monitored or assessed, and therefore may be 
lost to the system. The fact that at the upper end of the range, the highest number of 
misclassifications occurred in the Gross Motor facet is especially important seeing that 
The Development of a Screening Tool to Evaluate Infants who are HIV Positive  
 129 
gross motor function is most severely affected in this population of children (Potterton 
et al, 2009b; Bailieu and Potterton, 2008). 
 
9.1.2.3 Classification Accuracy of the Bayley-III Screening Test for Children 
Identified by the BSID III as Competent 
Classification accuracy of the Bayley-III Screening Test was ‘very accurate’ for 
children with scaled scores of 8-19 in the standardisation sample (Bayley, 2006c). The 
range of correct classification of children in the Competent category by the Bayley-III 
Screening Test as compared with the BSID III for the standardisation sample was 
84% for Cognitive function to 92.1% for Receptive Communication (Bayley, 2006c). 
None of the children in the standardisation sample who were classified by the BSID III 
as Competent were misidentified as being At-Risk on the Bayley-III Screening Test 
(Bayley, 2006c).   
 
In this study, the range of correct classification of children in the Competent category 
on the Bayley-III Screening Test as compared with the BSID III is 68.8% for Fine 
Motor function to 94.7% for Expressive Communication. In this study, children with 
Expressive Communication in the Competent range were correctly identified more 
often than those with Receptive Communication skills in the Competent range. Fine 
Motor function had the lowest accuracy, which is different to the standardisation 
sample where the Bayley-III Screening Test identified children with cognitive skills in 
the Competent range least accurately. In this study, far fewer children were correctly 
identified on the lower end of the range (68.8% as compared with 84% in the 
standardisation sample), which brings into question the statement that Classification 
accuracy of the Bayley-III Screening Test was “very accurate” for children with scaled 
scores of 8-19 in the standardisation sample (Bayley, 2006c), as 68.8% is not 
sufficiently accurate. There were a few cases (2.3%) where children were 
misidentified as being in the At-Risk category by the Bayley-III Screening Test where 
the BSID III identified the children as being Competent, which did not occur in the 
standardisation sample (Bayley, 2006c). The range for children misidentified by the 
Bayley-III Screening Test as having Emerging skills was 5.3%-31.3% which is much 
higher. This is also important, as these children would be monitored or evaluated 
further, which again places an added burden on the system. Therefore in this study, 
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the Bayley-III Screening Test was not found to be sufficiently accurate in identifying 
children with skills in the Competent category. 
 
Overall, the Bayley-III Screening Test did not show adequate agreement with the 
BSID III in order to be used clinically on this population. The reasons for this are as 
follows: Classification accuracy of the Bayley-III Screening Test is highest for those 
children in the Competent category, and lowest for those children in the At-Risk 
category according to testing against the BSID III in the standardisation sample 
(Bayley, 2006c), which is problematic for the population of HIV positive infants for 
which we are evaluating its suitability, as they are at increased risk for developmental 
problems in all areas (Potterton et al, 2009a; Potterton et al, 2009b; Baillieu and 
Potterton, 2008; Udgirkar et al, 2003; Blanchette et al, 2001; Pearson et al, 2000; 
Fragoso et al, 1999; Drotar et al, 1997; Wolters et al, 1997; Belman et al, 1996; 
Pollack et al, 1996; Chase et al, 1995; Nozyce et al, 1994; Belman, 1992; Belman et 
al, 1988; Epstein et al, 1986; Belman et al, 1985; Ultmann et al, 1985), and therefore 
this screening tool would not be accurate enough to consistently detect these 
problems. The use of percentages is not recommended, as it often overestimates true 
validity, as it fails to account for chance - therefore it would have been more useful for 
the authors of the Bayley-III Screening Test to use Pearsons, Spearmans, or Kappa to 
evaluate concurrent validity (Portney and Watkins, 2000).  
 
In this study population, mean BSID III scores for Cognitive function were in the ‘Low 
Average’ to ‘Borderline’ range, and mean Motor scores were in the ‘Borderline’ to 
‘Extremely Low’ range, indicating that cognitive and motor function are severely 
compromised in this population. It would therefore be expected that even though 
classification accuracy for the Bayley-III Screening Test may be compromised in a 
healthy population, when used on children with severe delays, that accuracy may 
improve due to extremely low scores. The fact that there were a number of 
misclassifications, and that the Bayley-III Screening Test identified between 58.8%-
83.3% of children who were in the At-Risk category on the BSID III indicates that far 
too many children would be missed if this tool were to be implemented. It has been 
demonstrated over and over again that neurological and developmental abnormalities 
are frequent complications of HIV infection in children, especially in younger 
perinatally affected children (Potterton et al, 2009b; Baillieu and Potterton, 2008; 
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Raskino et al, 1999; Nozyce et al, 1994; Belman, 1992), therefore most children in the 
study population would be at risk for developmental problems, and this tool would not 
be accurate enough to detect these.   
9.2 Development of a New Screening Tool 
Following the analysis of the agreement between the BSID III and the Bayley-III 
Screening Test, it was clear that a new screening test should be developed, which 
was more appropriate for the paediatric HIV infected population. The choice of a tool 
in a clinical context needs to reflect the purpose for which the tool is to be used. If the 
purpose is to screen for problems in high-risk populations, a tool is needed that is 
quick and easy to administer, yet has good sensitivity and specificity (Scott et al, 
2007).  
 
As described in chapter eight, the following aims and objectives for the Infant Gross 
Motor Screening Test were drawn up in order to ensure that it would be suitable for 
use in a busy clinic in a developing country:  
• It should identify those children who are experiencing developmental problems, so 
that they may be referred for further assessment 
• It should be sensitive enough to distinguish between children who are experiencing 
problems and those who are not 
• It should be quick and easy to administer due to time constraints 
• It should not require profession specific training, so that counsellors and nurses 
may also administer it, should the need arise 
• It should be inexpensive enough to reproduce, and should not require any special 
equipment 
 
HIV clinics in South Africa have a number of human resource challenges which 
include shortages of staff, and little mentorship and training of doctors and nurses 
(Meyers et al, 2007). It is therefore vital that a screening tool which is developed for 
use in these clinics meets the criteria outlined above.  
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9.2.1 Developmental Domains of the Infant Gross Motor Screening Test 
Through analysis of the BSID III composite scores, and of the literature on HIV and 
neurodevelopment, a gross motor screening tool would be most suitable for this 
population. This is discussed in 9.2.1.1 below:  
 
9.2.1.1 Analysis of Literature and BSID III Composite Scores 
It has been consistently found that motor development, more specifically gross motor 
development is the facet of development which is most severely affected in HIV 
positive infants. Motor development is compromised from an early stage and HIV 
positive infants and children may start presenting with motor impairments in the first 
few months of life (Potterton and Eales, 2001; Chase et al, 1995; Nozyce et al, 1994). 
Muscle strength is decreased in children infected with HIV (Blanchette et al, 2001; 
Pearson et al, 2000), which may be a factor contributing to the fact that gross motor 
development is often more affected than fine motor development (Baillieu and 
Potterton, 2008; Potterton and Eales, 2001; Parks and Danoff, 1999).    
 
The composite scores of the infants in this study give an indication as to the 
developmental status of the sample. Language function is the area which is least 
affected in the sample, although the only scores which fell into the Average range in 
the Language domain were those in the two younger age groups.  This may be that 
language function at this stage is less demanding, and language relies mainly on 
receptive function at younger ages, which is consistently less affected in HIV positive 
children than expressive language (Wolters et al, 1997; Wolters et al, 1995). The 
scores in the Language domain were highest throughout the groups, which is 
consistent with studies done worldwide, where language function is the developmental 
domain which is least affected (Wolters et al, 1997; Wolters et al, 1995).  
 
Cognitive function is less affected than motor function in this sample, although the 
scores are still very low and fall into the ‘Low Average’ and ‘Borderline’ categories. 
Motor function is the area of development which is consistently most severely 
affected, and falls into the ‘Borderline’ or ‘Extremely Low’ categories. This is also 
consistent with the findings of previous studies on similar populations, where gross 
motor function is the area which is most severely affected (Potterton et al, 2009b; 
Baillieu and Potterton, 2008).  
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9.2.1.2 Analysis of Factors Leading to Poor Developmental Scores 
In this study, in all developmental domains, the developmental scores worsened as 
the children got older.  It was found that immunological and virological status improved 
with age, which is most likely due to the effect of HAART, which has a direct effect on 
immunological status, especially HAART containing a PI, which the regimen used at 
Harriet Shezi contains. The PI used at Harriet Shezi is Kaletra ® (Lindsey et al, 2007).  
Lindsey et al (2007) found that HAART containing a PI had a limited positive effect on 
neurodevelopment in the first two years of life, and that infants with severe immune 
suppression were at the highest risk for poor neurodevelopmental outcomes. This 
indicates that preventing immune suppression may be better than treatment which is 
initiated once the immune system is already suppressed. Patel et al (2009) examined 
the CNS penetration capacities of antiretroviral drugs and ranked each drug according 
to its penetration capacity (See Table 2.2). Antiretroviral regimens with scores of less 
than four are classified as low CNS-penetrating regimens, scores of four to five are 
classified as medium CNS-penetrating regimens, and scores greater than or equal to 
six are classified as high CNS-penetrating regimens (Patel et al, 2009). Children who 
were on a high CNS-penetrating regimen had a 41% decrease in the incidence of 
encephalopathy compared with those children on a low CNS-penetrating regimen 
(Patel et al, 2009).  
 
Children who are treated at Harriet Shezi clinic receive a first-line treatment regimen 
that has a CNS penetration score of seven, indicating that it is a high CNS-penetrating 
regimen. Despite this, infants in this study had very low developmental scores, which 
is most likely due to late HAART initiation once irreversible damage of the CNS had 
already occurred.  This highlights the need for a screening tool, which is able to detect 
developmental problems early, and help to identify children in need of developmental 
and medical assistance.     
 
9.2.1.3 Cultural Considerations in the Development of Screening Tools 
Culture has an effect on the appropriateness of assessment tools. Gladstone et al 
(2008) adapted the Denver-II for use in Malawi, and state that in all domains of 
Western tests, there are items which are culturally inappropriate for a rural African 
population. Gladstone et al (2008) found that items such as ‘‘prepares cereal’’ or 
‘‘plays board games/card games’’ are uncommon activities for children in rural Africa. 
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They also found that the pink doll in the Denver II kit was terrifying to most children. 
There are similar items in the BSID III, and the Bayley-III Screening Test, and the 
same problems have been encountered in South Africa (Potterton et al, 2009b; 
Baillieu and Potterton, 2008).  
 
Language assessment is also difficult, and many assessment tools have pictures of 
objects that children in a peri-urban/rural African setting have never seen before 
(Gladstone et al, 2008). This makes it difficult to name objects, especially as many 
children have also never seen a book, or pictorial representations of these objects. 
Gladstone et al (2008) found that social skills were the least universal across cultures, 
and gross motor skills were the most universal when comparing African and Western 
outcomes on an assessment tool, which has been developed for children growing up 
in a Westernised setting.  
 
Abubakar et al (2007) found that the lack of culturally appropriate and standardised 
measures of childhood outcome has been a major impediment in adequately studying 
the effects of disease exposure in sub-Saharan Africa. Their results indicate that it is 
feasible to develop culturally appropriate measures that are sensitive to the effects of 
HIV. This therefore reitrates that a gross motor screening tool would be appropriate for 
use in the paediatric HIV setting, as gross motor function is universal, and less 
culturally sensitive than any other developmental skills (Kelly et al, 2006).  
9.2.2 Characteristics of the Standardisation Sample of the New Screening Tool 
According to the American Psychological Association (1985) the normative sample 
should be determined by the country’s census using racial, geographic, and 
socioeconomic distributions.   
 
The Infant Gross Motor Screening Test was developed specifically for the study 
population: that is, HIV positive infants living in low urban socioeconomic conditions, 
and aged between 6-18 months, and therefore testing was carried out on this specific 
population against the BSID III. The infants varied in their developmental, virological 
and immunological status. The socioeconomic status of the sample was low, but this 
sample is representative in terms of socioeconomic background of HIV positive infants 
attending urban paediatric HIV clinics in the government sector in Gauteng. Maternal 
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education of the sample was low, with only 31.3% having completed school. The 
sample consisted primarily of black African infants, who live in Soweto, in Gauteng. 
The Infant Gross Motor Screening Test was developed for use on this population, and 
therefore should it be considered for use on other populations, further standardisation 
will need to be carried out.  
 
9.2.2.1 Risk-factors Affecting Gross Motor Development in the Standardisation 
Sample 
Socioeconomic disadvantage has been shown to have a negative educational effect 
on language and reading skills, as well as on the motor skills of children (McPhillips 
and Jordan-Black, 2007). In this study 81% of primary caregivers were mothers, with 
grandmothers taking on this responsibility where mothers were no longer alive. Most 
primary caregivers had not completed school, and therefore maternal education levels 
were low. When taking the average number of people per household (4.8 people) 
together with the fact that 45% of the families live in a shack, and in 45% of families 
there is only one adult bringing in an income, the socioeconomic status of the sample 
was determined to be low.  
 
The mediating effect of socioeconomic status (SES) on neurodevelopment was 
examined by Abubakar et al (2008b), where it was found that SES has a significant 
effect on psychomotor development through its influence on height-for-age (stunting) 
and weight-for-age (malnutrition) which were both examined in this study. In terms of 
malnutrition in this sample, only the youngest group (6-8 months) was affected, with a 
mean weight-for-age of -2.29, which is indicative of moderate malnutrition. The older 
groups fall within the normal range (0 to -2) for this measure. This may be that the 
younger group has not had access to antiretroviral therapy, or nutritional counselling, 
having most likely been recently diagnosed, and therefore would not have attended 
many clinic sessions.  
 
Stunting was a problem in this study population, and was most severe in the 6-8 
month old age group, where there is moderate stunting (height-for-age = -2.26). The 
children in the 9-14 month age group were not affected by stunting, but the children in 
the 15-18 month old age range also had moderate stunting (height-for-age = - 2.87). It 
has been found that HIV infected infants are more commonly stunted than wasted 
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(Tindyebwa, 2004). There is likely to be an effect due to the above anthropometric 
factors on gross motor development. This is due to the mediating effect of SES on 
growth, and the subsequent effect of poor growth on motor development (Abubakar et 
al, 2008b). Due to the fact that muscle strength is decreased in children infected with 
HIV (Blanchette et al, 2001; Pearson et al, 2000), gross motor function may also be 
affected. Again this highlights the fact that this population is at great risk for gross 
motor delay, and the Infant Gross Motor Screening Test must therefore have excellent 
classification accuracy in order to identify these potential problems.  
9.2.3 Selection of Items  
As discussed in chapter two, a review of the literature on the development of 
screening tools revealed that item selection is based on the following:  ‐ Review of the literature (Bart et al, 2010; Kirby et al, 2010; Martin et al, 2009; 
Bayley, 2006c; Harris et al, 2003; Beckung, 2000) ‐ Review of similar screening tools (Kirby et al, 2010; Harris et al, 2003) ‐ Items taken from an existing assessment tool (Gladstone et al, 2008; Bayley, 
2006c; Aylward, 1995) ‐ Interviews with people who have the relevant condition (Bart et al, 2010) ‐ Clinical experience (Bayley, 2006c; Harris et al, 2003; Beckung, 2000) 
Gladstone et al (2008) adapted the Denver-II for use in Malawi, and found that many 
items from Western tools can work well when adapted and translated for other 
settings. This is due to the fact that they have already been rigorously tested for 
reliability and validity. They found that when creating new items, these items were less 
reliable, and had poorer goodness of fit in logistic regression analysis (Gladstone et al, 
2008).  Due to the fact that gross motor function is universal, and all children develop 
the same milestones and components of movement, there is also a limited pool of 
gross motor assessment items. When examining the gross motor components of 
assessment tools, there are very similar items used in each one (Bayley, 2006c; 
Harris et al, 2003; Aylward, 1995; Bricker et al, 1995; Frankenberg et al, 1992; Piper 
et al, 1992). In this study, item selection was based on items from the BSID III. These 
items were selected according to how well they distinguished between children who 
were At-Risk, children with Emerging skills and children who were Competent. Items 
had undergone rigorous reliability and validity testing (Bayley, 2006c), and were 
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therefore more likely to be robust in use (Gladstone et al, 2008).  
9.2.4 Scoring Outcomes of the Infant Gross Motor Screening Test 
The first version of the Infant Gross Motor Screening Test had three scoring 
outcomes, namely At-Risk, Emerging and Competent, so that the results could be 
compared with those obtained on the BSID III. Aylward (2000) states that the 
moderate level of risk was developed to include infants whose developmental level is 
in the ‘grey zone’ at the time of testing, and who would require, at minimum, 
developmental surveillance.  Aylward (2000) states that three levels of risk preclude 
the determination of sensitivity or specificity or estimations of relative risk based on 
odds ratios. However, three levels of risk can help determine which infants need to be 
monitored (infants obtaining a score in the Emerging group) and which infants should 
be enrolled in intervention programs (infants in the At-Risk group). However, in favour 
of scoring with only two levels of risk, Aylward (2000) states that caregivers and 
parents are more likely to understand a two-level outcome of either At-Risk or 
Competent. Sensitivity and specificity are also able to be calculated with only two 
levels of risk.  
 
Aywlard et al (2000) found that the moderate-risk group had the most variation in risk 
consistency over the first three years and that the trend in infants falling into the 
moderate-risk groups was towards improvement, which may be related to the positive 
effects of the intervention which many of them received. Longitudinally, infants in the 
moderate-risk group were found to be more similar to their low-risk counterparts than 
to those with a high-risk classification (Aylward, 2000). In South Africa, the trend of 
HIV infected infants in the moderate-risk group may be towards decline, and 
increased similarity to high-risk counterparts as intervention is not given, and HIV 
infected infants have many other risk factors including socioeconomic status, the 
effects of HIV on neurodevelopment, and repeated hospital admissions with long 
stays which may lead to regression in development (Cooper et al, 2004; Fiser et al, 
2000). In a longitudinal randomised control trial conducted in South Africa, where half 
the children were given a home stimulation programme, although their developmental 
scores improved over time, at the end of a year’s intervention, their developmental 
scores were still well below normal levels (Potterton et al, 2009a).  
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Given that intervention may be more beneficial to infants with less severe delays, 
identification of moderate-risk infants, and provision of intervention may move these 
infants to a more optimal level of function (Aylward, 2000). This may be possible in 
well-resourced developed countries where early intervention may be provided to all 
infants, even those who are not at high-risk, but this would not be feasible in a 
developing country such as South Africa, where all therapy departments are 
understaffed and cannot manage with the high case loads they have. Therefore, the 
value of having an “Emerging” category in a developing country may not be as great, 
as there are no adequate resources for these children, and only those At-Risk would 
be considered to be eligible for intervention.  
 
9.2.4.1 Conversion of the New Screening Tool from Three Scoring Outcomes to 
Two Scoring Outcomes 
Aylward et al (2000) converted the BINS into two scoring outcomes, and tested the 
predictive validity of the screening tool against the version with three scoring 
outcomes. When converted to two scoring outcomes, the BINS produced similar 
results to the version with three outcomes – an early classification of high-risk was 
indicative of risk status at 36 months, and therefore changing the scoring categories 
did not change the developmental predictory outcome (Aylward, 2000). This indicates 
that having two scoring outcomes is not detrimental to the tool’s discriminatory ability. 
Therefore in this study, the new screening tool was also converted to two scoring 
outcomes for the following reasons:  ‐ The results are easier for parents and health professionals to understand ‐  The moderate risk group is not lost to follow-up, and there is a clear 
management plan for those in the At-Risk category, and those in the Competent 
category ‐ Sensitivity and specificity can be calculated.  
 
In converting the BINS to a two-outcome measure, the following procedure was 
undertaken (Aylward et al, 2000):  the moderate-risk group was subdivided, based on 
the cut-off score in the BINS manual that offered the best measures of sensitivity and 
specificity. Moderate-risk scores falling between the cut-off point and the BINS high- 
risk category were combined into a moderate-/high-risk group, and named ‘High Risk’. 
Moderate-risk scores falling between the cut-off point and the BINS low-risk category 
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were combined with the low-risk category to form a ‘Low Risk’ group (Aylward et al, 
2000).  
 
A similar procedure was undertaken in this study but because there were no 
measures of sensitivity and specificity as there were in the BINS manual, the BSID III 
scaled scores which translated into the ‘Emerging’ category were dealt with as follows:  
• Scaled scores of 5 and 6 were classified as “At-Risk” 
• Scaled scores of 7 were classified as “Satisfactory” 
 
The word “Satisfactory” was chosen due to the wide range of normal development that 
is possible in children between 6 and 18 months. The conversion of the “Emerging’ 
scores was done through thorough item analysis and the use of clinical judgement to 
determine whether a child who could not perform the items that they received a ‘no 
credit’ for on the BSID III Gross Motor scale would be considered to be 
developmentally Satisfactory, or At-Risk for developmental problems. On the Infant 
Gross Motor Screening Test, the Emerging category was always converted to ‘At-
Risk’. This is due to the fact that HIV infected infants are at increased risk for 
developmental delays, and even though there may be an improvement in 
development over time, their scores are likely to be well below average (Potterton et 
al, 2009a).  
9.3 Statistical Properties of the New Screening Tool 
It is essential to establish whether a study will provide evidence of the validity of a 
measuring instrument and its reliability. A high level of reliability gives no firm 
evidence that the instrument is measuring what it is supposed to, and therefore the 
validity also needs to be examined. It is equally important to consider the clinical 
context to which any findings are likely to be applied (Sim and Arnell, 1993). 
Screening tools should be both valid and reliable. The definitions of the types of 
validity and reliability tests have been outlined in chapter two. The statistical properties 
of the Infant Gross Motor Screening Test with regards to validity and reliability are 
discussed below.  
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9.3.1 Validity 
A measure should be valid for the purpose for which it was developed (Rosenbaum, 
1998). The Infant Gross Motor Screening Test was developed in order to identify 
gross motor delays in HIV positive infants at the time of screening. Testing of the 
validity of the Infant Gross Motor Screening Test was undertaken to determine the 
content validity and criterion validity of the Infant Gross Motor Screening Test.  
Rothstein et al (1991) in the Standards for Tests and Measurements in Physical 
Therapy Practice states that content validity and criterion-related validity should be 
evaluated when developing a new tool.   
 
9.3.1.1 Content Validity 
Content validity is an essential step in the development of new measuring tools as it 
represents a starting mechanism for linking abstract concepts with observable and 
measurable indicators (Wynd et al, 2003).  Content validity is often the first step in 
examining the validity of a newly developed tool (McEwan et al, 2003). This may be 
done through consultation with a panel of experts (Harris and Daniels, 1996) to obtain 
consensus on each item, as well as the consensus on the scale as a whole. When 
assessing content validity, it is necessary to define the domain of content of the 
concept being measured (in this case, gross motor function) and then to determine 
whether this is adequately covered by the instrument.   
 
Content validity is largely a matter of judgement, involving two distinct phases: the 
scale developer should enhance content validity through careful conceptualisation 
prior to item generation, and the relevance of the scale’s content should be assessed 
through expert assessment (Beck and Gable, 2001; Mastaglia, et al, 2003; Polit and 
Beck, 2006). During the development of the Infant Gross Motor Screening Test, items 
based on the BSID III were selected due to the fact that they had undergone validity 
testing, and came from the Gross Motor facet of the BSID III, indicating that they were 
developed to test that construct (Bayley, 2006b).  This gives evidence for 
conceptualisation prior to item generation.  
 
Expert assessment may be carried out in a number of different ways. A modified form 
of the Nominal Group Technique (NGT) was used to determine content validity of the 
new screening tool (Potter et al, 2004). The NGT has been shown to be a reliable 
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method to establish the content validity of new instruments (Hyrkas et al, 2003). This 
was successfully used during the content validation of the Gross Motor Function 
Classification System (GMFCS) (Palisano et al, 2008), and provides immediate 
feedback to the participants, thus increasing satisfaction with participation (Potter et 
al, 2004).  
 
In this study, as discussed in chapter seven, a panel consisting of seven experts was 
used, and experts were asked to examine and provide feedback on each of the 
following questions:  
- Appropriateness of each item selected (item itself, and item wording) 
- Appropriateness of the age groups which had been selected 
- Appropriateness of the items for the age-group in which they fell 
- Appropriateness of scoring 
 
The NGT protocol, which is described in chapter two was followed. All concerns from 
participants were discussed and appropriate changes were suggested. There was 
100% agreement for objectives two, three and four, and 71.4% agreement for 
objective one. The changes suggested and made are outlined in chapter seven. Once 
the concerns and suggested changes had been outlined, there was 100% agreement 
from all the participants for all objectives. This meets the defined percentage of 
consensus (80% of participants) as outlined by Palisano et al (2008). The NGT (Potter 
et al, 2004) has been successfully used to obtain consensus during content validity of 
new tools (Dyrbye et al, 2010; Palisano et al, 2008; Shea et al, 2007; van der Camp et 
al, 2006), and was used successfully in this study in order to obtain consensus during 
content validity.  
 
9.3.1.2 Criterion Validity 
The American Physical Therapy Association's Task Force on Standards for 
Measurement in Physical Therapy distinguishes three varieties of criterion-related 
validity: (1) concurrent validity, (2) predictive validity, and (3) prescriptive validity 
(Rothstein et al, 1991). Criterion-related validity underpins quantitative research and is 
obtained by comparing the measurements obtained on the new instrument with a 
measurable criterion that is accepted as a standard indicator of a concept or variable 
(Rothstein et al, 1991). If the instrument gives an accurate representation of the 
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concept or variable, criterion-related validity has been demonstrated (Sim and Arnell, 
1993). In this study, criterion validity was evaluated using the BSID III, which has long 
been considered the ‘gold standard’ in infant assessment (Harris et al, 2005; Tieman 
et al, 2005).  
 
9.3.1.3 Concurrent Validity  
Concurrent validity is the degree to which outcomes on one test correlate with 
outcomes on a criterion test, when both tests are given at the same time (Portney and 
Watkins, 2000). This is obtained by comparing the measurement being validated with 
another validated measurement at approximately the same time.  Concurrent validity 
should be assessed when the new test claims to be able to give information about the 
current status of a person at the time that the measurements are obtained (Rothstein 
et al, 1991). Correlations of 0.6 or greater should be obtained (Glascoe, 1991; 
American Psychological Association, 1985). In this study, concurrent validity of the 
Infant Gross Motor Screening Test was assessed against the Gross Motor facet of the 
Bayley Scales of Infant Development III. This was done using two versions of the 
Infant Gross Motor Screening Test: the first had three scoring categories, and the 
second version had two scoring categories.  
 
Concurrent Validity of the Infant Gross Motor Screening Test with Three Scoring 
Outcomes 
For the version with three scoring outcomes, the agreement was analysed using a 
Kappa Statistic and was K=0.63 for the total group, which indicates that there is 
moderate agreement between the tools (Landis and Koch, 1977). The agreement 
ranged from K=0.51 to K=0.69 per age group, again, indicating only moderate 
agreement (Landis and Koch, 1977). Some of these values were below the 
recommended cut-off point by Glascoe (1991), and the American Psychological 
Association (1985), and due to having three categories, sensitivity, specificity and 
predictive value could not be calculated (Aylward, 1995). A Kappa value of 0.75 or 
above which indicates excellent agreement (Landis and Koch, 1977) would be 
acceptable in order to indicate that the Infant Gross Motor Screening Test is suitable 
for clinical use.  
 
The Infant Gross Motor Screening Test assessed the children more conservatively 
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than the BSID III, and therefore where there were discrepancies in scoring, the Infant 
Gross Motor Screening Test score was always within one category of the BSID III, 
and was always one score category below. For example, for a child whose scores 
differed on the two tools: where a score on the BSID III was in the competent 
category, the Infant Gross Motor Screening Test score would place the child in the 
Emerging category.  All scores between the tests which did not correlate were within 
one category of the other test’s score, and there were no infants who were placed in 
the At-Risk category on one measure and in the Competent category on the other 
measure. The Emerging category was the category which was most often involved in 
the scores which did not correlate between the BSID III and the Infant Gross Motor 
Screening Test, indicating that this was a problematic category on both tests.   
 
Concurrent Validity of the Infant Gross Motor Screening Test with Two Scoring 
Outcomes 
After consultation with staff at the Harriet Shezi clinic, and examination of the 
literature, it was determined that a screening tool with two scoring outcomes would be 
more suitable in this setting, as the management of those with Emerging skills is 
difficult in a poorly resourced setting. Therefore, both scales were converted to two 
scoring categories: At-Risk, and Competent, as described in chapter eight (8.3). 
Again, concurrent validity was assessed between the Infant Gross Motor Screening 
Test and the BSID III, this time with two scoring categories.   
 
The concurrent validity for the tools with two scoring categories was much higher – a 
Kappa value of 0.85 was obtained overall, which indicates excellent agreement 
(Landis and Koch, 1977). The Kappa scores per age group ranged between K=0.60 to 
K=1. All these scores are above the recommended cut-off point of 0.60 (Glascoe, 
1991; American Psychological Association, 1985). The outlying scores were examined 
to determine why they did not agree. Only four out of sixty cases did not agree, and in 
three of those cases, the BSID III classified the child in the Competent category, and 
the Infant Gross Motor Screening Test classified them as At-Risk. There was only one 
case where the Infant Gross Motor Screening Test classified the child as being 
Competent, where the BSID III score was At-Risk. Although this may tend towards 
over-referrals on the part of the Infant Gross Motor Screening Test, the population is 
at extremely high risk of gross motor delay (Potterton et al, 2009b; Ferguson and 
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Jelsma, 2009; Baillieu and Potterton, 2008), and therefore in terms of further 
management, it would be better for the child to be referred for further assessment 
based on an over-referral, than wait three to six months for a further screening at the 
next clinic appointment, and then be classified as At-Risk, especially for those with 
progressive encephalopathy.  
 
Glascoe (2001) found that children who receive false-positive results in screening 
tests perform substantially lower than children with true-negative scores on measures 
of intelligence, language, and academic achievement, which are the three best 
predictors of school achievement. These children also carried more psychosocial risk 
factors, such as limited parental education. Thus, she concluded that children with 
false-positive screening results are an At-Risk group for whom diagnostic testing may 
not be an unnecessary expense but rather a beneficial and needed service that may 
help focus intervention efforts (Glascoe, 2001).  
 
The population for which the Infant Gross Motor Screening Test was developed has 
been shown to have motor, cognitive and language developmental delays in studies 
carried out worldwide (Potterton et al, 2009b; Baillieu and Potterton, 2008; Udgirkar et 
al, 2003; Blanchette et al, 2001; Pearson et al, 2000; Fragoso et al, 1999; Drotar et al, 
1997; Wolters et al, 1997; Belman et al, 1996; Pollack et al, 1996; Chase et al, 1995; 
Nozyce et al, 1994; Belman, 1992; Belman et al, 1988; Epstein et al, 1986; Belman et 
al, 1985; Ultmann et al, 1985), as well as socioeconomic risk-factors and are therefore 
at risk for lower scores on all domains of developmental testing. In keeping with 
Glascoe’s (2001) conclusions, again, for those infants who receive false positive 
results on the new screening test diagnostic testing may be beneficial.  
 
The results of the concurrent validity of the Infant Gross Motor Screening Test 
compared with other commonly used screening tests are shown in Table 9.1 below:  
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Table 9.1 Concurrent Validity of the Infant Gross Motor Screening Test 
Compared with Other Commonly Used Screening Tools 
 
Tool 
 
Concurrent validity 
 
BINS With BSID II: Motor scale r = 0.35 
                      Mental scale r = 0.40 
 
ASQ Only sensitivity, specificity and PPV available – no concurrent 
validity for second version 
 
Denver II Only sensitivity, specificity and PPV available – no concurrent 
validity for second version 
 
AIMS BSID II motor scale r = -0.98 
Peabody Developmental Motor Scale r = -0.97 
 
HINT BSID II motor scale r = -0.89 
BSID II mental scale r = -0.73 
 
Bayley III Screening 
Test 
Against the BSID III 
At-Risk: moderate (41.82% - 65.91%) 
Emerging: accurate (63.87% - 77.78%) 
Competent: very accurate (83.84% - 92.11%) 
 
Infant Gross Motor 
Screening Test  
Against the BSID III Gross Motor facet K = 0.85 
 
 
The Infant Gross Motor Screening Test fares well in terms of other commonly used 
screening tests, with concurrent validity of K=0.85 against the BSID III Gross Motor 
facet. The BINS (Aylward, 1995) has low concurrent validity with the BSID II on both 
the Motor (r=0.35) and Mental scale (r=0.40), even though the BINS was based on the 
BSID II, and items were taken directly from it. The problem with the concurrent validity 
could stem from the fact that new items were added along with the items taken from 
the BSID II, and this has been shown to affect validity (Gladstone et al, 2008).  
 
The ASQ (Bricker et al, 1995), and the Denver II (Frankenberg et al, 1992) have both 
been revised, but concurrent validity for the revised, and now more commonly used 
versions has not been carried out. Only sensitivity, specificity and positive predictive 
values are available for these versions. Concurrent validity of the AIMS (Piper et al, 
1992), against the BSID II Motor scale (r = -0.98), and Peabody Developmental Motor 
Scale (r=-0.97) was very high which is most likely due to the fact that the AIMS only 
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measures motor development, and that there are a limited number of motor 
assessment items, which are common across most motor assessment tools. The 
concurrent validity of the Infant Gross Motor Screening Test is not as high, but it has 
fewer items than the AIMS, and therefore less chance of correlating on all items.  
 
Concurrent validity of the HINT (Harris et al, 2003) against the BSID II Motor scale (r = 
-0.89) and BSID II Mental scale (r=-0.73) was also high, and the authors state that the 
HINT is predominantly a neuromotor screening test, which is why the correlation with 
the BSID II Motor scale was higher (Harris et al, 2003). Concurrrent validity of the 
Infant Gross Motor Screening Test is similar to that of the HINT.  
 
The Bayley-III Screening Test used percentages of agreement against the BSID III as 
follows:  
At-Risk: moderate (41.8%-65.9%) 
Emerging: accurate (63.9%-77.8%) 
Competent: very accurate (83.8%-92.1%) 
The use of percentages is not recommended, as it will often overestimate true 
reliability because it fails to account for chance agreement (Portney and Watkins, 
2000).  
 
Therefore, against the seven other screening tests, the Infant Gross Motor Screening 
Test’s concurrent validity is excellent, considering that for some of the commonly used 
tests such as the Denver-II and ASQ (2nd version), concurrent validity studies have not 
yet been conducted.  
 
9.3.1.4 Sensitivity, Specificity, Positive Predictive Value and Negative Predictive 
Value 
Screening tests must offer information on sensitivity, which is how well they detect the 
people who have the condition being screened for, and the specificity of the screening 
tool which is the ability to accurately rule out those who do not have the problem. The 
significance of these statistical considerations is both economic and clinical, as over-
referrals lead to further, often more expensive and time consuming, in-depth 
assessments and may be upsetting to parents (Rosenbaum, 1998).  
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Sensitivity and specificity of developmental screening tools are measured by 
comparing the test results to those of gold-standard developmental evaluation tools 
(Glascoe, 1997). In this study, this was done against the BSID III (Bayley, 2006a), as 
the Bayley Scales of Infant Development have long been considered the ‘gold 
standard’ of infant assessment (Harris et al, 2005; Tieman et al, 2005). 
 
Sensitivity is a measure of validity of a screening procedure based on the probability 
that someone who has the condition will test positive (Portney and Watkins, 2000). 
The overall sensitivity for the Infant Gross Motor Screening Test was 97.4%. For each 
age group, the sensitivity was tested, and the following results obtained: 6-8 months: 
85.7%, 9-12 months: 100%, 13-16 months: 100% and 17-18 months: 100%. Glascoe 
(1997) recommends that a screening test should have sensitivity levels of 70 – 80% 
due to the nature and complexity of measuring the continuous process of child 
development. Meisels (1989) suggested that more conservative criteria should be 
used with sensitivity levels of no less than 80% in order to avoid too many over-
referrals. A value of 90% is recommended by the American Psychological Association 
(1985). Therefore the overall sensitivity of the Infant Gross Motor Screening Test, as 
well as the sensitivity per age group is over the suggested figures, which indicates that 
children who have gross motor delays will be identified by the screening tool.  
 
Specificity is a measure of validity of a screening procedure based on the probability 
that someone who does not have the condition will test negative (Portney and 
Watkins, 2000). There often is a trade-off in specificity if the sensitivity of a measure is 
very high. Again, Glascoe (1997) recommends that a screening test should have 
specificity levels of 70-80% due to the nature and complexity of measuring the 
continuous process of child development. Meisels (1989) suggested that more 
conservative criteria should be used with specifity levels of no less than 80% to avoid 
under-referrals. The recommendation by the American Psychological Association, 
(1985) is 90%. This indicates that there is a wide variation in acceptable levels of 
specificity, but when combining the above recommendations, it should be between 70 
-90%. The overall specificity for the Infant Gross Motor Screening Test was 85.7%. 
For each age group it was as follows: 6-8 months: 87.5%, 9-12 months: 100%, 13-16 
months: 100% and 17-18 months: 50%. Overall, the Infant Gross Motor Screening 
Test has excellent levels of specificity apart from the 17-18 month age group where 
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only four children were Competent, and the new screening tool correctly identified two 
out of the four. The levels achieved overall are acceptable according to suggested 
levels of between 70 and 90% (Glascoe, 1997).  
 
Screening tests need to give information as to the probability that the test will give the 
correct diagnosis (Altman and Bland, 1994). This information cannot be obtained from 
sensitivity and specificity values, and therefore the predictive values need to be 
examined in order to obtain this information (Altman and Bland, 1994). Positive 
Predictive Value (PPV) is an estimate of the likelihood that a person who tests positive 
actually has the condition (Portney and Watkins, 2000). The lower the prevalence of a 
disorder, however, the lower will be the positive and negative predictive values. A 
positive predictive value of 50% would be acceptable in developmental screening, 
although 30% and above is often found, because some of the low average children 
will be over-referrals (Aylward, 1997). The positive predictive value of the Infant Gross 
Motor Screening Test is 92.7% and for each age-group 6-8 months 85.7%, 9-12 
months 100%, 13-16 months 100% and 17-18 months 84.6%. This indicates that the 
PPV value in the Infant Gross Motor Screening Test is high, and that the likelihood 
that the children who are diagnosed as At-Risk on the new screening tool will have 
gross motor delay. This value is very high, due to the high prevalence of gross motor 
delay in this population.  
 
Negative predictive value (NPV) is the proportion of patients who are correctly 
diagnosed by the test as not having the condition (Altman and Bland, 1994). This 
result is less commonly presented, and ideal values for this result could not be found. 
The negative predictive values are: Overall: 94.7%. Per age group: 6-8 months: 
87.5%, 9-11 months: 100%, 13-16 months: 100 % and 17-18 months: 100%. The 
negative predictive values for the Infant Gross Motor Screening Test are also very 
high, indicating that overall, the proportion of children who were correctly diagnosed 
as having no gross motor delay, did not have the condition. The prevalence of the 
condition is the probability before the test is carried out that the subject has the 
condition (this is known as the prior probability of the disease) (Altman and Bland, 
1994). The positive and negative predictive values act as revised estimates of the 
same probability for the patients, and are known as posterior probabilities (Altman and 
Bland, 1994). The difference between the prior and posterior probabilities is one way 
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of assessing the usefulness of the test (Altman and Bland, 1994). Based on previous 
studies where it was found that up to 95% of the children in a sample had gross motor 
delay (Baillieu and Potterton, 2008), the Infant Gross Motor Screening Test is suitable 
for use in this population, as it detects this high prevalence. The sensitivity, specificity 
and PPV of the Infant Gross Motor Screening Test are compared with those of 
commonly used screening tests in Table 9.2 below: 
 
Table 9.2 Sensitivity and Specificity of the Infant Gross Motor Screening Test 
Compared with Other Commonly Used Screening Tools 
 
Tool 
 
Sensitivity, specificity and PPV 
 
BINS Sensitivity: 75-86% Specificity: 75-86% PPV: 0-52% 
 
ASQ Sensitivity: 75% Specificity: 85% PPV 46% 
 
Denver II Suspect w/normal group:  Sensitivity=56% Specificity=80% 
PPV= 37% 
  
Suspect w/abnormal group: Sensitivity=83% Specificity=43% 
PPV=23%  
 
AIMS Not available 
 
HINT Testing currently underway  
 
Bayley III 
Screening Test 
Not available 
 
 
Infant Gross 
Motor 
Screening Test 
Sensitivity: 97.4% Specificity: 85.7% 
PPV: 92.7% NPV: 94.7% 
 
 
The sensitivity of the Infant Gross Motor Screening Test is 97.4%, which is higher than 
any of the other commonly used screening tests as shown in the table above. The 
specificity of the Infant Gross Motor Screening Tool is 85.7%, which is similar to that 
of the ASQ and the BINS. The combination of sensitivity and specificity that the Infant 
Gross Motor Screening Tool has achieved is excellent, as in many cases (such as the 
Denver II), there is a trade-off between the two if one is very high. The ASQ and the 
BINS have also achieved a good combination of sensitivity and specificity. 
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The PPV of the Infant Gross Motor Screening Test is 92.7%, which is extremely high, 
due to the high prevalence of gross motor delay in the HIV infected infant population 
for which the tool was developed. The ASQ has a much lower PPV, due to the 
samples on which the validity studies were conducted, where the prevalence of motor 
delay was lower. The Denver-II and BINS have achieved particularly low PPV, even in 
high-risk populations, which should be investigated further (Hess et al, 2004; Glascoe 
and Burne, 1993). The BINS sample was at environmental risk (families with low 
income) rather than biological risk, which may contribute to the low PPV, and 
therefore the BINS may be better suited for use on a population with biological risk, 
and better-defined developmental problems (Hess et al, 2004).  
 
9.3.1.5 Predictive Validity 
Predictive validity examines the justification of using a measurement to say something 
about future events or conditions (Rothstein et al, 1991). Information about predictive 
validity should be provided when a measurement claims to be able to provide 
information about future status (Rothstein et al, 1991). Marks et al (2008) express 
concern at conducting predictive validity studies on developmental screening tools, as 
by design, screening tools are developed to provide information on the current status 
of a child, and not give an indication of future outcome. The American Academy of 
Pediatrics (2006) states that a screening tool should generate referrals to early 
intervention, where the child may receive more in-depth assessment, or monitoring 
through surveillance.  Therefore it is not necessary to evaluate predictive validity at 
this time, as this screening instrument was not developed to predict later functional 
status of the child, and will be used to assess the developmental status of the child at 
a particular point in time, based on the score of the screening tool achieved. The 
Infant Gross Motor Screening Test may be used for surveillance purposes, that is, it 
may be administered at each clinic visit in order to monitor development.  
 
9.3.1.6 Prescriptive Validity 
Prescriptive validity refers to the validity of a test when the results are used to 
determine what treatment the person will receive (Rothstein et al, 1991). Information 
regarding prescriptive validity should be provided when the results of a measurement 
will be used to determine treatment options. Therefore, due to the fact that at present 
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rehabilitation options are not based on the results of this screening test, it is not 
necessary to evaluate prescriptive validity at this point.  
9.3.2 Reliability 
Measures should be reliable, which means that they give consistent results from one 
administration time to another, and from one assessor to another, when the person 
being assessed has not changed (Rosenbaum, 1998). The instrument might be 
reliable but untrained assessors may not be capable users of the instrument. 
Therefore, before deciding to use any clinical assessment instrument, would-be users 
should obtain appropriate training in both the application and interpretation of the 
measures they wish to apply (Rosenbaum, 1998). Reliability is defined as the 
consistency or repeatability of measurements (Rothstein et al, 1991). According to 
Rothstein et al (1991) the following forms of reliability should be considered when 
developing a test:  
 
9.3.2.1 Internal Consistency 
Internal consistency is defined as the extent to which items or elements that contribute 
to a measurement reflect one basic phenomenon or dimension. The Infant Gross 
Motor Screening Test only assesses gross motor function, and items were based on 
those from the BSID III Gross Motor scale, on which internal consistency had been 
conducted (r=0.92) (Bayley, 2006b).  
 
9.3.2.2 Interrater Reliability 
Interrater reliability is the consistency of measurements when more than one person 
takes the measurements at the same time, and indicates the agreement of 
measurements taken by different examiners (Rothstein et al, 1991). Interrater 
reliability is best measured when all raters are able to measure a response during a 
single trial (Portney and Watkins, 2000). If interrater reliability has not been 
established, it cannot be assumed that other raters would have obtained the same 
results, which therefore limits the application of the findings (Portney and Watkins, 
2000). Studies should be conducted in a clinical context consistent with the intended 
use of the measurements (Rothstein et al, 1991).  
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In this study two raters evaluated preliminary interrater reliability, and did so during a 
single trial as suggested by Portney and Watkins (2000). The child’s response was 
scored by both raters simultaneously. The context in which interrater reliability was 
conducted was consistent with the intended use of the measurements in that it was 
conducted at Harriet Shezi Children’s clinic, which is a paediatric HIV clinic. Children 
on which the reliability testing was conducted were all HIV positive, and attending the 
clinic for scheduled visits. The interrater reliability was excellent (r=1) (Portney and 
Watkins, 2000), and indicates that different raters would obtain the same score when 
using the Infant Gross Motor Screening Test. The scoring on the Infant Gross Motor 
Screening Test is simple, and the outcomes to be assessed are clear, which 
contributes to the high interrater reliability.  
 
9.3.2.3 Test-retest Reliability 
Test-retest reliability is the consistence of repeated measurements over time where 
the subject has not changed (Rothstein et al, 1991). Within-day and between-day 
studies should be conducted in a clinical context consistent with the intended use of 
the measurements (Rothstein et al, 1991). In the reviewed literature on developmental 
screening and performance tests, the time between testing for test-retest reliability 
differed significantly, and ranged from two days to thirty days (Thomas-Stonell et al, 
2010; Bayley, 2006b; Bayley 2006c; Saigal et al, 2005; Harris and Daniels, 2001; 
Squires et al, 1997; Coster, 1995; Frankenberg et al, 1992).  
 
In this study, preliminary test-retest reliability was carried out in the wards at Rahima 
Moosa Hospital. The context in which test-retest reliability was carried out was 
consistent with the intended use of the measurement instrument as suggested by 
Rothstein et al, (1991), was achieved by that fact that the children assessed were HIV 
positive, and the future use for the tool would be in both in-patient and outpatient 
paediatric HIV settings. Portney and Watkins (2000) state that the interval between 
tests should be considered very carefully: they should be far enough apart to avoid 
fatigue, learning or memory effects, but close enough to avoid changes in the variable 
to be measured. They state that the primary criteria for choosing an appropriate 
interval are the stability of the response variable, and the purpose of the test. In 
addition, they also state that measurements of infant development might need to be 
taken over a short period to avoid the rapidly occurring changes of early infancy. In 
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this study, the interval of two days between tests was chosen for the following 
reasons: it was far enough apart to avoid fatigue, but close enough to avoid changes 
in the patient, as in this case, the patients were in hospital, and were subject to 
change due to improvements in their condition. Care was taken to assess children at 
the same time of the day, so that the effects of medication could be taken into 
consideration.  
 
The results of the test-retest reliability study were excellent (r=0.98) (Portney and 
Watkins, 2000), and indicate that the Infant Gross Motor Screening Test is stable over 
time, and produces the same test results. In the two cases in which the score did not 
agree, the score on the first assessment was one point higher, which may be due to 
the fact that the child’s medical condition had deteriorated slightly, therefore producing 
a lower score on the second assessment. The category in which the child was placed 
by the Infant Gross Motor Screening Test was the same, despite the one point 
difference in scores, indicating that the child would have received the same 
management following administration of the Infant Gross Motor Screening Test.  
 
Portney and Watkins (2000) state that caution should be given to carry-over effects, 
which may occur with repeated measurements, and concepts such as motor learning, 
which may result in an improvement on the first test score. The Infant Gross Motor 
Screening Test is an observational test, and therefore motor learning would not occur, 
as there is no facilitation or handling of the infant.   
 
9.3.2.4 Intrarater Reliability 
Intrarater reliability refers to the stability of data recorded by one individual over two or 
more tests. This is usually assessed using trials with short intervals in-between where 
carryover effects are not an issue (Portney and Watkins, 2000). In a test-retest 
situation, when a rater’s skill is relevant to the accuracy of the test, intrarater and test-
retest reliability are essentially the same estimate (Portney and Watkins, 2000). In this 
study, the rater’s skill was relevant to the accuracy of the test, and therefore test-retest 
reliability and intrarater reliability are the same estimate. In this study, the intrarater 
reliability was excellent (r=0.98) (Portney and Watkins, 2000), and indicates that the 
test shows good stability of data recorded by one individual across two trials (Portney 
and Watkins, 2000).  
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9.3.2.5 Reliability of the Infant Gross Motor Screening Test in Relation to other 
Screening Tests 
The results are shown in relation to the reliability values of other commonly used 
screening tools in Table 9.3 below:  
 
Table 9.3 Reliability of the Infant Gross Motor Screening Test Compared with 
other Commonly Used Screening Tools 
Tool Interrater reliability Test-retest reliability 
BINS .79 to .96 .71 to .84 
ASQ 94% (SEM = 0.12)  94%  
Denver II 141 items had 100% 
agreement, 7 had 90 – 
99% and one had 
83%.  
Excellent agreement for 59% of 
items (k≥0.75), 23% of items:  
fair to good agreement (k≥ 
0.40). 
AIMS 0.99.  0.98.  
HINT 0.996 and above 0.86 to 0.99.3  
Bayley III Screening 
Test 
Not described 0.80-0.83 
Infant Gross Motor 
Screening Test 
r=1 r=0.98 
 
The Infant Gross Motor Screening Test showed excellent results in comparison to 
other well-known screening tests. The results obtained are similar to those of the 
HINT and the AIMS, which have been shown to be reliable screening tests (Harris and 
Daniels, 2001; Coster, 1995).  
9.4 Clinical Findings in Relation to the Sample 
In the process of developing the Infant Gross Motor Screening Test, a lot of clinical 
data were collected, which have important clinical implications for the management of 
paediatric HIV in South Africa.  
9.4.1 Developmental Outcomes of the Sample 
HIV is a neurotropic disease, and has been shown to affect all aspects of 
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development (Potterton et al, 2009b; Baillieu and Potterton, 2008; Udgirkar et al, 
2003; Blanchette et al, 2001; Pearson et al, 2000; Fragoso et al, 1999; Drotar et al, 
1997; Wolters et al, 1997; Belman et al, 1996; Pollack et al, 1996; Chase et al, 1995; 
Nozyce et al, 1994; Belman, 1992; Belman et al, 1988; Epstein et al, 1986; Belman et 
al, 1985; Ultmann et al, 1985). Gay et al (1995)  and Msellati et al (1993) reported an 
increase in prevalence of developmental delay with increasing age in the first 18 
months of life, which has been demonstrated in this study. The extent of delay in 
language, cognitive and motor function will be discussed in the following section:  
 
9.4.1.1 Language Development 
HIV CNS disease in children is associated with deficits in both receptive and 
expressive language, although expressive language skills are more severely impaired 
(McClowry, 2000; Blanchette et al, 2001; Tardieu et al, 1995; Wolters et al, 1995; 
Nozyce et al, 1994; Papola et al, 1994; Pizzo et al, 1988; Epstein et al, 1986). 
Language is affected later in life than gross motor development and is thought to be a 
reflection of both the chronicity of the disease as well as direct CNS involvement 
(Bisiacchi et al, 2000; Msellati et al, 1993).  
 
The mean Language composite score for the total group was 88 (±17.68), and 
individual age groups ranging from 79 (±14.19) in the 17-18 month age group, to 95 
(±18.68) in the 6-8 month age group, and the Language composite scores 
deteriorated with increasing age in the first 18 months of life, which is similar to 
findings by Msellati et al (1993) and Gay et al (1995). Just over 41% of infants 
obtained Language composite scores in the Average range. Just over 17% obtained 
scores in the Low Average range, 16.1% in the Borderline range, and 15.2% in the 
Extremely Low range, which indicates that the prevalence of language delay in this 
sample is 49.1%. Just over eight percent of infants obtained scores in the High 
Average range, and just over one percent obtained scores in the Superior range. 
When analysing the scaled scores obtained in this study in order to differentiate 
between Expressive and Receptive Communication function, it was found that 
Expressive Communication was slightly more affected than Receptive 
Communication, which is in keeping with previous literature (Baillieu and Potterton, 
2008; Blanchette et al, 2001; McClowry, 2000; Tardieu et al, 1995; Wolters et al, 
1995; Nozyce et al, 1994; Papola, 1994; Pizzo et al, 1988; Epstein et al, 1986). In 
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comparison with the BSID III standardisation sample (Bayley, 2006b), where 50% of 
infants obtained scores in the Average range, 16.1% of infants obtained scores in the 
Low Average range, just over six percent obtained scores in the Borderline range, and 
just over two percent fell in the Extremely Low range (Bayley, 2006b), there were 
more infants in this sample who fell into the Low Average, Borderline and Extremely 
Low ranges. There were also far fewer in the High Average range.  In comparison with 
a previous study done in South Africa, the prevalence of language problems is lower, 
as the previous study found that 82.5% of infants had language delay (Baillieu and 
Potterton, 2008). It is encouraging to note that the prevalence of language delay is 
lower in this study compared with previous studies (Baillieu and Potterton, 2008), 
which is most likely due to the fact that children now have access to HAART, which 
may result in slightly higher scores on developmental tests due to less rapid 
developmental deterioration.  
 
Verbal expression is highly correlated to motor function, thus motor deficits, including 
those in muscle coordination and motor programming may affect oral-motor skills and 
contribute to feeding problems, articulation errors and speech difficulties (Wolters et 
al, 1997). The fact that motor developmental delay has a lower prevalence in this 
study compared with previous studies conducted on similar populations may account 
for the lower prevalence of language delays. Chronic otitis media is extremely 
common in children who are HIV positive and while this may explain language delay 
due to impaired hearing to some extent, it cannot account for all the deficits in speech 
and language experienced by these children (Layton and Scott, 2000). Children who 
experience an AIDS-defining illness early in life score significantly lower on verbal, 
perceptual performance, quantitative abilities, and memory subtests than infected 
children with no AIDS-defining illness or non-infected children (Abubakar et al, 2008a). 
This has implications for children reaching school-age, and the support they may need 
before reaching school, as well as extra support at school.  
 
9.4.1.2 Cognitive Development 
HIV infected infants have cognitive impairment, CNS dysfunction and deficits in 
neuropsychological functioning, and often present with microcephaly and mental 
retardation (McGrath et al, 2006a; Mazzoni et al, 2000; Fragoso et al, 1999; Belman et 
al, 1996; Henry et al, 1996; Fowler, 1994; Belman, 1992; Diamond et al, 1990; 
The Development of a Screening Tool to Evaluate Infants who are HIV Positive  
 157 
Belman et al, 1988; Epstein et al, 1986; Belman et al, 1985; Ultmann et al, 1985). It 
has been found that cognitive deficits increase with increasing age (Drotar et al, 
1997). HIV Infected children with brain abnormalities perform worse on measures of 
cognitive development (Brouwers et al, 1995). Deficits in visual scanning, academic 
achievement and psychomotor speed have been found (Cohen et al, 1991). HIV 
infected school-going children have memory and visuopraxic impairments, but in the 
early stages of infection only minimal impairment of executive functions has been 
noted (Bisiacchi et al, 2000). Children infected in utero appear to be the most severely 
affected (Brouwers et al, 1995; De Carli et al, 1993). The cognitive deficits described 
in HIV positive children exist independently of environmental and social risk factors 
(McGrath et al, 2006b; Chase et al, 2000; Knight et al, 2000; Henry et al, 1996). 
 
The mean cognitive composite score for the total group (n=112) was 80 (±18.04), 
which falls into the Low Average range. Individual age groups ranged from 74 (± 
15.22) (17-18 months) to 85 (±20.85) (6-8 months), and the cognitive composite 
scores deteriorated with increasing age, which is similar to findings by Msellati et al 
(1993) and Gay et al (1995).  In a previous study by Potterton et al (2009b), the mean 
MDI was 65.61 (±21.93) (Severely Delayed), which was far lower than this study. The 
mean MDI obtained during the validation of the BSID II on a group of 35 HIV infected 
infants was 79.6 (±19.8), which falls into the Mildly Delayed category (Bayley, 1996). 
This is similar to the mean classification in this study. The difference between previous 
and current studies conducted in South Africa may be explained by the fact that the 
children in the validation sample in the United States all had access to antiretrovirals 
whereas only 14.5% of the children in Potterton et al’s (2009b) study were on HAART, 
and 69% of infants in this study were on HAART.  
 
Just over thirty percent of infants obtained Cognitive composite scores in the Average 
range. Just over 18% obtained scores in the Low Average range, 17% in the 
Borderline range, and 28.6% in the Extremely Low range, which indicates that the 
prevalence of language delay in this sample is 63.4%. Just over three percent of 
infants obtained scores in the High Average range, and less than one percent 
obtained scores in the Superior and Very Superior range. 
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In comparison with the BSID III standardisation sample, where 50% of infants 
obtained scores in the Average range, 16.1% of infants obtained scores in the Low 
Average range, just over six percent obtained scores in the Borderline range, and just 
over two percent fell in the Extremely Low range (Bayley, 2006b). There were far 
more infants in this sample who fell into the Low Average, Borderline and Extremely 
Low ranges. There were also far fewer in the High Average range.  In comparison with 
previous studies done in South Africa, the prevalence of cognitive delay is lower. It 
was found that 90% of infants had cognitive delay, when no children had access to 
HAART (Baillieu and Potterton, 2008), and in a recent study, 78% of infants had 
cognitive delay, when 14. 5% had access to HAART (Potterton et al, 2009b). This high 
level of developmental delay is in keeping with findings from studies conducted in 
other parts of the world where prevalence rates of 50% or higher have been 
documented, but with more children having access to HAART (Pollack et al, 1996; 
Chase et al, 1995; Belman et al, 1986; Epstein et al, 1986). 
 
9.4.1.3 Motor Development 
Young children’s motor development, coordination, muscle tone and reflexes are most 
consistently and strongly affected by HIV infection (Drotar, 1997).  The delay is either 
a reflection of the chronicity of the disease or a direct expression of CNS involvement 
(Bisiacchi et al, 2000; Msellati et al, 1993). Motor function is compromised early in 
development in infants with HIV and it is mainly gross motor skills that are delayed 
(Chase et al, 1995; Nozyce et al, 1994).  This may be because gross movements 
require muscle groups and some degree of physical effort, whereas fine movements 
are associated with more precise outputs but lower force. Therefore gross motor 
performance deficits may be related to an overall loss of strength (Parks et al, 1999).  
 
The mean Motor composite score for the total group was 72 (±20.32), and individual 
age groups ranged from 68 (±15.59) (17-18 months) to 76 (±23.95) (6-8 months), and 
the Motor composite scores deteriorated with increasing age, which is similar to 
findings by Msellati et al (1993) and Gay et al (1995).  In a previous study by Potterton 
et al (2009b), the mean PDI was 53.67 (±23.77) (Severely Delayed), which was far 
lower than this study. The mean PDI obtained by Bayley (1996) when validating the 
BSID II on a group of 35 HIV infected infants was 81.1 (±27.2), which falls into the 
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Mildly Delayed category. This is also higher than the mean in this study. Again, the 
difference may be explained by the differences in access to HAART.  
 
Just over 19 percent of infants obtained motor composite scores in the Average 
range. Just under 17% obtained scores in the Low Average range, 18.8% in the 
Borderline range, and 42% in the Extremely Low range, which indicates that the 
prevalence of language delay in this sample is 77.7%. Just over two percent of infants 
obtained scores in the High Average range, and no infants obtained scores in the 
Superior or Very Superior range. When analysing the scaled scores obtained in this 
study, it was found that Fine Motor function was less affected than Gross Motor 
function, which is in keeping with previous studies (Baillieu and Potterton, 2008; Parks 
et al, 1999). Muscle weakness has been associated with poor motor function in 
children infected with HIV (Blanchette et al, 2002; Pearson et al, 2000) and could be a 
result of muscle atrophy secondary to malnutrition. Pearson et al (2000) found that 
decreased muscle bulk was an independent predictor of disease progression in HIV 
infected infants.  
 
In comparison with the BSID III standardisation sample, where 50% of infants 
obtained scores in the Average range, 16.1% of infants obtained scores in the Low 
Average range, just over six percent obtained scores in the Borderline range, and just 
over two percent fell in the Extremely Low range (Bayley, 2006b), there were far more 
infants in this sample who fell into the Low Average, Borderline and Extremely Low 
ranges. There were also far fewer in the High Average range. In comparison with 
previous studies done in South Africa, the prevalence of Motor delay is lower. It was 
found that 87.5% of infants had motor delay, when no children had access to HAART 
(Baillieu and Potterton, 2008), and in a recent study, 87% of infants had motor delay, 
when 14.5% had access to HAART (Potterton et al, 2009b). This high level of 
developmental delay is similar to findings from studies conducted in other parts of the 
world where children have access to HAART (Pollack et al, 1996; Chase et al, 1995; 
Belman et al, 1986; Epstein et al, 1986). 
 
It has been found that children with HIV infection who experienced an early AIDS-
defining illness exhibit significant impairment in their overall cognitive and motor 
ability, relative to their HIV infected, but relatively healthy, counterparts and non-
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infected peers (Abubakar et al, 2008a; Nozyce et al, 1994). Children in sub-Saharan 
Africa are more likely to experience an early AIDS-defining illness, due to lack of 
resources, late diagnosis and up until recently, lack of access to HAART. With early, 
appropriate, antiretroviral therapy, not only does the child stand a better chance of 
survival, but may also avoid significant developmental impairment due to decreased 
chances of an early AIDS defining illness. In the meantime, HIV infected children of 
school-going age may need additional educational and psychosocial resources in the 
classroom and regular re-evaluation of their progress and learning needs (Smith et al, 
2006). The South African Department of Health’s policy to provide ARV’s to all 
children less than one year of age from 1st April 2010, will hopefully help this goal to 
be attained (DOH, 2010). Along with this, regular monitoring of development, and 
timeous referral to appropriate services is needed in order to detect developmental 
problems early on.   
 
Previous studies have shown that home stimulation programmes may be effective in 
helping with the developmental delays seen in these children (Potterton et al, 2009a), 
and therefore due to overloaded therapy services, this may be a more effective means 
of management.  
 
Research Implications 
• Further research should be conducted to clarify the trends being seen in studies 
where expressive language is more affected than receptive language.  
• Further research should be conducted to evaluate the cognitive problems of 
school-age children in sub-Saharan Africa.  
• Imaging studies should be carried out in order to correlate areas of brain damage 
with clinical presentations. 
Clinical Implications 
• The above findings highlight the need for a screening tool which is able to detect 
developmental issues early on. Gross motor function is consistently most 
severely affected in HIV infected infants, and therefore a gross motor screening 
tool would be suitable for this setting, and may serve as a ‘net’ to identify 
children with developmental problems. Children who present with gross motor 
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problems on screening may then be referred for further assessment in the 
language and cognitive domains, as they are at risk for problems in all areas.  
• Children who are HIV positive should be referred for routine hearing tests due to 
the prevalence of otitis media in this population, which may contribute to 
language problems. 
• Simple home exercises and stimulatory activities should be given to all children 
in order to help combat some of the developmental delays seen. Due to the 
high case loads of HIV positive infants in the public sector this may be an 
effective management strategy, which would also help to empower caregivers.  
9.4.2 Immunological Status of the Sample 
A lower CD4 count and higher viral RNA load are associated with increased severity 
of disability, growth failure and slower attainment in milestones in infants and children 
with vertically transmitted HIV (Pearson et al, 2000; Belman et al, 1996; Pollack et al, 
1996; Chase et al, 1995). Children with more advanced degrees of immune 
suppression early in life and those with high-plasma viral load in infancy also have 
higher rates of encephalopathy (Nozyce et al, 1994).  
 
The immunologic status of the sample was poor, with the highest mean CD4 
percentage being 28% (±0.45) for infants in the 17-18 month age group, and the total 
mean CD4 percentage being 23% (±9.9). Mean viral load was 1766.4 (±67.16), which 
is also an indication that the immunological status of the sample is poor, as with the 
NASBA assay which is used at the clinic, an ideal viral load of 25 is expected to 
indicate low viral load. This together with the low CD4 percentage of the sample 
indicates that these infants are at risk for increased severity of disability, growth failure 
and slower attainment in milestones as found by Pearson et al (2000), Belman et al 
(1996), Pollack et al (1996) and Chase et al (1995). This is despite the fact that 67.9% 
of the sample was on HAART, and indicates that their immunologic status and 
developmental status was very poor. The regimen used at Harriet Shezi is a high CNS 
penetrating regimen according to Patel et al (2009), and therefore less severe effects 
on development would be expected.  
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The children in this sample have a number of risk factors, including poor maternal 
education, low socioeconomic backgrounds, as well as being HIV infected in a 
developing country, which has been shown to be associated with more opportunistic 
infections. Many children in developing countries are exposed to multiple risk factors 
for poor development including poverty, poor health and nutrition. A conservative 
estimate is that more than 200 million children under five years of age in developing 
countries are not developing to their full potential due to poverty and the associated 
health, nutrition and social factors (Grantham-McGregor et al, 2007; Walker et al, 
2007). This, together with the fact that up until April 2010, stringent guidelines for the 
initiation of ARV’s have had to be followed in children under one year of age meant 
that timeous initiation of HAART did not occur. Adherence to taking medication is also 
problematic, with stigma, coupled with the need for refrigeration, poor palateability and 
regularity of doses being major factors (Davies et al, 2008). It has also been found 
that mothers/caregivers with secondary education were more likely to be successful in 
giving dosages correctly (Davies et al, 2008). All these factors may have had an 
influence on the sample in this study, which may partly account for the poor 
immunologic and virologic status of the sample, and in turn, their poor developmental 
outcomes.  
 
Research Implications 
• As children have better access to ARV’s in South Africa, further research should 
be conducted to determine whether their immunological status improves 
further, and in turn, what effects this has on neurodevelopment. 
• Further research into adherence issues and potential improvement of adherence 
should continue. 
Clinical Implications 
• The immunologic and virologic status of the infants still has a huge impact on 
their neurodevelopmental status, and therefore cannot be assessed in isolation.  
• Education should be provided to caregivers as to the global effects of 
immunologic and virologic status on neurodevelopment, general health, and 
eventual school function, and the role of the caregiver in providing medication, 
which will help to facilitate improved development.  
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9.4.3 Growth 
Growth parameters have previously been identified as being markers of disease 
progression (Bobat et al, 2001) as has developmental delay (Mintz, 1999). It has also 
been demonstrated that anthropometric status is predictive of developmental status in 
HIV infected children (Potterton et al, 2009b; Abubakar et al, 2009; Wiznia et al, 
1996). There is an association between poor growth and neurodevelopmental delay in 
HIV positive children especially in children with advanced stages of the disease 
(Pollack et al, 1996). Infants with the most severe growth delay have significant 
cognitive and motor delay even if this only becomes apparent later (Pollack et al, 
1996). Wiznia et al (1996) report a strong correlation between poor weight-for-age and 
decreased cognitive function and a low CD4 count. Missmer et al (2000) found that a 
decreased height-for-age z-score is a strong predictor of decreased functional status, 
suggesting that height may be used as an indicator of disease severity. HIV infected 
children in developing countries show a decline in length and weight within the first 
months of life, and eventually manifest a picture of chronic malnutrition (Tindyebwa et 
al, 2004). This may result from HIV infection itself, underlying disease such as 
tuberculosis, inadequate macro/micronutrient intake or a combination of any, or all of 
the above. A high viral load in children is associated with increased risk of failure to 
thrive, while infections such as pneumonia, diarrhoea and tuberculosis further 
exacerbate growth failure (Tindyebwa et al, 2004).  
 
In this study, the mean height-for-age z-score (-2.21 ±1.7) was indicative of moderate 
stunting, and moderate malnutrition was present in the youngest age group. In a study 
by Potterton et al (2009b) weight-for-age was found to be positively related to BSID II 
Mental Developmental Index (MDI) scores. Weight-for-height and height-for-age were 
related to MDI scores but were not as important as weight for age. This has also been 
found by Wiznia et al 1996. Potterton et al (2009b) found that weight-for-age z-scores 
were strongly predictive of BSID II Psychomotor Developmental Index (PDI) scores. 
This has also been found by Abubakar et al (2009) who showed that weight-for-age 
and disease stage were predictive of psychomotor outcome.  
 
Stunting is an indication of slow skeletal growth and is often associated with poor 
socio-economic conditions, chronic or repeated infections as well as inadequate 
nutrition. Stunting takes a long time to correct once adverse circumstances have been 
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corrected as skeletal growth is a slower process than growth in body mass (WHO, 
1995). Children with growth failure may have decreased weight-for-height (wasting) 
and decreased height-for-age (stunting). Malnutrition initially causes wasting, while 
stunting is associated with prolonged malnutrition (Chantry and Moye, 2005). It has 
commonly been found in HIV positive children that stunting but not wasting is present 
(Tindyebwa et al, 2004; Nathan et al, 2003; Bobat et al, 2001). 
 
In this study, head circumference z-scores were very poor, and the mean head 
circumference z-score was -3.01 (±2.2).  Head circumference has previously been 
linked to the extent of developmental delay by a number of authors (Mitchell, 2001; 
Macmillan et al, 2001; Mintz, 1999).  This could therefore be an indication as to why 
the cognitive developmental scores of the sample are low.  
 
One of the primary targets of HIV-1 infection is brain tissue, which also commonly 
results in reduced brain growth (Macmillan et al, 2001). Acquired microcephally has 
been noted by a number of authors and is usually due to impaired brain growth and 
cerebral atrophy secondary to encephalopathy (Mitchell, 2001; Macmillan et al, 2001; 
Mintz, 1999). Cortical atrophy is associated with disease progression and 
neurodevelopmental delay (Llorente et al, 2003; Pearson et al, 2000). Overall, the size 
of the head predicts the size of the brain, which is associated with IQ (Wickett et al, 
2000). Brain development during infancy and early childhood is more important than 
foetal brain growth in determining adult cognitive abilities (Gale et al, 2003). This has 
implications for the children in this study, as their head circumference z-scores were 
very low, which could indicate that cognitive abilities could be impaired, and therefore 
school difficulties may be encountered.  
 
Regular monitoring of weight, height and head circumference is recommended in all 
HIV infected children (Chantry and Moye, 2005; Nachman et al, 2002; Coovadia and 
Meyers et al, 2000; Bobat et al, 1998). Chronic malnutrition has been associated with 
decreased intellectual capacity, and therefore decreased earning capacity in later life, 
which perpetuates the cycle of poverty (Bridge et al, 2006). In a child who is not 
meeting his growth milestones, vitamin and micronutrient deficiencies should be 
considered as well (Mintz, 1999). 
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Research Implications 
• Little is known as to the effects of HIV on school function in developing countries. 
More longitudinal studies need to be conducted to analyse school outcomes in 
relation to early growth and developmental parameters. 
Clinical Implications 
• Regular monitoring of weight and height is recommended at every clinic visit in 
order to monitor growth, and to determine ART eligibility or response to ART 
(DOH, 2010). 
• It should be noted that growth is predictive of developmental status, and 
therefore both should be monitored closely.  
9.5 Challenges 
There are many challenges associated with conducting research in a developing 
country such as South Africa. These will be outlined below and their impact on the 
results of this study will be discussed.  
9.5.1 Standardisation Sample 
The Infant Gross Motor Screening Test was developed for use on HIV positive infants 
between the ages of six and eighteen months. The tool was therefore standardised on 
this population, and its applicability to other populations is not yet known. 
Standardisation on normal children has not yet been conducted, but due to the 
pressing need for the tool, and the encouraging reliability and validity results on the 
HIV infected population, it should prove useful for these children. Further research 
should be directed towards standardisation on infants from a variety of backgrounds in 
order to ensure that the standardisation sample is representative of the South African 
population. Gross motor screening may be useful in other populations such as 
premature infants, and therefore before the tool can be used on these populations, 
further standardisation, reliability and validlity studies should be carried out.  
9.5.2 Age Range 
The age range for the Infant Gross Motor Screening Test is currently six to eighteen 
months, which may need to be extended in the future, especially downwards, so that 
infants with gross motor developmental problems may be identified even earlier.  This 
age range was chosen due to the low number of children under six months of age who 
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attend the clinics, as they are usually only diagnosed with HIV once they present with 
clinical symptoms.  
9.5.3 Reliability and Validity 
For the purposes of this study, preliminary testing was carried out to determine the 
reliability and validity of the Infant Gross Motor Screening Test. Larger studies should 
be conducted in the future in order to expand on this. Depending on the future uses 
for the tool, predictive validity studies may need to be conducted.  
9.5.4 Test Manual 
Instructions and guidelines have been drawn up for the purposes of this study, but 
should the Infant Gross Motor Screening Test need to be widely distributed, a full test 
manual would need to be printed, containing the information required by Rothstein et 
al (1991) as outlined in the Standards for Tests and Measurements in Physical 
Therapy Practice.  
9.5.5 Test Domains 
The Infant Gross Motor Screening Test is limited in that it assesses gross motor 
development only, but in this population, this is the aspect of development, which is 
most severely affected, and the assessment of the other areas of development is 
problematic for a number of reasons. The assessment of cognitive development 
requires equipment, which would make the tool costly, and bulky, and in many other 
studies, cultural differences have been shown to affect outcomes, for example, puzzle 
building. Language assessment is problematic firstly due to the fact that there are 
eleven official languages in South Africa, and receptive language assessment requires 
picture recognition, which is often not culturally appropriate. Gross motor function has 
been shown to be the most universal aspect of development, and is the easiest aspect 
to assess, as no equipment is required.  
9.5.6 Conclusion 
This study has therefore resulted in the development of The Infant Gross Motor 
Screening Test, which may be used in clinics to assess the gross motor function of 
infants between six and 18 months of age. The study has also provided important 
anthropometric and developmental data which further highlight the issues that HIV 
infected children in South Africa face.  
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Chapter 10 
CONCLUSIONS 
The main conclusions drawn from this study are outlined below:  
 
The Bayley-III Screening Test and the BSID III do not correlate well, and therefore the 
Bayley-III Screening Test is unsuitable for use in the context of paediatric HIV in South 
Africa. A new gross motor screening tool was therefore developed in order to detect 
gross motor delays in HIV positive children between the ages of six and 18 months. 
Important clinical findings resulting from the study are as follows: HIV infected children 
are at high risk of developmental delay in all domains, most markedly gross motor 
development. Despite the ARV rollout in South Africa, developmental delay and HIV 
encephalopathy continue to be problematic, and the immunologic status of the 
children remains poor. The infants in the study population have many additional risk 
factors which have an impact on their developmental status including poor 
socioeconomic status, malnutrition and stunting. There is therefore a need for a 
screening tool which will help to identify children with developmental delays so that 
they may be referred for further more in-depth assessment in all areas, and 
intervention where necessary. Monitoring of development has also been outlined in 
the South African Department of Health Guidelines for Antiretroviral Treatment (2010) 
as an ARV initiation criterion, and a treatment response criterion.  
The Infant Gross Motor Screening Test has been developed for use on an HIV 
positive paediatric South African population. The statistical properties of the Infant 
Gross Motor Screening Test are excellent, and the tool has been shown to be both 
reliable and valid. The statistical properties of the Infant Gross Motor Screening Test 
are within the ranges recommended by the American Psychological Association, and 
the tool has been developed in accordance with the Standards for Tests and 
Measurements in Physical Therapy Practice. The statistical properties of The Infant 
Gross Motor Screening Test after preliminary testing are presented in Table 10.1 
below:  
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Table 10.1 Statistical Properties of The Infant Gross Motor Screening Test 
Content Validity Assessed using the NGT 
Concurrent Validity K=0.85 
Sensitivity 97.4% 
Specificity 85.7% 
Positive Predictive Value 92.7% 
Negative Predictive Value 94.7% 
Interrater Reliability r=1 
Intrarater Reliability r=1 
Test-retest Reliability r=098 
 
The final version of the Infant Gross Motor Screening Test is presented below:  
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Consent from Harriet Shezi Clinic 
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Appendix III 
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Appendix IV 
Information sheet and informed consent 
 
Good Morning 
 
My Name is Nicole Hilburn. I am a Physiotherapist from the University of the 
Witwatersrand. I am doing a study to look at how we can test your child’s development 
at your visits to the clinic so that the doctors can include this in their services to you.  
 
HIV can affect a child’s development, and make your child slower to develop. If we 
can test your child’s development, and he/she needs some help to catch up, then we 
will be able to send you to the correct place for help. We would like to try this test of 
development on children so that we can see if it is able to tell us whether the child is 
developing on time. The test uses toys and is fun for the child. We want to try and 
make the test as short as possible so that it does not take up too much of your time.  
 
I would like to test your child’s development this morning, using a test that takes about 
an hour. You will not lose your place in the queue, as you will be called when it is your 
turn. The test is not painful, and involves toys and games, so your child will enjoy it. I 
am also seeking your permission to look at your child’s medical file, so that we can 
find out about his/her height, weight and CD4 count to see what may cause slow 
development. Your information will be kept confidential at all times and your child’s 
name will not be used. You may withdraw from the study at any time without a reason; 
this will not impact on your treatment the clinic in any way.  
 
Nicole Hilburn 
Physiotherapist      Telephone: 011 7173702 
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Informed Consent 
 
If you would like to take part in this study, please sign below 
 
I___________________(your name) and my child_______________(child’s name) 
agree to take part in this study. I give permission for Nicole Hilburn to obtain 
information from my child’s file. I understand that I may withdraw from the study at any 
time.  
 
Signed: ________________________ Date: ________________________________  
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Appendix V 
Example of data capture for item analysis 
Key 
8 month olds 7 month olds 6 month olds 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Emerging  
Competent 
At-Risk 
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Appendix VI 
Information sheet and informed consent for study five 
 
Good Morning 
 
My Name is Nicole Hilburn. I am a Physiotherapist from the University of the 
Witwatersrand. I am doing a study to look at how we can test your child’s development 
at your visits to the clinic so that the doctors can include this in their services to you.  
 
HIV can affect a child’s development, and make your child slower to develop. If we 
can test your child’s development, and he/she needs some help to catch up, then we 
will be able to send you to the correct place for help. We would like to try this test of 
development on children so that we can see if it is able to tell us whether the child is 
developing on time. We want to try and make the test as short as possible so that it 
does not take up too much of your time.  
 
I would like to test your child’s development this morning, using two tests that will take 
about half an hour. You will not lose your place in the queue, as you will be called 
when it is your turn. The test is not painful, and involves toys and games, so your child 
will enjoy it. If your child is found to be delayed, information will be given to you that 
will help you to make your child stronger.  
.  
Your information will be kept confidential at all times and your child’s name will not be 
used. You may withdraw from the study at any time without a reason; this will not 
impact on your treatment the clinic in any way.  
 
Nicole Hilburn 
Physiotherapist      Telephone: 011 7173702 
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Informed Consent 
 
If you would like to take part in this study, please sign below 
 
I___________________(your name) and my child_______________(child’s name) 
agree to take part in this study. I understand that I may withdraw from the study at any 
time.  
 
Signed: ________________________ Date: ________________________________  
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Appendix VII 
Consent from CEO of Rahima Moosa Hospital 
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Appendix VIII 
Information sheet and informed consent for test-retest reliability 
Good Morning 
 
My Name is Nicole Hilburn. I am a Physiotherapist from the University of the 
Witwatersrand. I would like to use a test of development to see if it is able to tell us 
whether your child is developing on time, and whether the score is the same over two 
tests.  
 
The test that takes about ten minutes, and is not painful for your child. If you agree to 
take part in the study, your child will be assessed twice, with the second test being 
done two days after the first. Your information will be kept confidential at all times and 
your child’s name will not be used. If your child is found to be delayed, information will 
be given to you which will help your child to get stronger. You may withdraw from the 
study at any time without a reason; this will not impact on your treatment in the 
hospital in any way.  
 
Nicole Hilburn 
Physiotherapist 
011 7173702 
 
Informed Consent 
 
If you would like to take part in this study, please sign below 
 
I___________________(your name) and my child_______________(child’s name) 
agree to take part in this study. I understand that I may withdraw from the study at any 
time.  
 
Signed: ________________________ Date: ________________________________  
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Appendix IX 
Information sheet and informed consent for inter-rater reliability 
 
Good Morning 
 
My Name is Nicole Hilburn. I am a Physiotherapist from the University of the 
Witwatersrand. I would like to use a test of development to see whether two people 
are able to get the same score for your child.  
 
The test that takes about ten minutes, and is not painful for your child. If you agree to 
take part in the study, your child will be assessed by myself, or Joanne Potterton, and 
the other therapist will watch the assessment and will score it at the same time. Your 
information will be kept confidential at all times and your child’s name will not be used. 
If your child is found to be delayed, information will be given to you which will help 
your child to get stronger. You may withdraw from the study at any time without a 
reason; this will not impact on your treatment in the hospital in any way.  
 
Nicole Hilburn 
Physiotherapist 
011 7173702 
 
Informed Consent 
 
If you would like to take part in this study, please sign below 
 
I___________________(your name) and my child_______________(child’s name) 
agree to take part in this study. I understand that I may withdraw from the study at any 
time.  
 
Signed: ________________________ Date: ________________________________  
 
 
 
